Intrapericardial delivery of Omega-3 Polyunsaturated fatty acids by Rolfes, Christopher David
  
 
 
 
 
Intrapericardial Delivery of Omega-3 Polyunsaturated Fatty 
Acids 
 
 
 
 
A DISSERTATION 
SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL 
OF THE UNIVERSITY OF MINNESOTA 
BY 
 
 
 
 
Christopher David Rolfes 
 
 
 
 
 
 
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS 
FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
 
 
 
Advisor: Paul A. Iaizzo 
 
 
 
 
August 2012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Christopher David Rolfes 2012  
 
  
  i 
Acknowledgements 
 
This thesis would not be possible without the contributions from numerous colleagues 
and support staff and the army of undergraduate volunteers.  First, a thank you goes to 
the staff at the Visible Heart Lab.  Monica, thank you for making everything run smoothly 
behind the scenes as well as a help with manuscript preparation and protocol 
submissions.  Gary, thanks for the help with everything electronic; from images and 
videos to fixing computer bugs, this job was made so much better with your help.  I owe 
a great thanks to Charles Soule, Bill Gallagher and Tinen Iles for the many hours of 
training and experimental preparation.   
 
My research would also not have been possible without the unique collaboration with 
LifeSource.  A special thank you to the workers there, as well as the, the heart donors 
and their families for contributing to the collection of human hearts at the University of 
Minnesota. 
 
I would also like to thank funding sources that contributed to the work: Department of 
Education GAANN fellowship (Graduate Assistance in Area of National Need); the 
Institute for Engineering in Medicine at the University of Minnesota; the University of 
Minnesota Graduate School; and the National Institutes of Health Training Program for 
Muscle Research (T32 AR07612). 
 
 
  ii 
Large animal experimentation relies on a team effort.  Without the support of my fellow 
graduate students, many of my studies would not be possible.  In between corralling pigs 
at dawn to reanimating hearts at midnight, we have shared hobbies, videos and 
chocolate.  The good cheer and energy in this lab is unparalleled.   To those whose 
tenure in the lab preceded me: Mike Kimmel, Sara Anderson, Jason Quill, Eric 
Richardson and Mike Eggen, without your training and (sometimes critical) guidance, I 
would have been lost in this lab.  My current lab mates have put forth tremendous efforts 
for all the studies and activities in this lab, a load that would not be possible alone.  
Thanks to Mike Bateman, Steve Howard, Ryan Goff, Jules Eggum.  I am fortunate to 
have built up a close knit relationship with so many smart, friendly and generous 
students, who have become great colleagues and friends. 
 
My family has been supportive throughout my education.  Thank you mom and dad for 
fostering such a thirst for knowledge and understanding.  My siblings have become 
some of my best friends and have supported me whenever they can.  And to my 
wonderful wife, Melissa, thank you for your support and understanding.  And through this 
experience, you unveiled the true reason I married you: I needed someone to teach me 
statistics. 
 
An enormous thank you to Paul.  As an advisor, you helped to steer my studies in 
feasible directions, and always encouraging your students to step past expectations.  
You set an amazing example in your leadership and work/family balance.  You truly 
know how to walk the walk. 
  iii 
Dedication 
 
This dissertation is dedicated to Melissa Rolfes for her continuous love and support.  I 
am grateful to have you as a wife and friend. 
  iv 
Thesis Abstract 
 
Ischemic heart disease is a major cause of morbidity and mortality in the US, as well as 
other developed nations.  An estimated 1,255,000 Americans will suffer from acute 
myocardial infarctions (MI) in 2012 alone [1].  Further, in 2008, this contributed to over 
400,000 deaths from coronary heart disease [1].  Thus, many therapies have been 
investigated as treatments so to minimize damage after MI. Because of the 
unpredictable nature of acute MI, many of these therapies have been focused on 
reducing cell damage after the onset of symptoms, such as stenting, angioplasty and/or 
coronary artery bypass grafting.  Associated arrhythmias can be common in such 
patients. 
   
Atrial fibrillation (AF), is the most common arrhythmia, occurring in approximately 1% of 
the population [2].  While not immediately life-threatening, AF can have significant 
impact on the quality of life.  This self-propagating disease progresses from paroxysmal 
(self-terminating episodes less than 7 days) to persistent (recurrent episodes lasting 
more than 7 days) to permanent AF.  As with many cardiac diseases, AF sufferers 
generally respond better with early treatment. 
 
Cardiothoracic surgery poses a great risk for generating associated AF.  With elicitation 
rates of up to 25-40% in such patients, therapeutic or preventative treatments have 
gained much recent attention.  Importantly, in addition to lengthening a given patient 
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time in the intensive care unit (ICU), postoperative AF may increase rates of 
postoperative stroke and thus the total cost of the patient care [3]. 
 
Intrapericardial delivery of anti-arrhythmic agents 
The main goal of targeted drug development is to maximize effects on desired tissues 
while minimizing side-effects from drug accumulations in peripheral organs.  In other 
words, localized therapies are designed to deliver and maintain high drug concentrations 
in or near the desired tissue.  More specifically, such local deliveries often create or use 
natural barriers to contain the bulk of administered therapeutics in a specific region.  
These barriers minimize movements of the medication, keeping a large dose in the 
intended tissue with minimal crossover with the systemic circulation.  The pericardial 
space surrounding the heart provides one such unique reservoir and potential 
therapeutic benefits have been investigated by employing several antiarrhythmic agents, 
including: esmolol [4], solatol [5], atenolol [5], ibutalide [6], procainamide [7], [8], digoxin 
[7], amiodarone [9], arachadonic acid [10], nitroglycerin [11] and L-arginine [12].  The 
intrapericardial (IP) delivery of each of these agents has been shown to have beneficial 
electrophysiological effects when delivered within the pericardial space in various animal 
models.  Further, in those studies that measured plasma concentrations, they showed 
minimal crossover into the bloodstream [7–9] 
 
Delivering therapeutics to the pericardial space has the potential to produce high tissue 
concentrations while minimizing crossover into the plasma.  This local containment, in 
turn, reduces side-effects in other systemic organs, which can be a common problem 
with antiarrhythmic drugs.  In other words, while current regimens using approved drugs 
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achieve their end desired affects with conventional oral or intravenous delivery, the 
needed high concentrations of these agents within the bloodstream transports them to 
all tissues.  With IP delivery, however, not only are local concentrations increased, but 
tissue concentrations can more tightly controlled.  This control results in fewer variables 
to affect tissue delivery, the therapeutic levels can be better titrated with feedback loops. 
This is especially beneficial with drugs that may have a narrow therapeutic window. 
 
While numerous animal models and experiments have been performed with success, 
there has been limited translation to clinical use.  This is likely due to a lack of clinical 
trials and experience.  With new delivery techniques come new complications, and 
potentially altered effects.  For instance with pericardial delivery, agents need to diffuse 
into the myocardium, rather than being perfused through the blood and reaching each 
cell.  Thus drug pharmacodynamics must be understood with this new technique before 
clinical protocols can be established. 
 
Thesis objective 
The IP delivery of drugs is very promising, with positive results seen in numerous studies 
to date.  Yet, before specific clinical protocols can be established, a drug and target must 
be identified, and methods developed and carefully verified.  Typically, both preliminary 
work in vitro and in situ animal models must show positive results before clinical trials 
are initiated and subsequent human protocols can be put into practice.  Parameters that 
need to be determined include drug dosing, delivery rates and pharmacodynamic 
studies.  The primary purpose of this thesis is to evaluate the potential efficacies of 
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antiarrhythmic therapies delivered to the pericardial space so as to reduce susceptibility 
to arrhythmias during cardiothoracic procedures. 
 
To accomplish these objectives, I began by specifically researching AF mechanisms and 
consequences of cardiac ischemia/reperfusion injury.  Chapters one and two of my 
thesis incorporates this initial experimentations and learning with atrial fibrillation as well 
as localized drug therapies.  These chapters summarize my initial background work that 
serves as the foundation for additional investigations.  In chapter three of my thesis, I 
delve further into localized therapeutic delivery and make use of it in a porcine model of 
perioperative AF, treating with metoprolol directly in the pericardial space.  The 
remaining chapters focus on the pericardial delivery of omega-3 polyunsaturated fatty 
acids.  These chapters consist of the studies that make use of knowledge and 
experience gained in the first few chapters, then focuses on the effects of omega-3 
polyunsaturated fatty acids in several potential clinical applications.  These chapters 
make use of a surgical swine model, as well as exploring fatty acid delivery for 
preconditioning a donor heart prior to transplant transportation and post implant.  In the 
final section of my thesis I will summarize the potential benefits of the pericardial delivery 
of therapeutic agents and discuss the future investigations needed to make these 
approaches fully translations into a clinical setting 
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Preface 
As I started my research into cardiac disease and atrial fibrillation (AF), the human heart 
library within the visible heart lab became a valuable resource.  I began an investigation 
into anatomical changes during AF, measuring volumes and wall thicknesses in 
diseased and healthy hearts.  These measurements served to further my knowledge and 
understanding of AF.  This, along with the accompanying research into the disease 
progression and treatment, served to form much of my knowledge and understanding of 
cardiac anatomy and physiology. 
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Summary  
Background  Atrial fibrillation (AF) causes a continuum of atrial anatomical remodeling.  
Methods Using a library of perfusion fixed human hearts, specimens with atrial 
fibrillation were compared to controls.  During this preliminary assessment study, direct 
measurements were taken of atrial volume, pulmonary vein (PV) circumference, and left 
atrial wall thicknesses.   
Results  Hearts with AF typically had larger atrial volumes, as well as a much larger 
variation in volume compared to controls (range of 59.6-227.1mL in the AF hearts 
compared to 65.1-115.9mL in control).  For all hearts, right PVs were larger than left  
(mean 171.4 ± 84.6 for right and 118.2 ± 50.1 for left, p < 0.005).  Left atrial wall 
thicknesses ranged 0.7-3.1mm thick for both AF and control hearts.    
Conclusions  Hearts with AF had a large range of sizes which is consistent with the 
progression of atrial remodeling during AF.  The large range of thicknesses will influence 
the amount of energy needed to create transmural lesions during ablation procedures. 
 
 
Keywords:  Left atrial dimensions, volumes, pulmonary vein ostia, atrial fibrillation 
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Introduction 
Atrial fibrillation (AF) is the most prevalent tachyarrhythmia, with a prevalence of 1% in 
the general population [1]. One of the particular clinical features of this arrhythmia is its 
self-perpetuating nature. Paroxysmal AF (self-terminating episodes) may eventually 
turns into persistent (> 7 days) and then even permanent AF [2-4].  This progression is 
considered in part, due to both structural and electrophysiological remodeling of the 
tissue that provide substrates for maintenance of such arrhythmias. Structural 
remodeling associated with AF refers to physical changes, such as dilation of the atria 
and interstitial fibrosis. The electrophysiologic remodeling results the shortening of the 
atrial effective refractory periods, thus aiding the perpetuation of an arrhythmia and/or 
limiting the ability to terminate fibrillations. More specifically, the self-perpetuation is 
especially disturbing symptom when patient long-term prognosis is taken into account: 
mortality rate doubles and stroke occurrence averages up to 5% per year in patients with 
AF, which is 2 to 7 times the rate of individuals of similar ages whom are uninflected with 
AF [4].  
 
The prevalence of atrial fibrillation in relation to age and associated risks 
The clinical treatment of AF is an especially relevant topic in geriatric cardiology due to 
the well documented increasing prevalence with age. When considering an overall 
general population, the relative prevalence of AF is 1%, yet in persons over 40 years of 
age the prevalence reaches 2.3% and then climbs to 5.9% for individuals over 65 [5]. 
The geriatric population, defined by the WHO as persons with age greater than 65, 
contains over 75% of people suffering from AF [1]. It should also be noted that AF has 
also been found to be more common in men than women (1.1% versus .8%) [1].  
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Atrial fibrillation is well known to be associated with decreases in quality of life: as 
reported by as many as 68% of patients with paroxysmal AF [6]. Interestingly the 
psychological, not physical, quality of life may be impacted more [7]. In addition to stroke 
[4], AF has also been associated with many other health problems that would cause 
decreases in quality of life such as depression, professional and sex life complications 
[8], etc.  However, it is debated whether or not AF is or is not associated with cognitive 
decline [9-11].  It is highly probable that because AF causes an increased risk of stroke 
and emboli, that cognitive decline in part be linked to the potential for multiple small and 
transient cerebral infarcts, yet this will also be dependent on the given patient and their 
anticoagulation management [12].  
 
In addition to the above detrimental effects of AF, anatomical remodeling of the atria can 
occur within the heart.  Patients who have AF tend to have larger left atria and larger 
pulmonary veins which could potentially lead to the further propagation of AF [13]. 
Alternatively, the reverse has also been shown: upon return to sinus rhythm after 
radiofrequency ablation, there is a measureable reduction in left atrial size [14,15].  
Depending on the length of AF and the stage of remodeling, patients with the arrhythmia 
may have large variation in their anatomy. 
 
Left Atrial volume measurements 
Heart left atrial (LA) volumes have been selected here to be measured in this sample of 
perfusion fixed human hearts, due to reported AF related atrial remodeling (dilations). 
For example, the work by Leung et al. found that increases in LA volumes could be used 
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to independently predict the increased risks of cardiovascular death, heart failure, AF, 
stroke, or MI [16]. Further, subsequent reductions in LA volumes (reverse remodeling) 
has been found to be a strong predictor of the successful treatment of AF using either 
catheter based [17] or surgical [18] ablations. Relative LA volumes for a given patient 
have also been found to predict the potential for recurrence of AF after cardioversion 
[19] and conversion of atrial flutter to AF after successful ablation [20]. More specifically, 
the probability of relapse after catheter ablation was found to be significantly higher for 
LA volumes greater than 145 ml [17]. LA volume index greater than 135 ml/m2 was 
found to have 100% specificity and LA diameter greater than 60mm was found to have 
100% sensitivity for prediction of surgical Maze failure [18]. Not surprisingly, normal LA 
volumes have been found to be associated with absence of thrombus [21] and relative 
LAA dimensions have been found to be a positive predictor for stroke/TIAs in patients 
with AF [22].  
 
Pulmonary vein sizes  
Since the clinical discovery that the pulmonary veins (PVs) can be substantial site-
sources of ectopic beats [23], PV anatomy has attracted increasing attention.  A patient’s 
pulmonary vein sizes are useful measurements when planning for an ablation since 
some procedures, such as cryoballoon ablation, offer multiple sized devices to optimize 
PV isolation.  The PV circumference was chosen because even though the PVs 
(especially the left PVs) are typically oval in shape [24], they are also considered as 
compliant and a balloon pushed against the ostium will slightly change its shape.  In 
other words, using simply the long or short axis for planning may lead to the decision to 
use a balloon that is too big or small, respectively.  
  7 
 
Left Atrial Wall Thicknesses 
Left atrial wall thicknesses are also commonly assessed and were done so here as well.  
The area on the posterior wall near each of the PVs was measured as well as the center 
of the posterior wall.  These locations were selected not only because they are smooth 
in comparison to the left atrial appendage, but they are often areas of therapeutic focus 
during AF ablation procedures. Variation in LA wall thicknesses is also important to 
consider during radiofrequency ablation procedures, since it should influence the amount 
of energy to be applied [25].  
 
One of the primary goals of this preliminary assessment study is to present our ongoing 
investigations as to human cardiac anatomy.  Our Visible Heart® Laboratory has a 
current library of over 200 human heart perfusion fixed specimens that we can uniquely 
employ for such investigations.  In addition, many of our obtained images are and videos 
of functional cardiac anatomies are available to the general public, via our free-access 
web site, “The Atlas of Human Cardiac Anatomy” (http://www.vhlab.umn.edu/atlas). 
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Methods 
 Human hearts deemed not viable for transplantation were donated for educational and 
research purposes. Following similar guidelines for transplantation, the hearts were 
stopped, cooled and transported to our lab. Within 24 hours of being excised, these 
specimens were weighed and the aorta, superior vena cava, pulmonary artery, 
pulmonary veins and the inferior vena cava (when possible on a given specimen) were 
cannulated and attached to a perfusion fixation chamber as described previously [26]. 
This approach will preserve the hearts in a modified end-diastolic state (fully expanded 
atria and ventricles). These hearts were fixed with 10% formalin in PBS solution for at 
least 24 hours under normal physiologic pressure and then stored in formalin. 
 
Heart specimens have been collected and added to our library since 1997 and to date 
the library has grown to over 200 in the collection. Anatomical studies can be performed 
on this large collection so to better understand the variation in anatomy between 
different hearts. For most of such specimens, pertinent clinical histories are also 
available, thus allowing us to assess the variation in anatomy with respect to the relative 
disease state of the heart. In the present study, we identified and used hearts that had a 
clinical diagnosis of AF and compared them to hearts with no indication of AF or 
mitral/tricuspid regurgitation (normal anatomies). The AF hearts were sex, age, weight, 
and height matched to control hearts. For all but 2 of this sample of 10 AF hearts, 
acceptable control hearts were found and/or were measureable (Table 1.1).  
  9 
 
Table 1.1: Patient information from atrial fibrillation and their corresponding control hearts. For all 
but two AF hearts suitable matches were found as controls based on subject genders, ages, weights 
and heights for these collected specimens.  
 
To measure the volumes of the atria, the hearts were oriented such that the annulus of 
the atrioventricular valves would be parallel to the ground while measuring their 
respective side. To measure the volume of the left atrium (LA), the aorta and all but one 
PV were clamped off and the LA and left ventricle were filled with deionized water. After 
the LA was completely filled the water was drawn out and collected until the water level 
reached the level of the annulus of the mitral valve, which was determined by 
visualization using a fiberscope. The weight of the water was taken and this process was 
repeated a minimum of three times. The right atrium (RA) was measured the same way; 
however the pulmonary artery, inferior vena cava, coronary sinus and posterior 
interventricular vein were closed up and the water was drawn out to the level of the 
tricuspid valve. The siphoned water was weighed and repeated three times. Note, that 
since deionized water was used, the weight of the fluid is equivalent to the volume of the 
chamber.  
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All of the other anatomical measurements that were recorded were obtained using 
standard calipers or a C-clamp micrometer. The thicknesses of the LA were determined 
using the C-clamp at five distinct locations: the center of the posterior LA wall and the 
junction of the right superior, right inferior, left inferior and left superior PVs. The junction 
of a PV was defined as the location in which the vein transitioned into the wall of the left 
atrium. To determine the relative areas of the PVs, the opening of each vessel was 
pinched together to measure half of the circumference (Figure 1.1) and obtain an area 
assuming the vessel is circular. Although it has been found in the literature that the PVs 
are generally oval in shape, it was decided that comparing the vessels as circular would 
alleviate the problem of re-approximating the oval shape of the pulmonary veins. 
Furthermore, in some of these cases, the PV can be slightly distorted due to the nature 
of the fixation process.  
 
Figure 1.1: Illustration of the half circumference measurements taken to obtain diameters and area 
measurements of the various PVs. 
 
The size of the fossa ovalis (FO) in each specimen was also measured; it should be 
noted that since the FOs were not collapsed during the fixation process, we were able to 
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obtain accurate assessment of these structures. These areas were determined by 
measuring the diameters along the superior/inferior and the anterior/posterior direction of 
each FO.  
 
Values presented are mean with standard error unless otherwise noted.  For 
comparisons of continuous variables between two groups a Student’s t test was used. 
 
Results 
Within these investigated hearts, as expected the AF hearts had larger LA, RA and total 
atrial volumes compared to the controls hearts (Figure 1.2). However when we 
compared individual AF heart to their specific sex, age, weight and height matched 
control, there was no clear correlation as to which types of heart had larger atrial 
chamber sizes. Yet, the data did suggest that there was a higher variability within the 
hearts from the AF patients compared to the controls: with a range of 59.6ml to 227.1ml 
in the AF hearts compared to 65.1ml to 115.9 ml in the control hearts. Note that the 
differences in ranges for both atria are over 3 times larger in the AF group than in the 
control group.   
 
Table 1.2: The mean and median values of the pulmonary vein ostia between AF and control heart 
specimens. 
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Figure 1.2: Comparisons of the paired left, right and total atrial volumes between the matched AF 
and control hearts. Note that the AF hearts had greater variability of volumes compared to the 
controls.  
 
As noted above, the sizes of the pulmonary veins were assessed by assuming all as 
circular openings (Figure 1.3). Between the two groups, the control hearts had smaller 
PV ostia for both the left and right veins. One can observe two different peaks on these 
histograms; with the higher peak associated with the data from the AF hearts. This 
finding was consistent also when the right and left PVs were compared separately 
(Figure 1.3). Interestingly, there was also the observed trend that the left PVs were 
smaller than the right PVs in both the control and AF specimens (Table 1.2). Further, 
when trying to determine that the right PVs were larger than the left, while looking at the 
whole population of hearts, there was a significant difference seen between the two 
(mean 171.4 ± 84.6 for right and 118.2 ± 50.1 for left, p < 0.005).  
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Figure 1.3: The relative variation in pulmonary vein ostia sizes between the two groups of heart 
specimens.  The histograms provide the corresponding areas of these ostia.  Top: the relative 
distributions of pulmonary vein sizes of the right pulmonary veins; with means of 24.2mm2 and 21.6 
mm2 and medians of 23.1 mm2 and 19.9 mm2 respectively.  Bottom: the left pulmonary vein areas, 
means of 18.7 mm2 and 19.0 mm2 and medians of 18.4 mm2 and 17.7 mm2 respectively.  The trend 
lines depict the two point moving averages of the distributions and illustrate the relative differences 
between these two heart populations.  
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Although there were observed trends between the relative areas of the PV ostia of these 
two groups, in contrast there were minimal differences in the thicknesses of the LA walls 
within our samples: the means and medians were 1.19mm and 1.24mm for the AF 
population and 1.26mm and 1.21mm for the control population, respectively. The 
histograms and population spreads between the AF and control groups appear to elicit a 
fair amount of overlap; in other words, they appeared similar between the groups and 
were not dependent upon the diagnoses of AF (Figure 1.4).  Similar findings were also 
observed when examining the relative sizes of the FO in these hearts. The FO 
dimensions only had slightly larger sizes in the anterior-posterior (AP) vectors, whereas 
they elicited minimal or no differences in the superior-inferior vectors (SI) (Figure 1.5).  
 
Figure 1.4: Relative distribution of thicknesses of the left atrium between the AF and control hearts. 
These thicknesses values were determined by taking measurements from each of the four 
pulmonary vein junctions in each heart, as well as the center of the posterior walls of the left atria. 
The trend lines depict the two point moving averages of the population distributions. 
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Figure 1.5: Average widths and heights of the fossa ovalis sizes between the two populations of 
hearts. The relative widths of the fossa ovalis were designated as the fossa ovalis anterior-posterior 
(FOAP) measurements and the heights were designated as the fossa ovalis superior-inferior (FOSI) 
measurements (error bars represent the SEs). It was observed that there were no significant 
differences between the calculated averages of the measurements taken of and the distributions of 
the sizes showed similar trends between the AF and control hearts (data not shown).  
 
Discussion 
In the present study we describe novel measurements of relevant cardiac anatomies 
obtained from our unique library of perfusion fixed human hearts.  In this preliminary 
assessment study, we describe approaches to allow for the detailed quantifications of 
specific atrial anatomies.  The presented information provides useful insight as to the 
changes in structure that may occur when the human heart remodels following the 
development of AF, and we plan to continue these studies as our relevant library of 
specimens grows. 
 
Current imaging modalities, including MRI, ultrasound, and CT scans, allow for relative 
approximations of the volumes and sizes of the LA and RA using algorithms available in 
various software packages or by simply estimating diameters. Yet, it is considered that 
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measurements of LA volumes are more accurate than diameter data, especially as a 
given heart dilates, i.e., small increases in diameter will provide for larger increases in 
derived LA volumes [27,28]. Our volume measurements take into account the variability 
of chamber anatomies from heart to heart, and thus resulted in a more accurate 
representation of the total chamber sizes. Therefore, these chamber volumes, along with 
thickness measurements of the LA, were considered to better point to variations in 
anatomies due to a given pathological state.  However based on our data on this 
somewhat small sample size, we could not make correlations as to the clinical state 
based solely on these measurements. Yet, it should be noted that even in the absence 
of AF, large atria are often indicative of other cardiovascular issues [29], thus in these 
hearts we studied from this elderly population of subjects it was likely that the non-AF 
hearts, or so-called controls, may have been not truly normal. 
 
Our initial characterization of these AF hearts confirmed various trends that have been 
reported within current literature, such as the increased sizes of right PVs compared to 
the left PVs [13]. However, as with most anatomical studies a large sample set is 
required so to potentially produce statistically significant results. With our growing library 
of these perfusion-fixed human hearts, we will be able to perform ongoing anatomical 
studies so to better assess the differences within various populations of heart disease 
states or demographics.  Our collection of specimens to date has allowed us to obtain 
useful insights as to the common anatomical features of the atria from patients with AF 
with a high degree of accuracy.  The variety of physical specimens also allows for 
physician education and therapeutic device feedback as any number of devices can be 
placed within the hearts.  The continued study of the details of human cardiac anatomy 
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will provide further insights as to the changes in structure that may occur when the 
human heart remodels or reverse remodels due the presence of disease or following 
treatment, respectively.   Though above study shows that PV measurements are not 
sufficient to diagnose AF, it illuminates the variety of anatomies that accompany the 
arrhythmia within the population.  This large variation observed in the diseased patients 
is important for the physicians who treat AF, the educators, and engineers who must 
design medical devices to fit the whole range of anatomies.  Using the fixed hearts we 
plan to continue to employ the study methods described here to further build an 
anatomical database, which we hope to compare to MRI, CT and 3-D models derived 
from each.    
 
Conclusion 
Atrial fibrillation comes with a great deal of anatomical and physiological changes.  
Anatomically, the size of the atria can vary greatly, but the pulmonary veins and vena 
cavae do not remodel significantly.  The variation in anatomy has great importance and 
should be considered when treating and designing devices for AF.   
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Preface  
With a solid foundation in cardiac anatomy and physiology, I continued my research into 
AF.  While investigating novel aspects of AF and its treatment, intrapericardial (IP) 
delivery of antiarrhythmic drugs provided opportunity for innovation and continued 
research.  Local delivery to the pericardial space also has the potential to reduce the 
variability seen with more conventional delivery routes, as seen in the GLP-1 
pharmacokinetics (study included in appendix). 
 
Chapter two of my thesis begins to focus on localized delivery of drugs, providing an 
overview of targeted drug delivery, with a specific focus on thoracic surgery.  It reviews 
several areas where targeted and localized drug deliveries have the potential for major 
improvements in organ and patient health.  A particular focus is given on drug delivery to 
the pericardial space.  This chapter has been submitted for publication in the book 
Thoracic Surgery, ISBN 980-953-307-096-9, to be published in the fall of 2012 
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Summary 
Localized and targeted drug delivery methods have become expansive areas of 
research in a number of fields including cardiac research. These methods have the 
potential to increase therapy levels at targeted tissues while minimizing systemic 
exposure, and thus reducing side-effects.  The focus of this chapter is to consider the 
local delivery of therapeutic agents to the patient’s heart during a given surgical 
procedure.  Yet prior to the discussion of such, one needs to consider typical routes of 
delivery and the validation studies required to confirm their utilities. This chapter outlines 
opportunities for delivery as well as therapies that are currently being developed to treat 
them.  Within the research field, cardiothoracic surgeons are uniquely positioned to take 
advantage of these new technologies as they emerge thus increasing the effectiveness 
and safety of the therapy while improving post-operative outcomes. 
 
Keywords: targeted delivery, local delivery, pericardium, cardioprotection 
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Introduction 
It is noteworthy to consider that extensive bioavailability and bioequivalence studies are 
typically required before new drug therapies can be approved [1].  These studies include 
pharmacokinetic studies that take into account: 1) dosing, absorption and elimination 
rates of the drug and its active metabolites, as well as 2) the potential effects of multiple 
doses, drug interactions, and the differences whether medications are taken with or 
without food. A major therapeutic factor that compounds the variations often seen from 
patient to patient is individual differences in absorption and elimination rates.  This will 
also cause variations in the amount of drug that reaches the desired targeted tissue 
when used as a clinical therapy. 
 
While oral administrations are common and the easiest means to deliver outside of a 
hospital or clinical setting, intravenous (IV) delivery can eliminate some of the 
aforementioned patient to patient variability by bypassing the ingestion and absorption 
into a patient’s bloodstream.  However, a major obstacle with either of these delivery 
methods is that once a drug is in the blood plasma, the medication will circulate 
throughout the patient’s body, not only reaching the intended site, but unintended sites 
as well. Hence, this will greatly increase the possibilities of causing unwanted side-
effects.  Thus, it is required that side-effects on each and every tissue be well described 
when therapeutic levels of the medication are administered. 
 
Importantly, many drugs have described narrow therapeutic ranges. Slight increases in 
levels could cause severe undesired effects, whereas slight decreases often eliminate 
any therapeutic benefit. We describe in detail here how the targeted and local delivery of 
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medications may overcome many of these obstacles in traditional delivery methods by 
simplifying the pharmacokinetics, reducing variability and allowing higher doses to reach 
the intended target. 
 
Targeted Drug Delivery 
“Targeted drug delivery” is a general term that describes a variety of methods that can 
be used to increase the concentrations of a given drug at a primary location within the 
body relative to others body tissues. Often called “smart therapies,” targeted delivery 
includes methods such as antibody labeling, ultrasonic release and/or localized delivery 
that can increase drug concentrations at the desired tissue. The primary intent is to 
increase the intended beneficial effects while reducing side-effects. 
 
Developments in targeted drug delivery were commonly pioneered with anti-cancer 
drugs.  These treatments are often highly toxic and have undesirable side-effects, which 
in turn can greatly reduce quality of life and limit the dose levels that can be 
administered.  Therefore, if the levels of these drugs can be increased specifically at the 
site of a tumor relative to the rest of the body, the same or reduced dose levels will have 
much greater effects at the site of the cancerous tumor. 
 
One commonly described method for accomplishing such is creating or adding 
components to cancer drugs that preferentially bind within the tumors.  More specifically, 
the identification of differences in endothelial surfaces in the growing tumors has led to 
the development of cancer medications that preferentially adhere to the endothelial 
surfaces within the vasculature of the tumor thus, increasing the desired effects.  This 
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results in lower exposures of non-target systemic tissues to the drug than were 
previously possible.  In a similar manner, numerous biomarkers have been identified that 
become upregulated in diseased cardiac tissue, and therefore have become targets in 
emerging therapies [2], [3].  Alternatively, drug treatments can be encapsulated in such a 
way that they are released at the desired location, such as where triggered by high 
frequency ultrasound, causing focal increases in drug concentrations [4–6].  Table 2.1  
summarizes many currently used and investigated targeted therapies, several of which 
are described in greater detail throughout this chapter. 
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Delivery Method Advantages Disadvantages 
Targeted Drug Delivery 
 Ultrasound or heat 
disrupted carriers 
non-invasive focal 
treatment to potential 
asymmetric areas 
equipment intensive, 
potential buildup within 
liver and spleen 
 Biomarker targeted simple administration 
designer molecules 
need to be created, 
approved 
Localized Drug Delivery 
 Pericardial delivery 
entire epicardium 
treated, well 
contained, easy 
access in surgery 
invasive, pericardium 
often left open after 
surgery  
Direct myocardial/tissue        
injection 
increases myocardial 
concentrations, long 
lasting 
invasive/minimally 
invasive 
 Drug eluting wafers 
long or short lasting, 
tunable degradation 
minimal migration small 
doses, reliant on 
resorbable wafer or 
must be explanted 
 Implantable pump 
local drug delivery on 
demand, larger 
continuous dosing 
possible 
invasive, needs 
refilling, shortcomings 
associated with 
implantable devices 
 Coronary injection 
increases myocardial 
concentrations 
invasive/minimally 
invasive, treatment still 
enters blood 
Table 2.1: Various targeted therapies and their advantages and disadvantages. 
 
Localized Delivery 
“Localized drug delivery” is defined as a specific form of targeted delivery where the 
medication is given at a certain site which allows for reduced movement and subsequent 
absorption into the bloodstream.  Localized delivery is often provided to a naturally 
enclosed space, such as the bladder or into the vitreous humor of the eye, but other 
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techniques can limit movement such as a gel or a patch.  In general, by delivering a 
given pharmacological treatment to a specific target tissue site via an implantable pump 
or acute access, localized therapy will have reduced systemic effects on peripheral 
tissue thereby limiting side-effects, while maintaining increased control.   
 
Just as IV delivery increases control and decreases variability over oral delivery, by 
eliminating the gastrointestinal tract, local delivery increases control and decreases 
variability by eliminating reliance on one’s circulation for distribution.  Thus localized drug 
delivery carries the potential for both increased effectiveness of treatments, while 
reducing the quantities needed (Figure 2.1).  These reductions have important applied 
implications when one employs either drug pumps or impregnated gels to delivery 
therapies, as they can only hold limited volumes. 
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Figure 2.1: Schematic of differences in drug delivery by oral, IV or local delivery modalities.  
Increasing the number of transport steps increases the amount of drug necessary and patient to 
patient variability increases at each step.  
 
Finally, an additional benefit often seen with localized delivery is a relative increase in 
the therapeutic drug half-lives.  For example, since localized treatments typically have 
minimal crossover with the patients’ circulation, there is limited exposure to their livers 
and kidneys, which are typical sites for drug metabolism.  Thus the relative therapeutic 
half-lives of many pharmaceuticals will be increased, which is another mechanism that 
could also decrease the amount of a given agent required to achieve sustained 
therapeutic dose levels [7].  
 
While targeted drug delivery is the focus of broad research, it is our intent with this 
chapter to narrow the focus more specifically on localized therapy and the unique 
Local 
Delivery 
Oral 
Delivery 
IV 
Delivery 
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opportunities provided by the access obtained during thoracic surgery.  For instance the 
pericardium surrounds the heart and provides a unique enclosed volume, in which one 
can target the myocardial epicardial surfaces.  In other words, the localized drug delivery 
to the pericardial space will allow the agent to diffuse into the myocardium while 
reducing those amounts present in the circulating blood.  During cardiothoracic surgery 
one has unique access to this otherwise difficult to reach space where subsequent 
therapy can be delivered throughout the perioperative period. Therefore, as therapies 
emerge to treat heart failure, local delivery during thoracic surgery is positioned to be a 
viable therapeutic option that can be delivered with minimal added time, few 
complications or complexities. At the same time it has the potential to reduce ischemic 
damage and arrhythmias, and hold great potential for improved outcomes, reduced 
morbidities and increased cardiac health. 
 
Known procedural complications and potential therapeutic 
opportunities: 
Cardiac surgery is typically defined by a broad class of surgeries intended to correct 
heart problems.  They can be broken down into several categories that include: 1) valve 
repair and replacements, 2) structural heart repairs, 3) implantations of devices for either 
the maintenance of rhythm or mechanical performance, and 4) heart transplant. Today, 
the most common cardiac surgery is coronary artery bypass grafting (CABG) [8]. Despite 
the recent trend towards minimally invasive cardiac procedures, there still remains a 
significant need for open surgical techniques. Due to the invasive, and many times 
emergent, nature of these procedures they are also excellent candidates for targeted 
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delivery (it should also be noted that many minimally invasive and scheduled procedures 
could also take advantage of target therapeutic delivery of various agents).   
 
It is generally accepted that open cardiac surgery is not without potential complications.  
On the other hand, the occurrences of such complications can be viewed as unique 
opportunities for introduction of localized drug delivery to improve patient outcomes. It is 
important to note that complication rates and outcomes can only be truly assessed on 
both procedural and patient population bases; yet there are often common complications 
across all classes of cardiac surgery. Statistics on the following procedural complications 
and proposed treatments using targeted delivery will be discussed: neurologic, 
arrhythmic, gastrointestinal, bleeding, and infection. These complications when present 
will impact both short- and long-term morbidities and mortalities, i.e., influence lengths of 
hospital stays, quality of life, as well as financial burdens on both patients and healthcare 
providers. 
 
To begin with, neurologic complications such as stroke, postoperative cognitive deficit, 
encephalopathy, and transient ischemic attack are of particular concern because of their 
much feared, potential long-lasting effects. Due to the nature of cardiac surgery and 
cardiopulmonary bypass, it can be foreseen that thrombosis or air emboli may occur 
from time to time, potentially causing these aforementioned complications. Poor 
neurological outcomes may also be caused by or related to arrhythmias, bleeding, or 
other complications. For example, prospective studies on the outcome of CABG patients 
show that the expected stroke rates vary from 1.5% [9] to 5.2% [8]. A broad range of 
disorders fall under the umbrella of post-surgical encephalopathy, a syndrome stemming 
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from many causes.  Its prevalence has been described to vary based on the definition, 
with as many as one third of patients eliciting an encephalopathy post-operatively [10], 
but prospective studies show that by day four the number is reduced to 11.6% [11] 
indicating a transient nature. Expectedly, these complications occur more frequently in 
combined procedures and/or more technically challenging cases.  
 
It should be mentioned that numerous modern surgical techniques, such as the no-touch 
aorta technique, have attempted to mitigate such neurologic complications. However, it 
will likely remain that current advances in surgical techniques may only reduce, but not 
totally eliminate these undesired events. Nevertheless, one can envision the added use 
of tailored drug cocktails with various procedures that could directly target the heart 
(pericardial space) or mixed within the blood returning from cardiopulmonary bypass. To 
date, potential therapeutic agents which have been shown to be effective have 
included:1) oxide scavengers 2) nitric oxide inhibitors [12], 3) agents to inhibit glutamate 
related neural excitotoxicity [13], and 4) the administration of aprotinin, a serine protease 
inhibitor [14]. It is possible that prior to patient rewarming, agents similar to tissue 
plasminogen activator could be administered in a manner that targets or localizes only 
the cerebral circulation and potentially destroys clots that were formed, thus mitigating 
negative effects prior to rewarming. 
 
It is generally considered that atrial fibrillation is the most common complication to occur 
after cardiac surgery, occurring in up to 30% of cases [15]. A recent meta-analysis of 94 
trials by Burgess and colleagues has shown that the five most common interventions 
were all effective at reducing incidence of atrial fibrillation, but to varying degrees. These 
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treatments included beta-blockers, sotalol, amiodarone, magnesium, and atrial pacing. It 
should be noted that amiodarone was the only intervention that was reported to reduce 
stroke on its own. Nevertheless due to the well documented negative systemic effects of 
such antiarrhythmics, several studies have begun to investigate the use of localized 
delivery to the pericardial space, discussed in more detail below. On the other hand, it 
should be noted that the systemic administration of modified agents could also prove 
both effective and avoid side-effects if targeting functionality was incorporated into the 
drug molecule. For example, this could be done by adding cardiac specific antibodies or 
ligands to therapeutic molecules. Nevertheless, such newly developed drug isoforms will 
require additional regulatory approval, perhaps only after clinical studies prove them safe 
and effective.  
 
Gastrointestinal complications after cardiac surgery are less common, but importantly 
are associated with high rates of morbidity and mortality. Reported incidences are in 
range of <1% but mortality associated with this complication were approximately 25% 
versus approximately 3% without gastrointestinal complications [16], [17]. The most 
common of these complications include: upper intestinal bleeding, intestinal ischemia, 
acute pancreatitis, and perforations.  
 
Despite the use of modern-day antibiotics, infection still remains a prevalent problem in 
cardiac surgery, as does administration of blood products. The two are commonly 
interrelated and it has been shown that transfusions of packed red blood cells(PRBCs) 
are significantly associated with postoperative infections [18]. However, this correlation 
does not necessarily imply causation, and the use of PRBCs may be related to 
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procedural difficulties, which may be the real underlying causation of such infection 
rates. It should also be considered that stored red blood cells also do not function 
normally and therefore, PRBCs may contain inflammatory and immuno-mediating 
substances. It was reported in a CABG patient series study at Duke University, that as 
many as 39.5% of patients received PRBCs [18]. Furthermore, out of the entire series, 
the postoperative infection rate was found to be 6.2% and specifically for those patients 
whom received PRBCs, they elicited infections rates ranging from 6-8.1% versus 5.1% 
for those who received no PRBCs [18]. Additionally, in a recent five year study on long-
term survival following transfusion for CABG procedures, it was observed that patients 
not transfused have an approximately 2.5-fold better survival rates than those that did 
[19].  
 
Interestingly, it has been proposed that actively targeted treatments could possibly 
restore normality to the RBCs prior to administration; such treatments could also 
incorporate anti-infection components. As mentioned above, RBCs can change 
drastically and immediately upon storage. It is considered that due to the low oxygen 
environment within the blood collection bag, RBCs switch to anaerobic metabolism, 
which in turn leads to lactic acid buildup and an overall reduction in blood pH. 
Furthermore, it is known the RBCs lose their signature bi-concave shape and become 
more spherical with storage: recall that it is this bi-concavity that is necessary for the 
cells to efficiently travel through capillary networks. Stored RBCs will also form 
aggregates due to activated surface proteins by crosslinking fibrinogen between 
GPIIb/IIIa binding sites [20]. This crosslinking increases the longer PRBCs are stored 
and potentially could contribute to neurologic complications and thus post-operative 
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cognitive deficits. Therefore, one could consider that prior to infusion of PRBCs, a 
targeted drug cocktail could be added to prevent or break these fibrinogen crosslinks 
and/or suppresses immuno- and inflammatory effects. 
 
Finally, one should also consider that infection rates could potentially be reduced by 
localized drug delivery at the end of a given cardiothoracic surgical procedure. For 
example, one such method might take form of an antibiotic that could be sprayed on or 
within the thoracic cavity immediately prior to and after closure of the surgical entrance 
site.  Such an application method may also have the potential to reach interstitial areas 
that are at risk for infections, specifically those with inherently minimal blood flows; in 
other words, these tissue areas would otherwise receive minimal amounts of orally or 
intravenously administered antibiotics. 
 
Other drug targets 
With recent advances in microfabrication it is feasible to locally deliver drugs in ways that 
were previously not possible. The field capsule endoscopy is a good example of these 
technologies and also one that may be further miniaturized and exploited for drug 
delivery. “Capsule endoscopy” is the swallowing of a pill with a video camera inside. The 
pill travels through the gastrointestinal system and records its journey. Even more 
sophisticated versions of these devices are being developed to be actively propelled by 
magnetic energy [21] or flagella type [22] propellers. It should also be noted that 
magnetic pills for drug delivery are currently under development as well [23]. One should 
consider that these novel technologies may also be exploited for cardiac use.  For 
example, a patient could have a magnetic pill guided endovascularly to the heart and 
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anchored to the endocardial surface where therapeutic (biologics or drugs) agents 
released. Furthermore, one could even envision that the administration of these 
therapeutics could be controlled wirelessly and facilitated by micropumps and valves.  
 
In the near future, it is considered that drug eluting microfabricated devices with 
incorporated biosensors could be implanted locally such that they release drugs in 
response to given physiological stimuli. For example, a small sphere, capsule, or micelle 
containing insulin producing cells could be implanted in the pancreas, subdermally, or 
intramuscularly.  The cells could then respond to fluctuations in glucose levels 
automatically.  Extensive research has gone into such closed loop systems for insulin 
delivery for diabetes patients, with the eventual goal of an artificial pancreas [24–27]. In 
the more distant future, genetically engineered cells could be programmed to produce 
other drugs as needed and subsequently deliver them at the proper rates or in response 
to particular stimuli. Furthermore, unlike implantable devices, such as drug eluting stents 
that can only deliver drugs for a few years, these cell-based drug producing devices 
have the potential to last a lifetime.  
 
It is generally considered that delivering therapeutic agents at or near the entrance to 
coronary arteries would be particularly useful in certain clinical situations. Such a 
delivery methods could then exploit the natural capillary system to perfuse the drug to 
the entire heart. This could in turn potentially reduce the amounts of drugs needed 
significantly and may also ameliorate undesired side-effects known for systemic 
administrations. In another approach, during surgical operations deployed degradable 
microcapsules with tuned drug release profiles could be injected into the myocardium 
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adjacent to the coronary arteries. Alternatively, resorbable patches could be adhered 
over the main coronary arteries and the therapeutic agent would then diffuse into the 
vessel and be transported to the entire organ. In addition, a delivery patch could also be 
adhered to local areas, such as one doped with angiogenic treatment placed on an 
infarct zone. 
 
In the future, combinatorial therapies could also be extended beyond current clinical 
practice such as drug eluting stents and pacing leads. This is an area of great 
opportunity for local drug delivery advancements. For example, ventricular assist 
devices could incorporate the ability to passively or actively deliver a variety of therapies. 
As such, their possible approaches and advantages may improve the use of these 
devices, e.g., when they are being used as a bridge to transplant or recovery.  
 
It should be noted that the direct injections of drugs, proteins or cells into the 
myocardium have also been proposed as a method of local delivery [28–31]. More 
specifically, these could be localized in areas of infarct or near atherosclerotic plaque 
deposits to aid in restoration of normal function. To date, it is noteworthy that positive 
results have been observed with injections of adenoviruses encoding for heat shock 
protein [28] or growth hormone [29], [30] in rabbit and rat models, respectively.  
Furthermore, clinically, gene transfer by direct injection of plasmid DNA coding vascular 
endothelial growth factor (VEGF) into ischemic myocardium has promoted angiogenesis 
[31]. 
 
  35 
It should be described for completeness that transmyocardial laser revascularization has 
been applied clinically to patients with inoperable coronary artery disease and often 
applied in conjunction with CABG. This procedure utilizes a laser to perforate the walls 
of the heart in areas of poor perfusion. The channels created act as conduit for blood 
and during healing neovascularization was also considered to improve perfusion. 
Perhaps this approach, if considered an option, could be supplemented with adjuvant 
use of local therapeutic agents to quicken the vascularization process, such as VEGF, or 
other therapeutics to potentially restore normal function. 
 
Alternative local delivery methods 
To date, numerous drug pumps and other devices and methods for delivering treatment 
to a localized area or region of the body have been shown to be successful. As 
mentioned previously there is a considered difference between a local delivery and a 
targeted delivery of treatments. Additionally, it is also possible that various therapeutic 
approaches incorporate one or both of these methods, in order to maximize the 
beneficial effects of the therapy and minimize the adverse side-effects.  
 
One such method, which has been studied significantly, is to create a polymer or 
biological scaffold in which the drug/protein has been imbedded.  Subsequent release is 
then dependent upon either degradation of the scaffold or diffusion of the drug out of the 
scaffold. Currently, there are such clinical devices available, such as the Gliadel® wafer, 
which is impregnated with a chemotherapy drug and used following surgical resection of 
cancerous tissue within the brain [32], [33]. Note that these drug delivery platforms have 
been made from a number of different polymers, synthetic or natural. Ultimately it is 
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considered that whichever material is used, it must be biocompatible and able to 
dispense the drug at appropriate rates for the desired particular treatment. Currently, 
such products have been developed relative to the treatments for cancers, which have 
included polymer structures for subcutaneous or intramuscular placements. More 
recently, similar scaffolds have been created for the treatment of cardiac diseases, but 
these are still within the research phase of the design.  
 
Myocardial patches, often made of a gel, collagen or other biocompatible material, are 
typically impregnated with stem cells or protein growth factors meant to diffuse into the 
heart to promote myocardial growth and revascularization.  These are placed locally on 
infarcted areas of the heart.  Alternatively, the scaffolds could be designed to promote 
growth within their structure, becoming a functioning part of the myocardium. If the 
device/scaffold is made such that it requires stem cell infiltration in an in vitro setting, it 
can be incubated with the particular cells needed prior to implantation onto the cardiac 
structure [34]. Both of these methods illustrate how tissue engineering approaches could 
be utilized to locally deliver drugs or therapies to the heart, however there are other 
mechanical devices that also allow a physician to deliver drugs directly to the site of 
interest.  
 
Localized Injections and Drug Pumps 
When discussing localized treatment of tissue, a method to deliver the treatment to a 
specific region of interest is essential. Various methods have been reported in the 
literature from simplistic methods of direct injections of the drug to the localized area to 
be treated, to the use of more complex microelectromechanical systems (MEMS). The 
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method for direct injection of a treatment into a specific diseased area is a fairly 
simplistic idea; however, the means to deliver a needle and treatment to the heart may 
pose a significant challenge. Current research is investigating injecting into the 
myocardium via angioplasty balloons to reduce the occurrences of restenosis. More 
specifically, small pores or openings within a catheter deliver gene therapy or alternative 
drug treatments to the diseased cardiac cells [35], [36]. Likewise a given drug can be 
coated directly onto the exterior surfaces of a balloon, i.e., when the angioplasty is 
performed the coating rubs off on the wall of the vessel to provide therapy.  Recently, 
Scheller and colleagues demonstrated that such a device was able to decrease the 
incidence of restenosis significantly [37]. Stents themselves can also be thought of as a 
method for localized delivery of a drug to a site specific location. This approach has 
been well developed and tested: drugs like paclitaxel have been coated onto the outside 
of a coronary stent so to minimize restenosis that can occur at sites of the stent 
implantation [38]. 
 
Other treatments that might be given to a patient may need to be localized but cover a 
greater area than a single location along an artery or vein. For those purposes, devices 
such as MEMS or osmotic pumps could perhaps be utilized to slowly delivery treatment 
to a specific site continuously or intermittently and with varying rates; i.e., delivery could 
last from days to months. When considering drug pumps, they generally fall into one of 
two categories, passive or active. The passive pump approach can be thought of as 
being similar to the gels or wafers discussed previously; however instead of the drug 
being imbedded within the polymer, it would be within a chamber that would be opened 
once the polymer had been degraded enough to release it. To date, multiple designs 
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have been implemented including multiple wells in a row with differing polymer closures 
to release at different times, as well as multiple chambers to release two different types 
of drugs simultaneously. As one could imagine the only limitations to these types of 
designs are the properties of the polymers and the size of the device [32], [39].  
 
One specific design described for a passive system is fairly unique, is the use of osmotic 
pressure to push out the drug from an almost syringe like device. These work on the 
principle that water will diffuse one way across a semipermeable membrane and 
increase the pressure on one side and thereby pushing out the drug slowly [39]. These 
types of devices have also been modified slightly to create pulsatile drug delivery 
pumps, i.e., in one case, a membrane was setup and had immobilized glucose oxidase 
which converted glucose to gluconic acid [40]. This causes an ionic change in the 
membrane and the electrostatic repulsion of the membrane causes an expansion and 
increased delivery of insulin. This has the added benefit of the ability to adapt to the 
specific needs of the patient at various times of the day, depending upon glucose and 
levels within their system [40].  
 
Another type of the MEMS approach for agent delivery is to release a bolus from a small 
reservoir; initially these devices relied on an electrochemical dissolution of a gold 
membrane blocking a reservoir of a solution. However, a number of published studies to 
date have reported that this approach could not be performed reliably, so it was modified 
to a localized melting of the gold membranes by resistive heating [32]. Another approach 
of an active delivery pump has been employed for patients with chronic pain, e.g., a 
pump with a reservoir filled with a pain medication can be implanted with a catheter 
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leading directly into the spinal column or other neuronal targets. It should be noted that 
more recently the ability to refill these devices has been greatly improved and this is an 
advantage over MEMS devices that cannot refill, however the size of the former devices 
are currently much greater [41]. Nevertheless, both of these types of pump systems 
have their own specific purposes, yet both intend to deliver a drug treatment to a 
localized area within the body to help reduce the effects of the drug on other organs or 
nearby healthy tissue.  
 
 
Ultrasound and Lipisomal Delivery Approaches 
Another delivery technique is encapsulating agents for release in specific areas.  As 
opposed to the local delivery pumps described above, where a drug is released into a 
specific location within the body, generally these packaged therapies can be 
administered intravenously with targeted release. In these cases, the drug will circulate 
throughout the entire body, but importantly the targeted drugs have been altered in a 
way to make them either: 1) released at a specific site, 2) preferentially bind within the 
diseased area, 3) be more readily taken up by the target cells, 4) preferentially released 
slowly over time or 5) any combination of these attributes. Ultimately the aim is to 
increase the effectiveness of the treatment whilst decreasing the toxic systemic effects 
of the drug.  These approaches can be considered compatible with localized delivery, 
especially in the setting of thoracic surgery.  For instance, a targeted drug could be 
infused into the coronary arteries, compounding the targeted design with local delivery. 
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Another specific way that investigators have been able to achieve the targeted delivery 
is by using liposomes that encapsulate the drug, relying on active or passive targeting of 
tissues to be treated. First, it can act passively, relying on various cells to uptake the 
liposomes, e.g., reticuloendothelial cells, which can be found concentrated within the 
liver and spleen. Thus if the treatment was designed specifically for cells within the liver 
or spleen, a passive approach might be found to be quite acceptable. It should be noted 
that this same approach has been discussed within nanoparticle delivery as well, taking 
advantage of the fact that the vasculature within tumors can be porous, allowing the 
nanoparticles to accumulate within the tumor region.  It is still important, however, to aim 
to limit peripheral exposures, since such liposomes may still be taken-up within the liver 
and other filtering organs [39], [42].  
 
More specifically an active targeting paradigm could be achieved by placing a 
recognition sequence on the outside of the liposome, so to develop ligand-receptor 
interactions that will in turn bind the carrier to the targeted cells. As such, these could be 
targeted to specific proteins or to biomarkers that are upregulated in specific tissues, like 
tumors or portions of the myocardium responding to ischemia or heart failure [2], [3]. 
One needs to consider that these modified liposomes may be still taken up by the liver, 
spleen or other non-targets; however, some specified modifications of the developed 
lipid layers may minimize uptake in these structures [42].  
 
Another reported means that treatments may be delivered to target specific cells is via 
microbubbles aided by ultrasound disruption. More specifically, the microbubbles can be 
formed by air or other types of gas and introduced into the bloodstream similar to those 
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techniques utilized in ultrasound imaging with contrast. Note that air bubbles are more 
readily dissolved into the blood following introduction into the venous system, giving 
them a shorter lifespan. By using perfluorocarbon gases the lifespan of the delivery 
bubbles increase and they can also be coated with a variety of materials including 
polymers, lipids or proteins which will also increase the lifespan even further. These long 
lasting microbubbles can then be disrupted by focused ultrasound—a trigger that can be 
applied nearly anywhere in the body [4–6]. It is considered that the ballistics of the 
cavitation not only disrupts the integrity of the bubble, but it will also momentarily disrupt 
the plasma membranes of the target cells, allowing for the drug and/or microbubbles to 
be passed through [43], [44]. While that this approach has resulted in detrimental effects 
on cardiac mechanical function [45], it has been shown to effectively increases 
absorption of certain drugs [46].  Alternatively, the capsules can be designed to release 
their therapeutic payload with a slight increase in temperature that can be triggered by 
local heating [47].   
 
Pericardial delivery 
It has been noted that the pericardium provides a unique space that holds a vast 
potential for localized drug delivery.  For example, such pericardial approaches may 
range from: 1)the delivery of preconditioning therapies during surgical preparation, 2) 
providing for therapies that promote vascular genesis after CABG, and 3) the 
prophylactic administration of antiarrhythmic agents in order to prevent postoperative 
AF.  We consider here the possible treatments for the myocardium are numerous and 
will provide a few specific examples below, but first we will review one’s pericardial 
anatomy. 
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Anatomy of the pericardium. 
The pericardium is made up of two connected structures.  The innermost layer is serous 
membrane, which is inseparable from the epicardial surface, is called the “visceral 
pericardium.” The continuous serous membrane is folded in on itself and the single layer 
also makes up the inner surface of the parietal pericardium.  The single layer of 
mesothelial cells is indistinguishable from the fibrous outer layer (Figure 2.2).  Together, 
the parietal and fibrous layers make up the outer layer, or “parietal pericardium.” This is 
the most prominent layer of the pericardium and is what we generally think of when we 
discuss the pericardium.   
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Figure 2.2: Schematic of the layers of the pericardium. The upper right shows a schematic diagram 
of the serous and fibrous pericardium is shown with respect to the heart. The expanded cross-
section view shows the attachment of two layers of the serous pericardium (visceral and parietal) to 
the myocardium and fibrous pericardium, respectively.  
 
The healthy pericardium contains between 20-60mL of pericardial fluid.  This fluid, an 
ultrafiltrate of the plasma [48], surrounds the heart, with the majority in the pericardial 
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sinuses and atrioventricular grooves.  This fluid normally drains into the lymphatic 
system at a relatively slow rate, measured to be a volume equivalent every 5-7 hours in 
sheep [49].  However, as pericardial fluid pressure increases, such as in the case of 
“cardiac tamponade,” investigators have found that not only does lymphatic drainage 
increase [50], but fluid may pass through the pericardium and enter the pleural space 
[51]. 
 
Though the volume of pericardial fluid is not evenly distributed, it is generally found to be 
well mixed due to the motion of the heart; thus agents can be considered to be quickly 
and evenly dispersed throughout [49].  Even though there is only a relatively small 
amount of fluid circulating around the ventricles, this aforementioned mixing action will 
help maintain even distribution of any additions to the pericardial fluid epicardially, thus 
maintaining consistent gradients relative to the myocardium. While the parietal 
pericardium is generally considered as non-compliant, the overall pericardial space can 
accommodate moderate increases in the amount of fluid by filling in the pericardial 
sinuses.  However, once this reserve volume space is filled, pericardial pressure quickly 
increases with added volume, i.e., symptomatic tamponade is elicited (). 
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Figure 2.3: Percardial pressure vs. pericardial volume. As pericardial fluid volume increases, the 
pericardial reserve volume is filled. Once the reserve volume is full, pressure within the pericardium 
rapidly rises causing cardiac tamponade and functional depression. 
 
The basic physiology associated with the pericardium 
The fibrous (parietal) pericardium is 1-3 mm thick in healthy humans, and as note above 
it is considered as minimally or non-compliant.  In fact, because of these features, 
multiple bioartificial replacement heart valves are made with leaflets of either bovine of 
swine pericardium.  As such, this tough layer has the primary function to physically 
constrain the heart.  While this may not have a large influence at rest, during physical 
exertion, cardiac filling becomes limited by the pericardium. Further, it has been noted 
that an intact pericardium also increases cardiac chamber interdependence, i.e., 
increased pressure in one chamber affects other chambers because the total volume is 
restricted by the pericardium.  A more detailed review can be found in the Handbook of 
Cardiac Anatomy and Devices [52].   
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Typically during cardiothoracic surgery, the pericardium needs to be opened so to obtain 
direct myocardial access and at the end of a procedure, the pericardium is not typically 
closed.  This in turn reduces the risk of post-surgical cardiac tamponade, as pressure 
cannot build up easily in an open pericardium.  However, the lack of a barrier between 
the heart and the healing incision site typically leads to scaring and epicardial fusions 
within this wound site.  Typically, this has minor consequences—that is until a 
subsequent open heart procedure needs to be performed, and both the initial incisions 
and heart access are complicated by these additional fibroses. It has been suggested 
that a barrier placed between the sternum and myocardium (with or without bypass 
grafts), would potentially limit the buildup of subsequent adhesions and make reentry 
less risky.  While synthetic barriers such as the absorbable CovaCard (BIOM’UP, Lyon, 
France) are being developed [53], the native or graft pericardium also may provide a 
natural and available option. 
 
Relative to physiological consequences, in addition to reducing reoperative 
complications, the closure of the pericardial sac following cardiac surgery has been 
proposed to reduce long term cardiac performance and aid to maintain diastolic 
functions and ventricular geometries, as well as reduce right ventricular dysfunctions 
[54], [55].  Additionally, one could also consider that a closed pericardium may also 
provide a reservoir space for subsequent pericardial therapies.  Yet, one reported 
limitation to pericardial closure is that it can acutely reduce cardiac indices and stroke 
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work [56].  More specifically, Rao et al. corroborated that these functions were reduced 
one hour postoperatively in patients who had pericardial closure (P<0.001).  However, 
they also reported no significant differences in functions between patient groups at 4h or 
8h postoperatively.  While increased risk of cardiac tamponade still exists with full 
closure, it has been reported that fenestrated techniques and pericardial drainage tubes 
have been used to mitigate the consequences of pericardial effusions [57], [58]. 
 
In summary the pericardial space potentially provides a natural barrier and is well suited 
for localized drug delivery.  Thus if pericardial access could be easily and reproducibly 
obtained, the possibilities of long- and short-term treatments include: antiarrhythmic 
therapies, the delivery of agents to reduce cellular injuries at reperfusion and/or the uses 
of angiogenic proteins to promote revascularization and regrowth specifically within 
infracted regions. 
 
Cardioprotective agents 
To date within the US, ischemic heart disease and myocardial infarctions remain as 
leading causes of clinical morbidities and mortalities.  Their occurrences often lead to 
congestive heart failure, which in turn causes further reductions in coronary flows and 
the necrosis in the myocardium and leads to further functional impairments. It is 
generally considered that compared to other body tissues, myocardial cells have poor 
regenerative abilities: a fact that has focused much research on methods for reducing 
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trauma and/or myocardial death, as well as methods for improving repair and 
regeneration. 
 
It has been reported that the local infusion of nitric oxide donors could promote local 
vasodilation without major systemic effects [59].  Additionally, the administration of 
vascular endothelial growth factor (VEGF) and other angiogenic agents into the 
myocardium have been associated with several benefits that include increased collateral 
vessel developments, increases in regional myocardial blood flow, improved myocardial 
functions in the ischemic regions, and/or increased myocardial vascularity [31], [60–62]. 
 
Relative to such, our laboratory has observed that intrapericardial delivery of omega-3 
polyunsaturated fatty acids can dramatically reduce both infarct sizes and ventricular 
arrhythmias associated with ischemia.  More specifically in this study, acute ischemia 
was induced for 45 minutes followed by 180 minutes of reperfusion while the omega-3 
fatty acid DHA was delivered to the pericardial space prior to ischemia as well as the 
initial period of reperfusion.  Importantly during the ischemic period, ventricular 
arrhythmias were reduced 50% (which in the control hearts require defibrillation and 
cause 20% mortality).  Upon completion of the reperfusion, the hearts were excised and 
ischemic damage was measured: hearts treated with DHA had a similar area at risk, but 
an 57% reduction in normalized infarct size was seen [63].  Ongoing research in our lab 
also suggests that omega-3 fatty acids may also reduce susceptibilities to AF during 
cardiac surgery. 
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Most recently, investigations in our laboratory have dealt with the pericardial delivery of 
specified bile acids noted to have anti-apoptotic benefits.  These molecules are 
upregulated within hibernating black bears and reports by others have suggested that 
ursodeoxycholic acid may be beneficial in reducing AF within myocytes [64].  In these 
ongoing studies to determine the potential beneficial effects within a large animal model, 
we specifically deliver a taurine conjugate of ursodeoxycholic acid within a formed 
pericardial cradle (the pericardial space) and periodically induce AF. Preliminary results 
have suggested that these molecules are effective in reducing the times a given heart 
will elicit AF: i.e., without having to give this therapy intravenously and thus potentially 
have undesirable systemic side effects (unpublished data).  
 
Antiarrhythmic agents 
Antiarrhythmic drugs are commonly known for their narrow therapeutic ranges and 
severe side-effects.  It has been previously suggested that delivery of these agents to 
the pericardial space would allow for myocardial diffusion while lowering undesired 
plasma drug concentrations [65], [66].  In other words, such a local delivery allows for 
higher doses of this class of agents to be safely administered to control focally the heart 
rhythm—an application  that could be especially applied during cardiothoracic surgery.  
To date, the intrapericardial delivery of antiarrhythmic agents has been attempted with 
numerous agents, e.g., esmolol [65], solatol [67], atenolol [67], ibutalide [68], 
procainamide [69], [70], digoxin [69], amiodarone [71], arachadonic acid [72], 
nitroglycerin [59] and L-arginine [73] have all been shown to have electrophysiological 
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effects when delivered to the pericardial space in various animal models.  Additionally, in 
those studies that also measured plasma concentrations, they showed minimal 
crossover of the delivered agent into the bloodstream [69–71] 
 
To date, despite these reported successes in treating arrhythmias in various animal 
models, the clinical practice of intrapericardial (IP) delivery is not widely employed.  
Possible reasons include:1) the lack of experience (no large clinical trials), 2) difficulties 
with access and removal of agents and/or 3) unknown potential complications with this 
delivery route.  It is important to note that one of the described major concerns with 
pericardial delivery is that it relies primarily on trans-epicardial diffusion to reach the 
myocardium.  In other words, while the thin atria and superficial SA node may be easy to 
treat via these mechanisms, the effects of possible ventricular drug gradients are not 
well defined.  Further, it has been hypothesized that moderately soluble or lipophilic 
molecules will not be evenly transported across the thicker ventricles, causing various 
degrees of electrophysilogical changes through the depth of the myocardium, creating a 
scenario where the epicardium and endocardium are not conducting and/or contracting 
at similar rates.  This electrical heterogeneity theoretically carries the possibility of 
initiating, rather than inhibiting, arrhythmias [70]. 
 
In our lab, we have investigated the pharmacokinetics and pharmacodynamics of IV and 
IP delivery of metoprolol [7].  While the β-blocker is typically used to treat angina and 
hypertension, it is also used to treat tachycardias.  With a tachycardic pig model, IV 
delivery of metoprolol was faster acting compared to IP, but only by several minutes. 
While the reductions in heart rates were similar for both, these effects were sustained 
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longer after IP delivery.  Importantly, IV delivery was accompanied by significant 
reductions in contractility, while IP delivery elicited minimal effects.  In other words, these 
findings indicated that IP deliveries of metoprolol may have similar bradycardic effects 
compared to IV deliveries, but without the reduced contractility. The other important 
finding in this study was the minimal pericardial crossover of metoprolol within blood, as 
well as the slightly increased half-life of the drug [7]. 
 
Clinical Pericardial Access 
Access to the pericardial space for the delivery of therapies, outside of cardiothoracic 
surgical procedures, may pose many difficulties.  However, multiple minimally invasive 
procedural methodologies are under development.  For example in the trans-atrial 
approach, access to the pericardium is achieved via a catheter coming up through the 
femoral vein into the right atrial appendage, where it then punctures through this thin 
myocardium to gain access into the pericardial space.  To date, success with this 
approach has been demonstrated in canines and swine [74].  Alternatively, a subxyphoid  
access procedure has been suggested [75].  While this method is often used to drain the 
pericardial space during episodes of cardiac tamponade, the minimal separation 
between the fibrous pericardium and the epicardium make this approach more difficult 
when there is not a substantial amount of intrapericardial fluid present. Several access 
tools have and continue to be developed to aid in subxyphoid access using minimally 
invasive access.  For instance, the PeriPortTM (Cormedics, TX) system is designed so to 
initially enter the thoracic space through a subxyphoid incision where it uses a vacuum 
on the distal end to grip the pericardium and separate it from the heart’s epicardial 
surface.  Once the pericardium is pulled into the vacuum chamber, a retractable needle 
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pierces the pericardium and allows for a near tangential entrance of a guidewire. Such 
designed access tools should enhance both the safety and simplicity of pericardial 
access and also have potential to increase the widespread use of localized therapies to 
treat pericardial and cardiac diseases.  Nevertheless, during cardiothoracic surgery, a 
simple syringe or perfusion pump is all that is clinically needed to delivery pericardial 
therapies.  Thus the hurdles to add localized pericardial delivery of drugs concurrent to 
surgery are much less compared to pericardial therapies on their own.  
 
Figure 2.4: Methods of pericardial access include the pericardium as a reservoir.  Pictured here is a 
pericardial cradle in a swine model.   
 
Protocols 
As noted above, the pericardial delivery of molecules, cells, nanoparticles, etc, becomes 
simplified with surgical access (Figure 2.4).  Without the requirement of added 
procedures and incisions, the pericardial delivery of therapeutics can be administered 
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with minimal additional equipment, time or complications, leading to numerous clinical 
scenarios that may benefit from for the use of pericardial delivery. While some of these 
applications, as described below, have gone through pilot studies in animals, future 
clinical studies have yet to be developed to confirm efficacy. 
 
In one such application, a common first choice of donor vessel for a CABG procedure is 
the internal thoracic artery.  Thus, while the surgeon initially frees and prepares this 
vessel for subsequent grafting, the pericardial administration of either a prophylactic 
antiarrhythmic or angiogenic agents could be infused into the pericardium.  Once the 
artery has been prepared and the pericardium is further opened, the drug will have had a 
chance to partially diffuse into the myocardial tissue.  Additional drug could also be 
added through direct myocardial injection to promote revascularization or prevent 
postoperative arrhythmias.  Alternatively, a procedure that requires access from the 
anterior surface of the heart may make use of the reservoir created by the remaining 
pericardium to treat the posterior myocardium during the procedure.   
 
Another important approach to consider is the postoperative administration of drugs, 
which could be accomplished via surgically placed transdermal drainage catheters.  
More specifically, with the placement of drainage catheters and temporary pacing leads 
at the end of a procedure, the addition of a catheter leading into the pericardium is 
sometimes included [76].  This catheter, whether through the main lumen or a second 
lumen, could hypothetically allow for continued access to the pericardial space and 
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delivery of appropriate antiarrhythmic, antibiotic, or other therapies to the myocardium.  
Therapies with such devices have been attempted with success in a porcine model [77]. 
 
As mentioned above, multiple techniques exist for low or no tension pericardial closures 
[58], [78], [79].  In addition to the reoperative benefits, the planned closure of the 
pericardium can create a useful reservoir for localized treatment. While the most 
common clinical reason for non-closure is to reduce the risk of cardiac tamponade, this 
could be mitigated with the placement of the aforementioned specially designed 
drainage/therapy delivery catheter.  We also believe that with full pericardial closure and 
access via the pericardial drain, a delivered therapy would reach all surfaces of the 
heart. 
 
Another clinical situation/option for localized drug delivery might be during 
cardiopulmonary bypass procedures.   To arrest the heart and often throughout the 
procedure, cardioplegia solutions are perfused through the coronary vessels.  Whether 
antigrade or retrograde, this perfused solution cools and protects the heart by minimizing 
metabolism.  It has been considered that myocardial damage can be further reduced by 
introducing cardioprotective agents via this delivery route [80–82].  It is important to 
note that in this unique situation, any administered drug reaches the entire myocardium 
via the capillaries, but will have no access to other tissues until after cross clamping is 
released.  In other words, high transmural and widespread myocardial concentrations 
can be achieved with remarkable speed and accuracy while minimizing side effects. 
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Similarly, organ transplantation offers ultimate accessibility in localized drug delivery. A 
typical transplant includes explant, transportation and re-implantation.  Because of the 
pre-explant recovery of additional organs, localized delivery is a viable option where the 
effects can be greatly enhanced post-re-implantation function.  Not only are options such 
as pericardial delivery still available, since the heart is typically the last organ removed, 
IV therapies just prior to cross-clamping become targeted.   
 
Next, the times between explant and implant can range from under six hours for hearts 
to up to 24 for the liver or kidney.  During these times, the heart is often in stagnant cold 
storage.  However, ideas and methods for continuous perfusion during the hypothermic 
period are almost as old has heart transplantation itself, e.g., continuous hypothermic 
perfusions (CHP) of the heart was first applied only a year after the first successful 
human heart transplant [83].  Since then it has been shown that it is possible to keep 
large mammalian hearts viable for up to 48 hours in baboons and swine [84], as well as 
improving functions compared to non-perfused hearts [85].  While CHP is not used 
clinically with heart transplant, it should be noted that the Organ Care System 
(Transmedics, Andover, MA) gained investigational device exemption status in 2007, 
and a clinical trial is currently underway.  This continuous perfusion during transport 
before implant provides another opportunity for localized therapies, as they could be 
simply added to the perfusates. 
Potential limitations of local and target deliveries 
Localized delivery methods such as those into the pericardial space are not without their 
potential limitations.  Without direct access to the bloodstream, an administered agent at 
a target tissue such as in the pericardial space must diffuse into the target tissue to 
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increase concentrations.  While this may ultimately limit the depths or distances a given 
therapeutic agent (drugs, cells, nanoparticles, etc.) might be able to migrate in a 
significant quantity, it is also one of the major advantages of localized therapies.   
 
Some areas for localized treatments, especially within the myocardium, may be 
considered as relatively difficult to access.  However, with a large number of cardiac 
surgeries currently being performed and an increasing number of catheter procedures 
being developed and implemented, these discussed therapeutic methods could 
piggyback on these procedures with few added complications or risks.  Finally, novel 
therapeutic deliveries, drugs or other interventions may need to go through additional 
approval in order to gain indication for localized delivery.  
 
Conclusions 
Cardiothoracic surgeries in themselves may allow for novel opportunities for local drug 
delivery, such as overcoming the hurdle to obtaining pericardial access.  Such clinical 
procedures also provide opportunities for localized injections or coronary infusions. The 
future opportunities for such therapies are not limited to the duration of the operation: by 
leaving a pericardial drainage catheter with delivery features, physicians could also 
incorporate subsequent therapeutic delivery.  In some cases, implantable drug pumps or 
biodegradable patches could provide therapy to the patient beyond their ICU stay.  The 
emerging field of localized therapy delivery shows great potential, but future human 
studies are needed to verify the positive results observed in pre-clinical studies.  
Nevertheless, the unique access afforded by cardiothoracic procedures may speed up 
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implementations of these promising local and target therapeutic delivery methods, thus 
placing surgeons at the cutting edge of these novel delivery approaches. 
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Preface  
In this chapter, I focus further on pericardial delivery, comparing pharmacodynamics and 
pharmacokinetics of intrapericardial (IP) delivery compared to the more conventional 
intravenous (IV) delivery.  While several surgical and minimally invasive methods were 
attempted in preparation for this study—including percutaneous and subxyphoid 
access—the most reliable and repeatable model we developed takes advantage of the 
pericardial access obtained during surgery.  This open chest model not only provides full 
access to the pericardial space, but also allows for easy epicardial lead placement for 
electrophysiologic monitoring. 
 
In order to develop an effective model, numerous stimulation protocols were attempted 
to induce AF.  The two second burst pace at 50Hz proved to be most effective.  This 
burst pace put all animals into AF for at least a few seconds, with about 10% if the 
animals maintaining AF for more than one minute, which we defined as “sustained.”  
When this stimulation is repeated several times, almost 50% of animals had a sustained 
episode, giving a comparison point if a treatment could reduce total AF. 
 
In order to perform this study, an acute model of sinus tachycardia was developed.  
Since a physical method such as a hemorrhagic model was deemed too risky, a 
pharmacological method was used.  Epinephrine effectively raised heart rates, but the 
excessive pressures made such a model risky as well.  Isoproterenol, however, proved 
to be a much more sustainable agent.  Using this beta-agonist, it was possible to titrate 
the heart rate to just above 180bpm for 60-90 minutes during the experiment.  This 
chapter has been published in the Journal of Cardiovascular Translational Research. 
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Summary  
Anti-arrhythmic drugs have narrow therapeutic ranges and typically can engender 
harmful side-effects. The intrapericardial (IP) delivery of anti-arrhythmic agents proposes 
to achieve higher myocardial levels while minimizing plasma concentrations, thus 
diminishing systemic side-effects. Furthermore, IP delivery enables concentrations at the 
target site to be more precisely controlled. Our study objective was to compare the 
relative cardiac effects of intrapericardial administration of metoprolol to standard 
intravenous (IV) delivery in a swine surgical model. 
 
In order to answer the question of how IP metoprolol affects sinus tachycardia, atrial 
electrophysiology, and pharmacokinetics compared to IV delivery, a medial sternotomy 
was performed on 21 swine that were divided into three groups. 1) After inducing sinus 
tachycardia, metoprolol boluses were delivered IP (n=4) or IV (n=4); 2) metoprolol was 
administered either IP (n=3) or IV (n=3) with saline controls (n=3), and electrophysiologic 
data were collected; 3) metoprolol levels were tracked both in the blood (IV, n=2) and 
pericardial (IP, n=2) fluid.  
 
After either IP or IV delivery of metoprolol, heart rates were lowered significantly to 70% 
and 73% of control rate, respectively. The therapeutic effect of IV-administered 
metoprolol was considerably reduced after 1 hour, but was sustained longer in the IP 
group. Additionally, ventricular contractility and mean arterial pressure parameters were 
significantly lower in IV-treated animals, but were nearly unaffected in IP-treated 
animals. With IP administration, the elimination half-life of metoprolol in pericardial fluid 
was 14.4 minutes with negligible accumulations in the plasma, whereas with IV delivery, 
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the elimination half-life in plasma was 11.1 minutes with negligible amounts found in the 
pericardial fluid.  
 
The targeted intrapericardial delivery of metoprolol effectively lowers heart rates for 
sustained periods of time, with minimal effect on either ventricular contractility or mean 
arterial pressure. We did not observe dramatic changes in induced atrial fibrillation times 
or refractory periods using this model. 
 
Key Words: Target drug delivery; anti-arrhythmic agents; hemodynamics; elimination 
half-life; intravenous administration 
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Introduction 
Anti-arrhythmic drugs are known for both their narrow therapeutic ranges and potential 
harmful side-effects. In contrast, the intrapericardial (IP) delivery of anti-arrhythmic drugs 
has been proposed to achieve high myocardial concentrations while inducing minimal 
plasma concentrations [1-3], i.e., lower drug plasma concentrations would minimize 
systemic side-effects. IP delivery of such agents also has the benefit that concentrations 
at the target site can be more precisely controlled. Furthermore, several anti-arrhythmic 
drugs have narrow windows of systemic therapeutic concentration, such that slight 
variations (higher or lower) could cause adverse effects or no effects at all, respectively. 
Therefore with the use of either oral or intravenous delivery, drug concentrations at the 
target cell must be extrapolated based on several assumptions, typically producing 
relatively poor control of concentrations within the heart tissues. Thus IP delivery may be 
more desirable when precise therapeutic control is needed. 
 
Intrapericardial delivery of anti-arrhythmic drugs has been attempted recently with some 
success. Esmolol [1], sotalol [2], atenolol [2], ibutilide [4], procainamide [5, 6], digoxin [5], 
amiodarone [7], arachadonic acid [8], nitroglycerin [9], and L-arginine [10] (a nitric oxide 
precursor) have been administered intrapericardially to prevent or treat arrhythmias in 
various animal models, all of which have been acute studies, with one exception [2]. 
Further, in several studies it was verified that high pericardial concentrations were 
achieved with minimal spillover into the plasma [4, 6, 7]. More specifically, the prevention 
of dangerous ventricular arrhythmias was shown with administration of nitroglycerin [9], 
arachadonic acid [8], or L-arginine [10]. In addition, with the use of less lipid soluble 
compounds [6, 7], higher concentrations in superficial structures were observed (such as 
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within the atria and the ventricular epicardium), but lower concentrations were detected 
within the ventricular endocardium. Some have exploited this concentration gradient to 
treat the superficial sinoatrial node with beta-blockers [1], assuming that there is little 
penetration into the ventricles. Such a concentration gradient associated with pericardial 
administration of agents could also be used to target atrial fibrillation with minimal 
ventricular side-effects [4, 6, 7].  
 
Despite many reported benefits, the clinical utilization of IP delivery has yet to be widely 
employed, possibly due to difficulty in access, lack of experience with this method, and 
unknown potential complications. For example, underlying aspects of cardiac physiology 
may be affected by IP delivery, particularly the cardiac autonomic nervous system [8]. 
Perhaps the major concerns related to utilization of this approach are the unknown 
effects of concentration gradients that less soluble drugs will elicit transmurally across 
the ventricular myocardium. For example, if the electrophysiologic properties of the 
epicardium are affected by the pericardial target delivery of a drug but endocardium is 
not, this may initiate rather than inhibit arrhythmias [6].  
 
One of the primary objectives of this study was to assess the acute effects of IP delivery 
of metoprolol on sinus tachycardia and compare this approach with the current clinical 
standard of intravenous delivery. In addition, we considered that the most likely clinical 
application of IP delivery would initially be in the post-operative setting, i.e., placement of 
an intrapericardial catheter would be trivial and the catheter could be removed before 
discharge from the hospital. Further, the occurrence of post-operative arrhythmias is 
extremely common, and intravenous metoprolol is often used in the event of post-
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surgical supraventricular tachyarrhythmias. However, metoprolol has an adverse effect 
on cardiac contractility, which is particularly dangerous to the recovering cardiac surgical 
patient. In the pericardium, the moderately lipid soluble metoprolol should be able to 
diffuse into the thin atria and SA node, but may have lower concentrations deep in the 
ventricle. Thus, we hypothesize that IP (target) delivery of metoprolol would be an 
effective means of treating post-operative arrhythmias without affecting contractility.  
 
Methods 
Twenty-one male Yorkshire swine (70-90 kg) were sedated with intramuscular telazol 
(500 mg), and thiopental (500 mg) was administered via an ear vein. Each animal was 
then intubated and anesthesia was maintained with isoflurane (>1.2 MAC). An arterial 
line was placed in a branch of the femoral artery, and a 5-lead EKG was employed to 
continuously monitor heart rhythms. A Swan-Ganz catheter (Edwards LifeSciences, 
Irvine, CA) was introduced through the right external jugular vein to measure cardiac 
outputs, right atrial pressures, and pulmonary artery pressures. Next, a pressure 
catheter (Millar Instruments, Houston, TX) was introduced into the left ventricle (LV) 
through the right carotid artery to continuously measure LV performance. A medial 
sternotomy was then performed on each animal, and a small incision was made on the 
anterior surface of the pericardium. The heart’s pericardium was then tented with suture 
to form a reservoir for drug/saline delivery, as further described by Ayers et al. [7] and 
shown in Figure 3.1. Animals were sorted into one of three protocol groups after 
stabilization. All surgical procedures were approved by the Institutional Animal Care and 
Use Committee of the University of Minnesota.  
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Figure 3.1: Pericardial sac tented with suture after a medial sternotomy. This tenting provided a 
reservoir for the metoprolol treatment, and could be easily performed during many cardiac 
surgeries.  
 
 
Metoprolol in Sinus Tachycardia (Group 1) 
Animals in Group 1 (n=8) received a slow infusion of isoproterenol (0.5-1.0 mcg/min) 
through the distal port of the Swan-Ganz catheter which was titrated until the heart rate 
was over 180 bpm; the infusion was kept constant for the remainder of the study. It was 
previously shown [7] that this is a reliable model of sinus tachycardia which can be 
sustained for hours in canine experiments. Additional electrodes were placed on the 
chest and limbs to approximate a full 12-lead EKG. After the heart rate stabilized, a 
bolus of 20 mg of metoprolol (1 mg/ml standard intravenous injection, Novartis 
Pharmaceuticals Corp., East Hanover, NJ) was given randomly, either intrapericardially 
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(n=4) or intravenously (IV; n=4 ). When metoprolol was given IV, 20 ml of saline was 
also administered into the pericardial space (sham procedure). Hemodynamic and 12-
lead EKG data were taken before delivery and up to one hour after the boluses of 
metoprolol. Sequential samples (500 μl) were drawn from the pericardial space at -5, 5, 
10, 20, 30, 45, and 60 minutes. Similarly, sequential arterial blood samples (5 ml) were 
obtained at -5, 2, 5, 10, 15, 20, 30, 45, and 60 minutes. High pressure liquid 
chromatography (HPLC) was employed to analyze the content of metoprolol in both 
plasma and pericardial fluid, using previously published methodologies [11].  
 
Refractoriness and Susceptibility to Atrial Fibrillation (Group 2) 
In Group 2 animals (n=9), we employed additional instrumentation to study 
refractoriness and relative susceptibility to atrial fibrillation. To do so, fluoroscopy was 
used to place endocardial pacing leads (3830 Bipolar Pacing Lead, Medtronic, Inc., 
Minneapolis, MN) in the high lateral right atrium and right ventricular apex. These leads 
were connected to a GEM III implantable defibrillator (Medtronic, Inc.), and a 
programmer/analyzer (Model 2090, Medtronic, Inc.) was used to control the defibrillator 
functional parameters during measurement of refractory periods. Epicardial pacing leads 
(Medtronic, Inc.) were also placed on the left atrial appendage (LAA) and the LV 
epicardium. Additionally, a decapolar electrophysiology catheter (Medtronic, Inc.) was 
placed transmurally through the LV myocardium to record activation times at different 
depths of the myocardium, i.e., to detect endo-epicardial activation discrepancies which 
could indicate whether the drug was affecting the myocardium spatially. Signals from the 
programmer, epicardial pacing leads, decapolar catheter, and EKG leads were all 
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recorded simultaneously using an ENSITE electrophysiology system (St. Jude Medical, 
St. Paul, MN).  
 
After instrumentation and stabilization periods, control electrophysiology data were 
obtained. Atrial effective refractory periods (AERPs), ventricular effective refractory 
periods (VERPs), and atrioventricular nodal effective refractory periods (AVNERPs) 
were measured as previously described [7]. Susceptibility to atrial fibrillation was 
assessed by delivering a 2-sec, 50 Hz burst pace of 2-msec pulses of 20 V to the LAA 
lead, using a stimulator (Grass Technologies, West Warwick, RI). These stimuli were 
administered three times, and subsequently each time the relative durations of atrial 
fibrillation (AF) were measured. Note that if an episode of induced AF lasted longer than 
1 minute, the heart was resynchronized (atrial defibrillation) with a 5 joule epicardial 
shock (Lifepak, Medtronic, Inc.). Finally, to assess relative hemodynamic stability during 
atrial fibrillation, a 30-sec burst pace in the LAA was used to induce AF in the animal, 
while hemodynamic measurements were recorded.  
 
After the control protocol data were collected, animals received either: 1) 20 mg of 
metoprolol (1 mg/ml standard IV formulation) in the pericardial space (n=3); 2) 20 mg of 
metoprolol intravenously (n=3); or 3) a bolus of 20 ml of saline within the pericardium 
(n=3). Saline controls were used in this group because it was of interest to determine 
how the electrophysiological parameters would change over the course of the study. 
Both blood and pericardial samples were taken throughout this protocol as previously 
described. Electrophysiology parameters were assessed at 5, 30, and 60 minutes after 
drug delivery.  
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Pharmacokinetics (Group 3) 
Metoprolol was given either intrapericardially (n=2) or intravenously (n=2) to the animals 
in Group 3, and both blood and pericardial fluid samples were taken as previously 
described.  
 
Statistical Analyses 
For measurements with respect to time, data were analyzed using two-way ANOVA with 
repeated measures, and one-way ANOVA was used to determine differences between 
the modes of metoprolol administration at given time points. To identify intergroup 
differences, Bonferroni post hoc tests were employed. All data are presented as mean  
SEM; a P < 0.05 was considered statistically significant. 
 
Results 
Metoprolol in Sinus Tachycardia 
After IP or IV delivery of metoprolol, heart rates were lowered significantly—to 70% and 
73% of control rate, respectively. While the onset of action was slightly slower with IP 
delivery, the effects were considerably prolonged ( 
Figure 3.2). It should be noted that the effects of the IV metoprolol bolus dose was 
markedly reduced after 1 hour. Left ventricular contractility (as measured by dP/dt) was 
significantly reduced in IV metoprolol-treated animals; contractility decreased to 73% of 
the control measurement, but returned to baseline after 1 hour. In contrast, the relative 
LV contractility was not significantly affected over time in IP-treated animals (Figure 3.3). 
Likewise, mean arterial pressure was lowered considerably during IV delivery, but was 
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nearly unaffected with the IP administration (Figure 3.4). No statistically significant 
differences were found between the groups relative to cardiac output, PR interval, or 
QRS duration.  
 
Figure 3.2: The effects of metoprolol on heart rate, delivered either intravenously (IV) or 
intrapericardially (IP) in a model of sinus tachycardia. The IP-delivered metoprolol took longer to 
induce changes in the heart rate. * significant difference between IP versus IV therapies; † IV was 
lower compared to -5 time point; ‡ IP was lower compared to -5 time point, P<0.05, n=4 for each 
group. 
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Figure 3.3: The effects of metoprolol on left ventricular contractility (LV dP/dt), administered either 
intrapericardially (IP) or intravenously (IV). Note that the standard clinical IV bolus delivery quickly 
reduced contractility for the first 15 minutes, whereas there were no significant changes in 
contractility with IP therapy. * significant differences between IP and IV therapies; † IV was lower 
compared to baseline values, P<0.05, n=4 for each group.  
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Figure 3.4: The effects of metoprolol on mean arterial pressure, delivered either intrapericardially (IP) 
or intravenously (IV). Note that no significant differences were observed between the two treatments 
or compared to the -5 minute baseline measurement (P=0.08 at t=60 min, n=4 for each group). 
 
 
Refractoriness and Susceptibility to Atrial Fibrillation 
The effects of therapeutic application of metoprolol on electrophysiology measurements 
were highly variable, thus no significant trends were observed with regards to AVNERP, 
VERP, or the relative ability to induce atrial fibrillation. It was considered that the porcine 
atrioventricular (AV) nodal physiology, and perhaps the presence of the AV node gap, 
made it difficult to measure the expected increases in AV node refractoriness with IV 
delivery. Furthermore, the transmural activation times, measured as the difference in 
activation times between the most epicardial and most endocardial electrodes, also were 
observed not to elicit significant changes between any of the study groups. Ventricular 
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rates during AF were above 150 bpm in all animals, but no significant changes were 
observed (). 
 
 
Figure 3.5: Ventricular heart rates (escape rhythms) during 30 seconds of atrial fibrillation (AF) 
induced via stimulation. No significant changes were observed either following the IP or IV therapies 
(P=0.54 at t=60 min, n=3 for each group).  
    
Nevertheless, it should be noted that there were observed trends in the relative effects of 
atrial electrophysiology, i.e., inter-atrial conduction times increased in saline control 
animals, but remained closer to their control values in both the IV- and IP-treated 
animals. Similarly, AERPs decreased in saline-treated animals, but remained more 
stable in both IP- and IV-treated animals ( and Figure 3.7).  
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Figure 3.6: Relative changes in inter-atrial conduction times after administration of intrapericardial 
(IP) metoprolol, intravenous (IV) metoprolol, or IP intrapericardial saline. No significant differences 
were observed relative to the observed changes in conduction time (P=0.21 at t=60 min , n=3 for 
each group). 
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Figure 3.7: Relative changes within atrial effective refractory periods (ERPs) after intrapericardial (IP) 
metoprolol, intravenous (IV) metoprolol, or IP saline administration. No statistically significant 
differences exist amongst the treatment groups (P=0.064 at t=60 min, n=3 for each group). 
 
Pharmacokinetics 
When given intrapericardially, the elimination half-life of metoprolol in the pericardial fluid 
was 14.4 minutes, with negligible detectable amounts within the plasma (Figure 3.8). In 
contrast, when given intravenously, the elimination half-life of metoprolol in the plasma 
was 11.1 minutes, with negligible amounts in the pericardial fluid (Figure 3.9). It should 
be noted that the pericardial fluid metoprolol concentrations during IP delivery were 
almost 600-fold higher than plasma concentrations during IV therapy. 
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Figure 3.8: Metoprolol concentrations in pericardial fluid after intrapericardial (IP) administration; 
half-life was calculated to be 14.4 minutes (n=2). 
 
 
 
Figure 3.9: Metoprolol concentrations within the plasma after intravenous (IV) therapy; half-life was 
determined to be 11.1 minutes (n = 2). 
 
 
  76 
Discussion 
We observed that the intrapericardial delivery of metoprolol lowers relative heart rate 
during induced sinus tachycardia for a sustained period of time, without affecting 
ventricular contractility or mean arterial pressure. Additionally, we noted that IP delivery 
resulted in slightly longer times to lower heart rates, compared to IV bolus administration 
(Figure 3.2). This was considered the result of time it takes for metoprolol to diffuse from 
the pericardial space into the myocardium. During AF, the ventricular rate for each group 
did not change with respect to baseline. The IV group remained the lowest throughout 
the testing period, likely due to the metoprolol reaching the AV node in this group. 
 
With regards to potential effects of metoprolol on altering cardiac refractory periods, we 
did not observe significant responses, a finding that we consider is associated with small 
sample sizes and/or high measured variability within our data. Nevertheless, the 
prevention of changes in either inter-atrial conduction times or atrial refractoriness may 
or may not be clinically significant. It was also observed here that activation times did not 
change across the myocardial wall, which may suggest that the transmural 
concentrations gradient will not induce ventricular arrhythmias. However, we suggest 
that more complete mapping studies should be pursued. It appears, therefore, that IP 
metoprolol might best be suited for the treatment of sinus tachycardia and not 
necessarily for atrial fibrillation (at least based on the findings of this study). Note that the 
AV node is a deep cardiac structure relative to the more superficial sinoatrial node so, if 
desired, IV therapeutic delivery may accomplish better rate control than IP 
administration.  
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Intrapericardial (or target) delivery to affect heart function could be easily accomplished 
utilizing a small catheter placed within the chest cavity, e.g., after cardiac surgery. This 
approach would add minimal time and/or cost to the procedure. In addition, excess drug 
(particularly if the drug is constantly infused) could be drained via placed chest tubes. In 
other words, such a therapeutic delivery would be similar to mediastinal irrigation of 
antibiotics, a procedure often performed for mediastinitis. 
 
Several important potential limitations of these investigations should be considered. 
First, in our study, the metoprolol delivered intrapericardially was an IV formulation; in 
the future, perhaps such drug formulations could be better optimized for IP delivery, e.g., 
accounting for characteristics such as pH. Also, the bolus dosages used in this study 
were the same as standard clinical IV doses, therefore, additional dose-response studies 
are needed to optimize the dosage. Nevertheless, as previous studies have shown [5, 
6], the IV concentrations of a given drug may be more critical to control than those of the 
same agent administered within the pericardial fluid. Further, while the IP delivery of 
metoprolol may lower heart rate, it is clinically important to address the underlying cause 
of tachycardia as well. Finally, as we noted using the current model, the pericardial 
delivery of metoprolol in a post-operative setting may not prevent induced AF.  
 
In conclusion, we propose that the pericardial delivery of anti-arrhythmic agents such as 
metoprolol holds promise for its potential to enhance the efficacy of the drug (i.e., the 
administration of higher concentrations to the target organ) while mitigating unwanted 
side-effects. Additionally, IP delivery of such an agent should enable concentrations at 
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the target site to be more precisely controlled; in this case, metoprolol following IP 
delivery was not present in detectable concentrations within the plasma. 
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Preface 
This chapter provides a review of the cardiac and electrophysiologic effects of omega-3 
polyunsaturated fatty acids.  It summarized the current state of research and includes 
background on the mechanisms of action.  The knowledge and understanding gained 
through this review formed the foundation that the subsequent experiments were based 
on. 
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Introduction   
As far back as the 1950s, the interplay of saturated and unsaturated fats in diet was 
correlated to the presentation of ischemic heart disease [1].  Further in the 1970s, Bang 
and Dyerberg widely publicized their findings on the effects of marine omega-3 poly-
unsaturated fatty acids (ω3PUFAs) on positive cardiac health, showing the dramatic 
differences in cardiovascular health of Inuit Eskimos compared to a Danish cohort.  
Specifically they observed a lower incidence of death due to acute myocardial infarction 
among the Eskimos, and this remarkable difference was attributed primarily to the 
Eskimos’ increased intake of ω3PUFAs [2], [3].  
  
Yet, as is the case with observational epidemiologic data, these studies showed a 
correlation, not causation.  However, in the four decades following Bang’s publications, a 
tremendous amount of research has been conducted on the underlying physiologic 
effects of ω3PUFAs. In addition to reportedly being protective against cardiovascular 
disease and death [4–8], additional health benefits of high levels of ω3PUFAs have been 
observed, including: (1) increased clotting time and decreased thrombus formation [9], 
[10], (2) reduced inflammation [11], [12], (3) the inhibition of apoptosis signaling during 
ischemia [13], (4) reductions in blood pressure [14], (5) reduced telomeric aging [15], 
and (6) antiarrhythmic effects [16].  Importantly, these latter antiarrhythmic effects were 
widely publicized after the GISSI Prevenzione trial.  This prospective, randomized 
controlled trial showed a 45% reduction in cardiac sudden death in the therapy group 
compared to controls [5].  However, not all follow up studies have affirmed these positive 
results [5], [17–21]. 
 
  82 
Background 
Long chain fatty acids consist of long (>12 carbons) hydrocarbon chains with a single 
terminal carboxyl group.  Fatty acids are typically described as saturated, mono-
unsaturated, or poly-unsaturated, depending on the number—if any—of double bonds 
present in the hydrocarbon chain. The major unsaturated fatty acids fall into omega-6 
(ω6) or omega-3 (ω3) groups, where the -3 and -6 suffixes refer to the position of the 
double bond in relation to the non-carboxyl end (Figure 4.1).  
 
 
Figure 4.1: diagrams of the most common ω6 and ω3 polyunsaturated fatty acids. 
 
Importantly, in 1930, Burr and Burr showed that mammals do not possess the enzymes 
required to synthesize the double bonds at the ω3and ω6 positions on the fatty acid 
chain, and therefore must obtain these essential fatty acids through their diet [22].  At 18 
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carbons long, linoleic acid (LA) is the parent ω6 fatty acid (C18:2n-6) and is present 
primarily in soy, corn, safflower and sunflower oils.  Through a series of enzymatic steps, 
LA is elongated and desaturated into arachidonic acid (C20:4n-6; AA).   
 
In the cholorplasts of plants, LA can be desaturated to the ω3 α-linolenic acid (C18:3n-3, 
ALA).  Similar to LA, ALA can be elongated and desaturated into the 20-carbon version, 
in this case known as eicosapentaenoic acid (C20:5n-3; EPA), which can be elongated 
into docohexanoeic acid (C22:6n-3; DHA).   
 
The 20-carbon PUFAs AA and EPA are the main sources of cell messengers, 
prostaglandins, leukotrienes, and lipoxines after conversion by the enzymatic actions of 
cyclooxygenase, lipoxygenase and epoxygenase.  Additionally, it has been established 
that eicosanoids from the ω6 AA have pro-inflammatory functions, whereas the 
eicosanoids derived from  the ω3 EPA are much less inflammatory [23].  It should be 
noted that both AA and EPA compete for the same cyclooxygenase, epoxygenase, and 
lipoxygenase enzymes to form their respective classes of eicosanoids; influenced by 
their relative concentrations.  A schematic diagram of the fatty acid types and 
conversions is included in Figure 4.2 
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Figure 4.2: chart of polyunsaturated fatty acids and their reactions from the parent molecules ALA 
and LA.  The prostaglandins and leukotrienes are produced by EPA and AA in competition for the 
sam cyclo-oxygenase and lipoxygenase enzymes.  Figure by David R. Throop. 
  
Because of man’s inability to interconvert ω-6 and ω-3 fatty acids, plants, plankton and 
algae are the original dietary source of ω3PUFAs.  Yet, while soybean, flax seed canola 
oils contain some ω3PUFAs, mainly ALA, most ω3PUFAs in the human diet, especially 
EPA and DHA, are consumed by eating fish and other marine animals.  And even 
among fish species, the values of ω3PUFAs per 3oz serving can range from 0.13g in 
pacific cod to 1.83g in Atlantic salmon [24]. Interestingly, in the typical Western diet, fatty 
acids categorized as n-6 are consumed 20-25-fold more than n-3 fats [12]. 
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Electrophysiology 
Not only have ω3PUFAs been observed to lower the incidence of CHD, but as noted 
above evidence suggests they have a direct antiarrhythmic effect.  More specifically, a 
series of animal studies performed by Billman et al. demonstrated the antiarrhythmic 
effects of ω3PUFAs when administered during ischemia [25–27].  To do so, an inflatable 
cuff was surgically implanted around the left circumflex artery in a dog model of 
ventricular fibrillation (VF), and after a healing period, VF could be reproducibly induced 
by inflating the cuff during exercise.  By administering ω3PUFAs immediately prior to 
cuff inflation, the heart was protected in 10 out of 13 dogs using fish oil concentrate, 
either as purified EPA,  DHA or ALA, without significant effects on ventricular contractile 
functions [28]. 
 
In a preliminary human study, electrophysiological testing was performed on patients 
with implanted defibrillators before and after an infusion of ω3PUFAs (Omegaven, 
Fresenius, Kabi, Germany). In the seven patients in whom ventricular tachycardia (VT) 
could be induced, the subsequently infused ω3PUFAs prevented stimulated ventricular 
tachycardia in five: but it should be noted that  the VT induced in the two patients was 
only after a more aggressive pacing protocol [29].  Given that this was only small pilot 
study, it preliminarily shows the potential for the antiarrhythmic effects of ω3PUFAs in 
humans as well. 
 
Multiple human trials have been performed to assess the efficacy of ω3PUFAs in 
preventing the occurrence of AF after coronary artery bypass graft surgery (CABG).  To 
date, CABG procedures has become common, with 158,000 procedures performed in 
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the US alone in 2010 [30].  It is important to note that post-operative AF is a common 
morbidity associated with thoracic surgery: e.g., in CABG patients there has been 
reported prevalence between 25-40% [31].  The study by Calo et al. observed that in 
patients administered 1.7g/day ω3PUFAs (1:2 EPA/DHA) for at least 5 days before 
CABG surgery had significantly lower incidences of postoperative AF (OR 0.35; 95% CI 
0.16 to 0.76) and shorter hospital stays [18].  In a similar study, in which they provided 
4.6 g/day of ω3PUFAs for at least 3 weeks before either CABG and/or valve repair 
surgeries also corroborated the reduction in hospital stay, but they observed a non-
significant reduction in postoperative AF (OR 0.63, 95% CI 0.56 to 1.11) [32]. 
 
In order to understand the biochemical and biophysical mechanisms of the 
antiarrhythmic action of ω3PUFAs, Kang et al. used cultured neonatal rat 
cardiomyocytes in an in vitro model of arrhythmogenesis [33–35].  Perfusion of these 
cultured cells with known arrhythmogenic agents i.e. isoproterenol, cAMP and cholera 
toxin, would increase intrinsic beating rates, induced contractures and/or cause 
fibrillations.  Noteworthy, the addition of polyunsaturated fatty acids (but not 
monounsaturated or saturated fatty acids) prevented all fibrillation.  Further, if arrhythmia 
was produced by one of the agents, the addition of EPA or DHA to the perfusate 
stopped the arrhythmia.  In both scenarios, the fatty acids could be removed from the 
culture by the addition of fatty acid-free bovine serum albumen and the arrhythmias 
would initiate (or return) [33–35].  The ability to wash out the ω3PUFAs with delipidated 
serum suggests that the ω3PUFAs acted directly on these heart cells without the 
formation of covalent bonds. 
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Subsequently, Kang and colleagues went on to show the effects of free ω3PUFAs on 
membrane excitability.  They observed that the ω3PUFAs, but not the monounsaturated 
or saturated fatty acids, reduced membrane excitability by significantly increasing the 
strength of depolarizing current required to initiate an action potential, as well as 
prolonging the refectory periods following an action potential. These changes were 
associated with an increase in the threshold required to initiate an action potential and a 
lower voltage resting membrane potential [36]. 
 
Cardiac ion channel effects 
Because the basis of action potential initiation and propagation involves several 
membrane ion channels, most drugs that have anti- or pro-arrhythmic effects act as ion 
channel agonists or antagonists.  Therefore, numerous single cell electrophysiology 
experiments have been performed to elucidate the mechanism of action of ω3PUFAs 
including patch clamp.  Interestingly, the administration of ω3PUFAs has been shown to 
have effects on Na+, Ca+, K+ ion channels as well as pumps such as the Na+/Ca+ 
exchanger. 
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Figure 4.3: summary of ion currents in cardiac action potential 
 
Na+ channels 
The voltage gated Na+ current (INa) is responsible for the primary depolarization (phase 
0; see Figure 4.3) of cardiomyocytes and also is known to play an important role in 
arrhythmogenesis.  It is the activation of these channels that leads to a quick inflow of 
sodium ions that initiates the action potential.  In cultured neonatal rat ventricular 
myocytes, whole cell patch clamp has revealed that extracellular application of EPA or 
DHA suppresses the INa.  However, monounsaturated or saturated fatty acids did not 
have significant inhibitory effects [37].  The ω3PUFA EPA also has been shown to 
significantly shift the steady-state inactivation curves of these channels to the 
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hyperpolarizing direction [37].  This shift in the steady-state inactivation indicates that the 
membrane potential in cells treated with ω3PUFAs must be more negative in order to 
produce the same INa seen in control cells. 
 
Further experimentation on rat cardiomyocytes has also shown that cells treated with 
EPA or DHA required larger depolarization currents to elicit action potentials (increased 
thresholds for action potential elicitation) [36].  Specifically, the addition of ω3PUFAs to 
such cultured cells shifted the steady-state inactivation curve of the Na+ current more 
negative (Figure 4.4). Furthermore, the addition of these ω3PUFAs to cells in culture 
also reduced the membrane resting potentials [36]. These effects of ω3PUFAs on these 
Na+ currents are considered to play significant roles in their antiarrhythmic effects.  
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Figure 4.4: The addition of ω3PUFAs shifts the steady-state inactivation curve to a more negative 
position, reducing response current at a given voltage.  (A) Superimposed currents in the absence 
and presence of EPA (10μM).  Currents were elicited with a double pulse: 30 ms testing pulse to -
30mV following a 500 ms prepulse varying from -140 to -30 mV from a holding potential of 80mV.  (B) 
Steady-state inactivation peak of sodium currents as a function of prepulse voltage, comparing 
control to EPA treated.  (C) Prepulse suppression effects of 10μM EPA on cardiac sodium currents.  
Relative currents as a function of prepulse voltage are plotted, and relative currents were calculated 
as a ratio of treated to control currents.  (D) Schematic of pulse sequence. Figure adapted from [37].   
 
It should be clarified that cardiac Na+ channels are made up of multiple parts: a larger α-
subunit that alone creates a functional membrane channel and smaller β1- and β2-
subunits [38]. It was reported that in a human kidney cell transfected with only the α 
subunit of the human Na+ channel, fatty acids reduced INa,α and shifted the steady state 
inactivation to the hyperpolarizing direction.  In these α subunit-only channels, this 
observed fatty acid effect was not limited to ω3PUFAs, but monounsaturated and 
saturated fat additions resulted in similar INa,α reductions [39].  
 
D 
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It is generally considered that β1-subunit modulates the voltage dependent Na
+ channel 
[40].  Note that the currents of human Na+ channels with both the α and β1 subunits were 
inhibited by PUFAs, but not saturated or monounsaturated fatty acids [41]. 
 
Following these observations, Xiao et al. went on to show that that a single point 
mutation on the α-subunit of human cardiac Na+ ion channel decreased the inhibitory 
effect of PUFAs on the Na+ current.  This suggests that the human cardiac Na+ channels 
haves a specific binding site for ω3PUFAs [42], [43]. 
 
These effects on the Na+ channel induced by ω3PUFAs may also account for the 
reduced arrhythmias during ischemia: i.e., within those border regions of cells that are 
mildly ischemic and thus lack of ATP.  In such cases, this results in reduced function of 
the Na+/K+ pumps and the resting membrane potentials slowly rises.  Consequently, an 
action potential can be triggered with very little additional stimulus, thus increasing the 
risk that such cells will depolarize during a vulnerable point in the cardiac cycle.  
However, cells with high ω3PUFAs that have a depressed resting membrane potential 
and require a larger depolarization current will have a stabilizing effect in the border 
region. 
 
Ca2+ Channels 
High intracellular concentrations of calcium within myocytes must be achieved for 
sufficient receptor binding to the regulatory protein troponin, which in turn allows for 
actin-myosin cross-bridge formation.  Initially, the intracellular Ca2+ initially comes from 
outside the cell through the L-type Ca2+ channels, but not in sufficient quantities for full 
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activation: this transmembrane Ca2+ intake through the L-type Ca2+ channels triggers the 
ryanodine receptors to release larger amounts of Ca2+ from the internal stores within the 
sarcoplasmic reticulum.  As such, an overload of intracellular Ca2+ may in turn cause 
arrhythmias. 
 
Interestingly, cellular reductions in Ca2+ L-type gating and releases from the 
sarcoplasmic reticulum were observed with the addition of ω3PUFAs, but not saturated 
or monounsaturated fatty acids [44].  Note, while the reductions in the sarcoplasmic 
reticulum Ca2+ current could also be from the reduction in the signaling L-type current, 
more specifically it was demonstrated that ω3PUFAs reduce the availability of Ca2+ for 
uptake and they inhibit the release mechanism [45]. 
 
K+ Channels 
The three main K+ currents in the cardiac membrane are: 1) the transient outward K+ 
current, 2) the delayed rectifier K+ current and 3) the inwardly rectifying K+ current.  It 
was reported that both the transient outward K+ currents and delayed rectifier K+ currents 
were inhibited within isolated ferret cardiomyocytes by both DHA or EPA,: whereas the 
inwardly rectifying K+ current was unaffected [46].  These differences in effects among 
the K+ channels may in part result from their differences in their innate channel 
structures [47].  Importantly, other saturated or monounsaturated fatty acids did not elicit 
any significant effects on the major K+ currents.  In theory this inhibition the outward K+ 
currents would prolong the action potential duration, therefore the inhibitory effects on 
the Na+ and L-type Ca2+ currents would have to override the K+ current effects in order to 
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explain the observed reduction in action potential durations observed in cultured 
cardiomyocytes [36]. 
 
ω3PUFAs and Atrial Fibrillation  
While the beneficial effects of ω3PUFAs on sudden cardiac death have considerable 
support to date, the evidence supporting reductions in AF are less robust.  Nevertheless, 
the potent effects of ω3PUFAs on cardiomyocytes ion channels, would suggest that the 
antiarrhythmic properties may extend to altering AF. 
 
Clinical uses of ω3PUFAs to treat and prevent AF have been reported as mostly—but 
not always—positive.  For example, concerning the occurrences of AF after coronary 
artery bypass grafting (CABG), Calo and colleagues [18] reported patients who started 
taking 2g/day supplemental ω3PUFAs for at least 5 days before elective coronary 
bypass grafting had lower incidences of post-operative AF.  A similar study was 
performed in Germany in which patients were given 100 mg fish oil per kg of body 
weight per day or a similar amount of soya oil as a control group, all at least 12 hours 
before CABG procedures until discharge.  Post-operative AF occurred significantly less 
in the ω3PUFA treated group, which also had a shorter ICU stay compared to controls 
[48].   
 
Yet as noted above, not all reported outcomes post-CABG have been favorable.  
Specifically, in a study by Saravanan et al., patients were treated with 2g/d ω3PUFA or 
olive oil for at least 5 days before CABG until discharge: they observed a slight but non-
significant increase in the amount in AF in those in the ω3PUFA arm of the study [17].  
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In another study, performed on patients undergoing CABG and/or valve surgery, they 
compared outcomes of patients taking 4.6 g/day ω3PUFAs or placebo starting 3 weeks 
before surgery.  Though the treated patients had a significantly shorter ICU stays, there 
were non-significant reductions in AF incidences [32]. 
 
Mixed results have also been observed in studies specifically aimed at measuring the 
potential prevention of AF by dietary ω3PUFAs.  Interestingly, in one prospective study, 
Mozaffarian et al. [49] found reduced incidences of AF in elderly individuals who 
regularly ate bake or broiled fish during 12 years of follow up, but not those who ate fried 
fish.   
 
Additionally, the clinical use of ω3PUFA administrations for the treatment of patients with 
AF has also been explored.  For example, the relative safety and effectiveness of the 
prescription ω3PUFA supplement, Lovaza (GlaxoSmithKline, North Carolina), was 
tested in patients with AF.  Specifically, during the six month follow up period, this high 
dose treatment (4g/day) for AF was observed to have no significant improvements in 
times to first AF events or in recurrences of symptomatic AF [50].  However, this type of 
ω3PUFA therapy was beneficial compared to placebo in reducing AF when either was 
used in combination with amiodarone and a rennin-agniotensin-aldosterone system 
inhibitor.  Furthermore, in a population who underwent cardioversion to return them to 
sinus rhythm, patients provided with additional ω3PUFA therapy were observed to be 
more effective at maintaining sinus rhythm during a one year follow up period [19].  
 
Anti-inflammatory effects of PUFAs 
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Eicosanoids are considered to be among the mediators of inflammation and are 
generated mainly from 20-carbon PUFAs.  The two main 20 carbon PUFA sources are 
AA and EPA.  The eicosanoids converted from AA generally promote inflammation, 
while those eicosanoids from EPA are typically less inflammatory or inactive.  
Inflammatory cells, like many others, often contain a large percentage of the ω6PUFAs 
relative to their ω3PUFA counterparts; thus, AA is typically the major substrate for 
eicosanoid synthesis.  When the concentration of ω3PUFAs is increased within tissues, 
there are less ω6PUFAs and fewer of the pro-inflammatory ω6 eicosanoids can be 
produced.   
 
More specifically, both ω3- and ω6PUFAs compete for the same cyclooxygenase and 
lipoxygenase enzymes.  Therefore, an increase of ω3PUFAs makes those enzymes less 
available and this competition further decreases ω6 eicosanoid production.  Additionally, 
it is considered that several of the ω3 eicosanoids produced will also counteract the ω6 
eicosanoids, increasing the anti-inflammatory effects of ω3PUFAs.   
 
Finally, in addition to these competitive effects with AA that can reduce inflammation, 
ω3PUFAs are considered to elicit several anti-inflammatory effects.  For example, 
dietary fish oil has been shown to result in: 1) decreased productions of reaction oxygen 
species, 2) decreased productions of pro-inflammatory cytokines, leukocyte chemotaxis, 
and 3)  lower adhesion molecule expressions [11] (Table 4.1) 
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Antiinflammatory effect Mechanism  
Decreased generation of AA-
derived eicosanoids (many with 
inflammatory actions) 
Decreased AA in cell membrane phospholipids; 
inhibition of AA metabolism, decreased 
induction of COX-2, 5-LOX and 5-LOX activating 
protein 
Increased generation of EPA-
derived eicosanoids (many with 
less inflammatory actions than 
AA counterparts) 
Increased content of EPA in cell membrane 
phosphlipids 
Increased generation of EPA and 
DHA-derived resolvins (with 
antiinflammatory actions) 
Increased content of EPA and DHA in cell 
membrane phospholipids 
Decreased generation of 
inflammatory cytokines  
Decreased activation of NFκB; activation of 
PPARγ, altered activity of other transcription 
factors, differential effects of AA vs EPA derived 
eicosanoids 
Decreased expression of 
adhesion molecules 
Decreased activation of NFκB, altered activity of 
other transcription factors 
Decreased leukocyte chemotaxis 
Unclear; perhaps decreased expression of 
receptors for some chemoattractants 
Decreased generation of reactive 
oxygen species 
Unclear; perhaps altered membrane 
composition affecting signaling process 
Table 4.1: Summary of the anti-inflammatory effects of ω3PUFAs,  [11], [51] 
 
Preconditioning with PUFAs 
DHA has been shown to exert preconditioning effects in hearts of rats provided with high 
levels in their diets.  Specifically, it was reported that after 6 weeks of one of three 
experimental diets: 1) ω3PUFA; DHA and olive oil; 2) ω6PUFA; sunflower oil and olive 
oil, or 3) saturated fats; beef tallow and olive oil.  The hearts from rats fed the ω3PUFA 
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diet had significantly lower heart rates, lower end-diastolic pressures and elicited fewer 
ischemic and reperfusion arrhythmias, as well as a smaller infarct size compared to the 
ω6PUFA and saturated fat groups.  In other words, it was also considered that 
preconditioning with ω3PUFAs was as effective as ischemic preconditioning in the 
ω6PUFA and saturated fat groups [52]. 
 
In another series of experiments, McGuinness and colleagues gave rabbits an 
intravenous dose of an ω3PUFA emulsion (Omegaven, Fresenius Kabi, Bad Homburg, 
Germany) or saline for 4 days before I/R injury was induced by occluding the large 
marginal branch of the left coronary artery for 30 minutes and this was then followed by 
and reperfusion for 3 hours. It was observed that in the group treated with ω3PUFAs 
saw a 225% increase in heat shock protein before ischemia (heat shock protein is a 
known preconditioning agent), and was also observed that there was a 40% reduction in 
infarct area after I/R injury [53].  In an acute swine model of ischemia/reperfusion, Xiao 
et al. administered DHA to the pericardial space immediately prior to ischemia.  This 
infusion reduced reperfusion injuries and infarct area by 50% compared to controls. 
 
It should be noted that in general, the differences between the terms cardioprotective 
and pre-conditioning are subtle.  By definition, with preconditioning, a physical or 
chemical stimulus activates natural cellular responses to protect against that cell from 
subsequent injury.  The researcher Hearse defined cardioprotection as “identifying key 
changes in the progression of ischemic injury and developing anti-ischemic agents to 
combat these changes, thereby increasing the tolerance of the heart to ischemia”  [54].  
It is considered that the beneficial effects of ω3PUFAs encompass both preconditioning 
  98 
and cardioprotective roles.  For instance, DHA has been shown to delay Ca2+ induced 
opening of mitochondrial permeability transition pores (MPTP) [55], a contributing factor 
to reperfusion injury.   
 
Potential mechanisms of action 
Several explanations have been put forward for why ω3PUFAs elicit their effects on ion 
channels, and thus the relative electrophysiologic properties of the whole heart.  It was 
proposed by Jahangiri et al. that the incorporation of ω3PUFAs into the cell membrane 
changes fluidity and thus membrane channels.  To study such, they use fluorescence 
anisotropy to monitor membrane fluidity, correlating ω3PUFA effects to fluidity [56].  
Interestingly, some of the observed effects on ion channels in other experiments noted 
above occur at much lower concentrations than those necessary to change membrane 
fluidity [37], [43], [44]. 
 
A second hypothesis put forth by Andersen and colleagues suggests that such cell 
membrane effects are more localized to the immediate vicinity of the channel proteins: 
they showed that two different detergents produce similar effects as the applications of 
ω3PUFAs.  This was explained as the change in tensions between the ion channels and 
their incorporating membranes; i.e., when the hydrophobic lengths of the channels do 
not match up with membrane thicknesses.  These mismatched lengths  result in slight 
conformational changes in the ion channels that is relieved by the localized action of 
incorporated ω3PUFAs [57], [58].  However, the detergents applications had similar 
effects in several instances where ω3PUFAs did not.  In specially designed Na+ 
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channels with a single point mutation on the alpha subunit, importantly the potent effects 
of ω3PUFAs were lost [42], [43], but the detergent effects were unaltered.   
 
The third hypothesis considers the possibility that the ω3PUFAs may bind directly to the 
ion channels, exerting a slightly different effect on each.  This was further supported by 
the easy removal of the ω3PUFAs and their action in cell cultures with the addition of 
delipidated serum albumin.  If was subsequently hypothesized that if the ω3PUFAs were 
incorporated into the membrane, this transition would be slower [43].  Further support of 
this hypothesis is provided in a study that showed a single point mutation in the α-
subunit of the Na+ channel mad it significantly less sensitive to the inhibitory effects of 
ω3PUFAs [43]. 
 
Negative effects of ω3PUFA 
While not all trials using ω3PUFAs have shown beneficial effects, nearly all studies to 
date have shown no harmful results.  As such, many options for ω3PUFA 
supplementation or fish oil dietary augments are available over the counter, and recent 
prescription grade ω3PUFAs have been approved in the USA and Europe.  
Furthermore, the FDA has declared ω3PUFA supplements “generally recognized as 
safe.”  Likewise, the American Heart Association recommends two servings per week of 
fatty fish. The most common negative effects of fish oil supplements include fishy taste 
and burping, as well as gastrointestinal upset.  At very high doses, risk of bleeding can 
increase, though the majority of studies with increased dietary fish or ω3PUFA 
supplements show that it is well tolerated.  
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In summary, there has been much basic and translation interest as to the potential 
mechanisms and clinical benefits of ω3PUFAs on cardiac function.  To date, one may 
consider that the potential benefits increase level of ω3PUFA within one body greatly 
outweighs any side-effects.  However, more research is required to further substantiate 
the optimal uses of ω3PUFA for the prevention or treatments of human cardiac 
disorders.     
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Preface 
Building off the pericardial delivery model created for metoprolol, this chapter 
investigates the effects of pericardial treatment with omega-3 polyunsaturated fatty 
acids.  Commonly, myocardial omega-3 levels are built up with increased dietary 
ω3PUFAs, requiring several weeks for the compounds to reach high myocardial 
concentrations in rodents [1–4].  To observe acute effects, one alternative would be high 
dose IV injection.  A noted complication with  injection is the possibility of hemolysis [5], 
as well as the reduction in available ω3PUFAs as they readily bind to the circulating 
albumin and become less available.  Intrapericardial delivery bathes the heart in the 
treatment, allowing for higher concentrations, as well as lower concentrations of albumin 
to bind to the fatty acids.   The pretreatment used in chapter 5 was designed based on a 
similar protocol previously completed in our laboratory that saw a 57% reduction in 
normalized infarct size and a 50% reduction in reperfusion arrhythmias in a swine model 
of acute ischemia [6] 
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Introduction 
Localized therapy delivery is seen as a method to accurately deliver treatments to 
individual tissues in tightly controlled quantities.  Because the therapeutic agent only 
contacts the targeted tissue, potentially harmful systemic interaction with the drug are 
often reduced or averted with localized delivery methods.  Additionally, localized drug 
delivery greatly enhances the proficiency with which drugs can be delivered.  Drug 
doses can be tailored to the specific tissue and higher doses can more safely be 
administered because other tissues beyond the target will be minimally affected. The 
pericardial space is an ideal setting for targeted therapy delivery.  The space, created by 
the pericardium as it surrounds the heart, is a small volume isolated from the rest of the 
thoracic cavity, with only a small turnover with the systemic circulation [7].   
 
Pericardial delivery has been evaluated in several animal models including rats [8], dogs 
[9], and pigs [6], [10], with a few case studies described in humans [11].  A number of 
experiments have been performed with anti-arrhythmic drug delivery to the pericardium, 
such as digoxin [10], procainamide [10], sotalol [8], atenolol [8], and amiodarone [7].  
These studies report high concentration of agent in the pericardial space4 as well as high 
concentrations in the myocardium [8], [10] with comparatively low concentrations in the 
blood plasma, indicating that the agents are truly localized to the pericardial space.   
 
There have also been several agents of cardioprotection described using the pericardial 
space.  This includes pericardial delivery of nitroglycerin [12] and L-arginine [9] to reduce 
ventricular arrhythmias and even using the pericardial space to circulate chilled fluid to 
  104 
induce cardioprotective cooling in an ischemia reperfusion model [13], resulting in 
reduced infarct size.   
 
 
n-3 Polyunsaturated Fatty Acids for Cardioprotection 
High levels of dietary omega-3 polyunsaturated fatty acids (ω3PUFAs) have been 
suggested to be protective against cardiovascular disease [14–16].  Specifically, 
ω3PUFAs have been shown to improve postischemic recovery from 
ischemia/reperfusion injury in rat [1] and swine [6] hearts.  Furthermore ω3PUFAs 
reportedly have antiarrhythmic properties, reducing incidences of atrial fibrillation (AF).  
Mozaffarian et al. [17] found reduced incidence of AF in elderly who regularly ate bake or 
broiled fish.  Calo and colleagues [18] reported patients who started taking n3PUFA 
supplements 5 days before elective coronary bypass grafting had lower incidences of 
AF.  These epidemiological studies indicate the efficacy of both short- and long-term 
ω3PUFA exposures on cardiac functionality. 
 
In most studies, ω3PUFAs are administered intravenously (IV) or through the animal’s 
diet.  In rodents, dietary administration of ω3PUFAs has been shown to take several 
weeks for the compounds to reach high myocardial concentrations [1–4].  Due to the 
amount of time required, dietary delivery would not be beneficial in an acute setting.  In 
this setting, IV delivery could increase plasma levels, but high doses of ω3PUFAs are 
required to achieve appropriate myocardial concentrations [5].  An unfortunate 
consequence of the high dose of ω3PUFAs is that it increases hemolysis, making it an 
undesirable treatment [19].  Delivery of ω3PUFAs to the pericardial space has been 
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proposed as a way to build up myocardial concentrations without inducing systemic 
hemolysis [6].    
 
Localized delivery may be able to play a key role in the administration of protective 
agents during cardiothoracic procedures.  Pericardial delivery during cardiothoracic 
surgical procedure would be a simple task.  This study examines a model for 
preconditioning the heart with omega-3 fatty acids using Intrapericardial (IP) delivery.  It 
is our hope that this model can be used in a preoperative or pre-transplant setting so as 
to improve patient outcomes.  The ω3PUFA docosahexaenoic (DHA) was chosen for 
this study since it is the most abundant n3PUFA form found in most tissues, including 
the myocardium [20].   
 
Measuring AF time and electrophysiology parameters, as well as using Visible Heart® 
methodologies, the specific aims of this study are to investigate the effects of DHA 
delivery into the swine pericardium on arrhythmias in situ and ischemic damage in the 
reperfused heart.  This will be accomplished by assessing: 1) changes in the myocardial 
refractory periods and conduction velocities, 2) differences in atrial fibrillation 
susceptibility during treatment, as well as 3) differences in hemodynamic performance 
and 4) differences in protein effluent during the first hour of reperfusion. We hypothesize 
that treatments with DHA will decrease AF in the animal as well as improve function in 
vitro as measured by increased maximum left ventricular pressure (LVP) and decreased 
minimum LVP. 
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Methods 
Surgical procedure 
A total of 33 healthy, castrated male Yorkshire swine, weighing 85±10kg, were used for 
this study.  Anesthesia was induced with telazol and thiopental, animals were then 
intubated and mechanically ventilated, maintaining a PCO2 of 40 ± 2 mmHg, with a 2:1 air 
to oxygen mixture throughout the duration of the study.  A surgical level of anesthesia 
was maintained with isoflurane (>1.2 MAC). Two Mikro-Tip catheter transducers (Millar 
Instruments, Houston, TX) were used to monitor ventricular pressures; arterial pressure 
was monitored with a femoral cannula and a Swanz-Ganz catheter was used to monitor 
right atrial and pulmonary artery pressures.  Endocaridal pacing leads (Medtronic 3830, 
Medtronic, Minneapolis, MN) were secured into the right ventricular apex and right 
atrium via fluoroscopy and connected to a GEM III pacemaker/defibrillator (Medtronic, 
MN).  A decapolar Marinr CS catheter (Medtronic, MN) was placed adjacent to the 
tricuspid valve in order to measure electric potentials along the bundle of His (Figure 
5.1). 
  107 
 
Figure 5.1: Anterior-posterior (AP) fluoroscopic view of an instrumented swine heart with leads in 
the right atrium (RA) and apex of the right ventricle (RV).  A decapolar electrophysiology catheter is 
positioned through the tricuspid valve and along the septal wall toward the RV outflow tract to 
detect His potentials.  In addition, a Swanz-Ganz catheter, also through traveling through the 
tricuspid valve and up the pulmonary artery, is measuring pressures in the RA and pulmonary 
artery. 
 
Access to the heart was then attained via a medial sternotomy and a small incision was 
made in the anterior portion of the pericardial sack.  Four sutures were then used to 
secure the edges of the incision to the sternum, creating a pericardial cradle (Figure 5.) 
Additional electrical monitoring was placed: epicardial leads on the left ventricle and left 
atria, as well as another decapolar electrophysiology catheter placed across the roof of 
the right atrium (Figure 5.). 
R L AP View 
RA Lead 
His Catheter 
RV Lead 
Swanz-
Ganz 
Catheter 
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Figure 5.2: the pericardial cradle is created by suturing the pericardium to the medially divided 
sternum.  LV =left ventricle, la= left atrium. 
 
Electrophysiologic measurements 
The electrical leads were used to measure refractory periods and susceptibility to AF. 
The signals from the pacemaker programmer (Medtronic 2090, Medtronic, MN), 
epicardial pacing leads, decapolar catheter, and EKG leads were recorded 
simultaneously by an ENSITE electrophysiology system (St. Jude Medical, MN).  
 
Atrial effective refractory periods (AERP), ventricular effective refractory periods (VERP), 
and atrioventricular nodal effective refractory periods (AVNERP) were measured 
following a standard protocol explained by Ayers et al. [7]. Briefly, a series of eight paced 
pulses captured the heart at 150 bpm followed by a 9th pule at an increasingly short 
interval.  Susceptibility to atrial fibrillation was measured by delivering 2-second, 50Hz 
burst pace of 2-msec, 20V pulses to the left atrial appendage using a stimulator (GRASS 
Technologies, RI). The duration of AF was recorded after each burst.  This was repeated 
LV pacing 
lead 
Infusion catheter 
LA pacing lead 
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up to ten times, unless the animal entered a sustained episode of AF (an episode lasting 
one minute or longer).  These electrophysiology parameters were taken just prior to drug 
delivery as well as at 5, 30, 60, and 90 minutes after drug delivery.  
 
At this point, the heart was given one of four treatments in the pericardial space: 1) a 90 
minute infusion of DHA (3mg/mL) for a total of 45mg, 2) a twofold higher dose for a total 
of 90mg DHA (2xDHA), 3) a control infusion of the vehicle (0.15mL ethanol) or 4) an 
infusion with normal saline.  All treatments were given with a loading dose (6mL/2min) 
followed by a slow infusion at 01.mL/min for the remaining 88 minutes. 
 
At the end of each treatment, the pericardium was removed and an aortic root cannula 
was sewn in.  The inferior vena cava was clamped off to stop venous return.  As the 
superior vena cava and aorta were cross clamped, the heart was arrested with a cold 
crystaloid cardioplegia.  The pulmonary artery was vented to decompress the heart and 
prevent distension.  Topical cooling was applied with ice and the heart was excised and 
placed in an ice and Krebs- Henseleit (krebs) buffer slurry.  The time to flatline was 
considered as the period of time from the start of flow of the cardioplegia to the 
cessation of all spontaneous electrical activity. 
 
In vitro performance 
After excising the heart, the great vessels were cannulated, and the heart was 
reperfused with krebs buffer using Visible Heart® methodologies (Figure 5.) [19].  The 
heart was warmed to physiological temperatures using Langendorff profusion and 
defibrillated to initiate a sinus rhythm.  After defibrillation, the heart was allowed to 
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stabilize for 2-4 minutes.  Once the heart entered a stabile rhythm, the heart was 
switched into full working mode and data was collected for 30 seconds.  This was 
considered time zero, and data collection was repeated at 11 additional time points.  
After both the 50 and 55 minute data storage periods, 3-4 liters of the Krebs solution was 
drained and replaced.   
 
 
Figure 5.3: Image of porcine heart on Visible Heart perfusion apparatus.  Ultrasound transducer 
position is shown adjacent to the right ventricle. 
 
Ventricular and atrial pressures were monitored using Mikro-Tip catheter transducers 
(Millar Instruments, Houston, TX), along with aortic flows using Transonic flow probes 
(Transonic Systems, Ithaca, NY).  The heart was perfused for 60 minutes, alternating 
between right-sided working and full-working modes.  During the reperfusion, just prior to 
switching to working mode, samples of the Krebs solution were taken for biomarker 
analysis.  The krebs perfusate was tested for Troponin-I and Myoglobin at the Fairview 
hospital clinical labs, and TBARS ELISA assays (Cayman) was also performed.  As the 
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heart was cycled in and out of working mode, short axis ultrasound images were 
recorded in order to classify myocardial edema (Vivid-i, GE, Fairfield, CT). 
 
Statistics 
Data are presented as mean with standard deviation.  Significance was determined 
using Student’s t-test or ANOVA, where appropriate.  An α of 0.05 was considered 
significant, with bonferroni corrections when appropriate.  Analysis was done using 
Microsoft Excel 2007 and STATA version 10.1 
 
Results 
33 pigs were used in this study, and in vivo data was collected from them all.  Four 
hearts were excluded from in vitro analysis due to complications unrelated to heart 
heath. (LA input clamped, EMKA failure, and 2 unknown).  There was no mortality or 
major morbidity prior to heart arrest and explant. 
 
There were no significant differences in animal weight or heart weight among groups 
(Table 5.2).  No differences exist among the groups in cold ischemia time, defined as the 
time between arrest and defibrillation to start reanimation. 
Treatment n 
Animal wt 
(kg) 
Heart Wt        
(g) 
cold ischemia 
time (min) 
DHA 8 85.1±14.9 423.9±85.3 78.0±7.0 
2xDHA 8 88.4±10.5 440.4±41.7 83.0±12.3 
Saline 9 85.1±8.7 418.8±43.9 72.3±5.8 
EtOH 8 84.0±11.7 431.1±30.9 76.5±12.6 
Table 5.2: baseline characteristics, including animal weight, heart weight and cold ischemia time.  
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During the explant procedure, time from cross clamp to cessation of electrical and 
mechanical activity was recorded as time to flatline.  Upon reanimation, the number of 
shocks required to restart the heart was also recorded (Table 5.3). 
Treatment n 
Time to 
flatline (sec) 
number shocks 
to restart 
DHA 8 44.5±16.3 1.2±0.4 
2xDHA 8 54.5±17.4 2.5±2.4 
Saline 9 61±44.0 4.3±4.1 
EtOH 8 48.3±17.4 2.3±1.5 
Table 5.3: Time to flatline upon cardioplegia administration and the number of defibrillation shocks 
required to restart the heart. 
 
Atrial fibrillation 
In this open chest model, pig hearts were induced into atrial fibrillation with a burst pace.  
At least one episode of sustained AF was seen in 51.5% of pigs.  Ethanol treatment 
increased the time in AF over baseline, but not a statistically significant amount (Figure 
5.).  The DHA and 2x DHA treated hearts saw trends of reduced AF, and statistical 
significant reductions from baseline were seen in the 2xDHA dose at 60 and 90 minutes.  
However there were no differences when compared to ethanol treatment.  There was 
almost no fluctuation in the time in AF in the saline treated hearts. 
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Figure 5.4: Change in time in AF from pretreatment baseline.  There was a significant reduction in AF 
from 2xDHA at the 60 and 90 minute points (*).   
 
Refractory periods  
Though most of the treatments made ventricular effective refractory periods (VERP) 
trend slightly upwards, there were no significant differences among the groups or 
significant changes from baseline (Figure 5.).  Atrial effective refractory periods (AERPs) 
stayed within 10ms of their starting values, with no statistically significant changes. 
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Figure 5.5: ventricular and atrial effective refractory periods.   
 
Hemodynamics 
Both the DHA and 2xDHA treatments slightly lowered heart rate in vivo, while the heart 
rate for the saline and ethanol treated hearts increased slightly. The DHA treated hearts 
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had significantly lower heart rate at 60 and 90 minutes and the 2xDHA hearts at 90 
minutes (Figure 5.). 
  
 
Figure 5.6: heart rate in vivo.  Both DHA treatments lowered heart rate, with statistically significant 
differences when compared to saline. The * indicates significant difference between DHA and saline, 
† indicates difference between 2xDHA and saline. 
 
Left ventricular pressures 
Both during treatment administration and upon reperfusion, the pressures were 
recorded.  The maximum and minimum LV pressures were measured both in vivo and in 
vitro on the Visible Heart® apparatus.   
 
Maximum LVP did not vary during the in vivo administration; however, there was a 15-
50% increase upon reanimation.  The 2xDHA treatment started out higher than most the 
other treatments, with statistical significance at 4 and 8 minutes (Figure 5.).  From there 
the pressure declined and returned to similar values as the other groups. 
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Hemodynamics  
Once the heart was removed and reanimated, hemodynamic data was taken for one 
hour of reperfusion.  The values were normalized to the pretreatment baseline measured 
in vivo in order to minimize any artifacts from the effect of the treatments. 
  
 
Figure 5.7: maximum left ventricular pressure. The * indicates 2xDHA significantly higher than saline 
 
Minimum diastolic pressure was also calculated.  There was no noticeable shift in vivo, 
with a slight increase of 1-3mmHg when reanimated in the Visible Heart apparatus.  
During the first hour of reanimation, the minimum pressure continued to increase, with 
no noticeable difference among the groups (Figure 5.). Maximum and minimum rates of 
contraction were also measured, with no differences observed. 
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Figure 5.8: Minimum left ventricular pressure.  All treatments had some increase in minimum 
pressures. 
 
Protein levels  
The levels of biomarkers measuring cell injury were also collected.  There was an 
observed buildup in levels of lactate, troponin and myoglobin over the course of the first 
50 minutes of reperfusion (Figure 5.).   
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Figure 5.9: biomarkers detected in the circulating krebs buffer.  While the levels of each continued to 
rise, there is little difference among the groups for each biomarker. 
 
Ultrasound  
In order to measure the myocardial edema, short axis echocardiographic images were 
captured during the hour of reperfusion.  The size was traced out on the ultrasound unit 
with the imbedded analysis software (GE, Fairfield, CT).  Myocardial cross-sectional 
area was normalized to the area in right-sided working mode.  There were slight 
increases in area for each treatment, with no significant differences (Figure 5.5). 
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Figure 5.5: Left ventricular cross-sectional area as measured on short axis ultrasound.  All 
treatments increased slightly, with no significant differences. 
 
Discussion 
Cardiothoracic surgical procedures carry with them the risk of the patient developing 
arrhythmias and thromboses.  Postoperative AF is a common morbidity, with 25-40% 
incidence after coronary artery bypass surgery [21].  We have shown in this study is that 
the administration of a high dose of DHA to the pericardial space can lower AF 
compared to baseline. Additionally, other studies have shown that ω3PUFAs can reduce 
heart rate.  In this study, we saw a slight decline in heart rate for both dose levels of 
DHA.  The maximum and minimum LVP did not change in vivo after the administration of 
any of the treatments.  This may have significant application in the post-operative 
intensive care unit, where AF is common and post-op arrhythmias increases ICU stays.  
Often an arrhythmic or tachycardic patient requires therapy, but using common options 
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like β-blockers or Na+ channel blockers may also have negative inotropic effects, which 
are typically undesirable in patients recovering from cardiac surgery.  While the 
antiarrhythmic effects of DHA are mild, it may still have a place as a preventative 
measure, especially with such an agent where the negative side-effects with other 
delivery routes are minimal. 
 
Though the exact mechanisms for its antiarrhythmic actions have not been identified, 
many of the effects of ω3PUFAs are known, leading to several hypotheses.  One 
explanation is the observation that fatty acids have the ability to suppress the voltage-
gated sodium channel, shifting the resting membrane potential more negatively [22].  
This shift increases the electrical stability of the cells and may reduce the susceptibility 
to arrhythmias. 
 
Some procedures, including many valve repair and replacement surgeries and all heart 
transplants also require cardioplegic arrest.  Though cardioplegia solutions and topical 
cooling provide great cardioprotection, there is still room to improve myocardial 
protection [23].  Upon reanimation, the 2xDHA treated heats generated significantly 
higher pressures during the first several minutes of operation on the Visible Heart 
apparatus.  The function of these hearts rapidly declined throughout the hour, returning 
to functioning levels similar to the function of hearts in other treatment groups.  This 
reduction in force may be attributed to the diffusion of DHA back out of the tissue, as the 
heart was no longer bathed in the solution at this point.  In cellular studies, the effects of 
DHA have been shown to be reversible [24], [25] and DHA has been shown to be able to 
diffuse quickly [6].  This increase in function may be sustainable with additional 
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administration of DHA to the heart post reanimation.  There was little differences among 
the groups in the measured biomarkers.  It may be several hours before troponin and 
myoglobin are clinically detectable with acute myocardial infarction.  Though an increase 
in levels was observed, perhaps a larger increase may be observed if the levels were 
tracked further out past the ischemic injury. 
 
The improvement in function after global ischemia may have implications for heart 
transplant.  The cardioplegic arrest and cold storage in these experiments is very similar 
to what a transplanted heart will experience.  An increase in function on the Visible Heart 
apparatus may be predictive of increase in performance of an implanted heart.  
Theobserved increases in maximum left ventricular pressure may be a result of the fact 
that ω3PUFAs have potent anti-inflammatory effects [26], [27] as well as anti-apoptotic 
effects [28], and ω3PUFAs have been shown to help decrease oxidative injury [29].  
These effects likely combine to reduce cell damage and death, contributing to the 
cardioprotective properties of ω3PUFAs.  
 
Most beneficial effects reported with ω3PUFAs are specific to DHA and EPA 
(eicosapentanoic acid).  For this study, DHA was chosen because it is the most common 
ω3PUFAs in cell membranes, including heart cells [20].  Additionally, previous studies in 
our lab have shown pericardial delivery of DHA can reduce arrhythmias and infarct size 
in a swine model of ischemia/reperfusion injury. 
 
Many studies investigating the cardiovascular effects of ω3PUFAs make use of long-
term dietary intake.  The advantage of such an approach is its non-technical and non-
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invasive nature.  However, a dietary loading method relies on dietary absorption, blood 
transport, and storage in cell membranes where it can be readily available; a process 
that may take weeks with high ω3PUFA intake and contains patient to patient variability.  
The proposed pericardial delivery simplifies the route to the myocardium, greatly 
reducing individual variability as well. 
 
Limitations 
Although the Visible Heart® approach provides an excellent model for studying cold 
ischemia and heart function, there are several limitations.  Because the circulating buffer 
has no oxygen carriers, the working heart undergoes minor global ischemia.  It is thus 
necessary to cycle the heart out of a full working mode into a “resting” right side working 
mode.  In this mode the right side of the heart is pumping little more than the coronary 
effluent. This lack of oxygen may also be responsible for the decline in function seen in 
the DHA treated hearts, i.e., the myocardial oxygen demand was higher due to the 
higher function, and these higher functioning hearts felt the lack of oxygen much more 
than the lower functioning hearts.  It is also important to note that a transplanted heart 
would have reduced neural connectivity, but it would maintain hormonal responses.  The 
tissue in this experiment lacks all neurohormonal influences from the body.  While this 
differs from the in vivo conditions, the Visible Heart® setup makes it possible to isolate 
cardiac responses from other influences. 
 
With pericardial delivery, one concern is the fact that agents have to diffuse through 
tissues instead of being perfused through the vasculature.  With high concentrations on 
the epicardial surface and very low concentrations on the endocardial surface, 
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myocardial gradients of the agent could possibly occur.  Theoretically, if a treatment 
alters conduction velocity, such a drug gradient could produce heterogeneous 
conduction within the ventricular myocardium, promoting ventricular arrhythmias.  While 
such gradients have been seen [7], no arrhythmias have been reported in published 
models 
 
 
Conclusions and future work 
We have shown here that the omega-3 polyunsaturated fatty acid DHA, when delivered 
to the pericardial space, can reduce induced atrial fibrillation and improve initial in vitro 
performance.  While pericardial delivery of antiarrhythmics and cardioprotective 
treatments hold great promise, dosing and timing will need to be optimized for the 
clinical scenarios.  The DHA used in this study was dissolved in ethanol, future studies 
may try to make use of a formulation that is not dissolved in a substance that is known to 
increase heart rate and decrease contractility [30].   
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Preface 
In Chapter 6, I continued the work into ω3PUFAs.  In the previous chapter, the DHA that 
is used is dissolved in ethanol, which has competing cardiac effects of its own.  For 
chapter 6, in addition to using an alternative ω3PUFA formula, Omegaven, steps were 
also taken to simplify the clinical procedure.  In other words, the DHA used in chapter 5 
was in a chemical formulation that would require additional approval for clinical use.  The 
path to approval for IP delivery may be simplified by using formulas that have been 
proven safe for IV infusion, such as Omegaven, which is used clinically as a fatty acid 
emulsion for parenteral nutrition.  
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Introduction 
The delivery of omega-3 polyunsaturated fatty acids (ω3PUFA) to the pericardial space 
holds great promise.  The antiarrhythmic and ischemic protection have been 
demonstrated in a swine model of acute myocardial infarction [1].  We have also show 
the potential for reducing atrial fibrillation (AF) in previous studies.   
 
The ω3PUFA that was used in previous study was in its free form, but dissolved in 
ethanol.  In this form, it is not clinically approved for injection, and would be difficult to 
translate it to clinical studies.  If beneficial effects can be seen in a formulation that has 
been approved for clinical use, it would be simpler to get approval since the formula has 
been proven safe for injection. 
 
Several fatty acid emulsions are approved for parenteral nutrition.  Mostly used in 
patients who have digestive abnormalities, these emulsions are administered 
intravenously (IV) to provide nutrition.  As such, they have been proven safe and 
effective for injection.  Thus minimal complications exist with myocardial tissue at 
recommended levels, and intrapericardial delivery would have precedence to cite when 
getting approved for investigational use and potentially for on label use. 
 
While the previously tested ω3PUFA was pure DHA, the available emulsions are 
mixtures of ω3PUFAs and ω6PUFAs.  The three compounds used in this experiment are 
outlined below in Table 6.1.  We hypothesize that the Omegaven treatment, which is an 
emulsion primarily made up of ω3PUFAs, will lower time in AF and improve 
hemodynamic function in vitro, while the primarily omega-6 compounds will have almost 
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no effect on AF time, but may exert a slight depression in hemodynamics due to the 
increase in pro-inflammatory signaling. 
 
Omegaven  Lipovenos  Intralipid  
50% Omega-3 
-20% EPA 
-23% DHA  
4% Omega-3  8% Omega-3  
10% Omega-6  22% Omega-6  45% Omega-6  
10% Omega-9  9% Omega-9  18% Omega-9  
25% Glycerol  42% Triglycerides  5% Phospholipids  
Saturated Fatty Acids  6% Phospholipids  10% Glycerol  
 10% Glycerol  Saturated Fatty Acids  
 Saturated Fatty Acids   
Table 6.1: Cocktail treatments composed of omega-3 and omega-6 PUFAs 
 
Methods 
Surgical procedure 
A total of 36 healthy, castrated male Yorkshire swine, weighing 87±9kg, were used for 
this study.  Anesthesia and instrumentation were set up as described in chapter five, 
with the exception of transmural and His bundle electrophysiology catheters. 
Endocaridal pacing leads (Medtronic 3830, Medtronic, Minneapolis, MN) were secured 
into the right ventricular apex and right atrium via fluoroscopy (see Figure 5.) and 
connected to a GEM III pacemaker/defibrillator (Medtronic, MN).  After medial 
sternotomy, access to the heart was then attained via a medial sternotomy and a 
pericardial cradle was created (Figure 5.).  
 
Electrophysiologic measurements 
The electrical leads were used to measure refractory periods and susceptibility to AF. 
The signals from the pacemaker programmer (Medtronic 2090, Medtronic, MN), 
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epicardial pacing leads, decapolar catheter, and EKG leads were recorded 
simultaneously by an ENSITE electrophysiology system (St. Jude Medical, MN).  
 
Atrial effective refractory periods (AERP), ventricular effective refractory periods (VERP), 
and atrioventricular nodal effective refractory periods (AVNERP) were measured 
following a standard protocol explained by Ayers et al. [2] and outlined in chapter 5. 
These electrophysiology parameters were taken just prior to drug delivery as well as at 
5, 30, 60, and 90 minutes after drug delivery.  
 
After the initial data collection, the heart was given one of three treatments in the 
pericardial space: Omegaven, Lipvenos, Intralipid (Fresenius Kabi, Hamburg, Germany).  
All treatments infused at a constant rate 0.5mL/min for 30 minutes for a total of 15mL. 
 
In vitro performance 
At the end of each treatment, the heart was arrested and excised as described in 
chapter 5.   The great vessels were cannulated, and the heart was reperfused with krebs 
buffer using Visible Heart® methodologies (Figure 5.) [3].  Hemodynamic data were 
collected throughout the first four hours of reanimation as described in chapter 5. The 
krebs perfusate was tested for Troponin-I and Myoglobin tested at the Fairview hospital 
clinical labs, and TBARS ELISA assays (Cayman) were also performed.  As the heart 
was cycled in and out of working mode, short axis ultrasound images were recorded in 
order to classify myocardial edema. 
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Statistics 
Data are presented as mean with standard deviation.  Significance was determined 
using Student’s t-test or ANOVA, where appropriate.  An α of 0.05 was considered 
significant, with bonferroni corrections when appropriate.  Analysis was done using 
Microsoft Excel 2007 and STATA version 10.1 
 
Results 
36 pigs were used in this study with no major morbidity or mortality detected from the 
treatments.  There were no significant differences in animal weight or heart weight 
among groups (Table 6.2).  No differences exist among the groups in cold ischemia 
time, defined as the time between arrest and defibrillation to start reanimation. 
Treatment n 
Animal wt 
(kg) 
Heart Wt        
(g) 
cold 
ischemia 
time (min) 
Saline 9 85.1±8.7 418.8±43.9 72.3±5.8 
Omegaven 9 88.9±8.6 433.6±40.8 67.2±6.1 
Intralipid 11 92.6±10.3 459.1±57.9 74.9±10.9 
Lipovenos 7 83.4±5.8 425.0±48.8 76.5±11.0 
Table 6.2: Baseline characteristics, including animal weight, heart weight and cold ischemia time. 
 
During the explant procedure, time from cross clamp to cessation of electrical and 
mechanical activity was recorded as time to flatline.  Upon reanimation, the number of 
shocks required to restart the heart was also recorded (Table 6.3).   
Tx n 
Time to 
flatline (sec) 
number shocks 
to restart 
Saline 9 61±44.0 4.3±4.1 
Omegaven 9 72.6±35.0 4.4±5.4 
Intralipid 11 53.7±29.5 2.9±2.0 
Lipovenos 7 51.8±24.8 3.8±3.9 
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Table 6.3: Time to flatline upon cardioplegia administration and the number of defibrillation shocks 
required to restart the heart. 
 
Atrial fibrillation 
In this open chest model, pig hearts were induced into atrial fibrillation with a burst pace. 
The saline control hearts had very little change from baseline.  The Lipovenos treated 
hearts reduced the time in AF from baseline, with significant differences seen at 5, 30 
and 60 minute, as well a significant reduction from saline treated hearts at the five 
minute time point (Figure 6.1).   
 
 
Figure 6.1: Change in time in AF from baseline.  There was significant reduction in AF from baseline 
in the Lipovenos treated hearts. The * indicates significant change over baseline; ᵻ indicated 
significant reduction over saline treatments  
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Though most of the treatments made ventricular effective refractory periods (VERP) 
trend slightly upwards, there were no significant differences among the groups or 
significant changes from baseline.  Atrial effective refractory periods (AERPs) stayed 
within 10ms of their starting values, with no statistically significant changes (Figure 6.2). 
  
Figure 6.2: Atrial and ventricular effective refractory periods.   
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Hemodynamics 
The Lipovenos treated hearts lowered heart rate at 5 and 30 minutes (compared to 
saline), and maintained a slight reduction in heart rate for the duration. The heart rate for 
the saline and Intralipid treated hearts increased slightly from baseline, but not a 
statistically significant amount (Figure 6.3). 
 
 
Figure 6.3: Heart rate was slightly lowered in the Lipovenos treated hearts at 5 and 30 minutes when 
compared to saline. 
 
Left ventricular pressures 
Both during treatment administration and upon reperfusion, the pressures were 
recorded.  The maximum and minimum LV pressures were measured both in vivo and in 
vitro on the Visible Heart® apparatus.   
 
0.80
0.85
0.90
0.95
1.00
1.05
1.10
1.15
1.20
-20 0 20 40 60 80 100
N
o
rm
al
iz
e
d
 h
e
ar
t 
ra
te
 
Time (min) 
Heart rate 
Saline
Omegaven
Intralipid
Lipovenos
* 
* 
  133 
Maximum LVP did not vary significantly during the in vivo administration, however, there 
was a 12-17% increase upon reanimation in all groups.  There were minimal differences 
among the groups for the first hour (Figure 6.4.  However, as pressure was tracked 
through the four hours of reanimation, the PUFA treated hearts maintained steady 
pressures, but the function of the saline treated hearts started to decline after two hours. 
 
 
Figure 6.4: Maximum left ventricular pressure stayed steady throughout most of the four hours in 
vitro for the three treated groups.  However the saline treated group began to contract with less 
force after two hours, with significant differences between Omegaven and Lipovenos seen at the 
four hour data point. 
 
Minimum left ventricular pressure was also calculated Figure 6.5.  The hearts started 
with a minimum LVP at 5mmHg, with no large changes in vivo.  Upon reanimation, there 
was a slight increase of 1-5mmHg.  During the course of reanimation, the minimum 
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pressure continued to increase, with both Omegaven and Lipovenos treated hearts 
having significantly lower pressures compared to saline by the end of four hours. 
 
Figure 6.5: Minimum left ventricular pressure.  The minimum LVP slowly increases over time for all 
groups. 
 
Protein levels  
The levels of biomarkers measuring cell injury were also collected.  There was an 
observed buildup in levels of lactate, troponin and myoglobin over the course of the first 
50 minutes of reperfusion (Figure 6.6) 
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Figure 6.6: Biomarkers detected in the circulating krebs buffer.  The levels of each continued to rise 
throughout the first hour of reperfusion, where there is little difference among the groups. 
 
Ultrasound  
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cross-sectional area was normalized to the area in right-sided working mode.  There 
were slight increasing trends for all groups, with no significant differences (Figure 6.7).  
 
 
Figure 6.7: Left ventricular cross-sectional area as measured on short axis ultrasound.  All 
treatments increased slightly, with no significant differences. 
 
Discussion 
In this study we infused three different fatty acid emulsions into the swine pericardial 
space to test their ability to reduce susceptibility to induced AF and improve 
hemodynamic function upon reanimation.  In this model, an infusion of Lipovenos 
significantly reduced time in induced AF both from baseline levels and compared to the 
60
70
80
90
100
110
120
130
140
0 50 100 150 200
%
 D
if
fe
re
n
ce
 
Time [min] 
Average Left Ventricular Cross-Sectional Area 
Saline Control
Omegaven
Intralipid
Lipovenos
  137 
saline controls (Figure 6.1).  None of the other treatments had significant effect on AF 
time, with the exception of a non-significant increase in AF time at 60 minutes for the 
Omegaven treated animals.  This spike is primarily caused by a single outlier at this time 
point.  If excluded from the analysis, the Omegaven time in AF would remain very close 
to zero. 
 
The heart rate of all groups stayed within 10% of baseline during in vivo portion of the 
experiment.  The Lipovenos treated hearts had a significant reduction in heart rate 
during the period of time in which the treatment was being infused (5 and 30 minutes); 
however the difference was reduced after the infusion ended (60 and 90 minutes). 
 
Upon reanimation, there was a slight jump in maximum left ventricular pressure in all 
groups.  Previous studies of performance in our lab have shown that heart function 
declines on the apparatus [3].  In the present study, the max LVP for the treated hearts 
maintained 90-100% of function throughout the four hours measured in this study, while 
the saline control group lost over 30% of its initial in vitro function in the same time 
period. 
 
Similarly in the minimum left ventricular pressure, values are expected to increase as the 
heart beats outside of the body and is mildly ischemic.  While the Lipovenos treated 
hearts increased 30-55% over in vitro baseline throughout reanimation, saline controls 
increased nearly three-fold, with significant differences for the last two hours. 
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While Omegaven is made up of a large percentage of omega-3 fatty acids, and Intralipid 
contains a large percentage of omega-6 fatty acids, Lipovenos is somewhere in the 
middle of these two.  The main component of Lipovenos that not present in the other two 
forms is a high concentration of triglycerides.  Most fatty acids in the body are stored in 
triglyceride form, and supplying treatment in this way may deliver them in a form such 
that they are readily available.  
 
The significant reduction in AF was only seen for the first 60 minutes, but not the final 90 
minute data point.  This may be because the delivery was complete and the diffusion of 
fatty acids out of the myocardium was greater than the rate going in.  However, it is 
important to note that there was still an improvement in the in vitro function compared to 
saline four hours after the treatment had ended.  This may be due to a higher 
concentration of fatty acids to elicit antiarrhythmic effects, while the protective effects are 
expressed at lower concentrations  
 
One advantage of using these fatty acid emulsions in the present formulation is they 
have been approved for clinical use, and proven safe infused into the venous system.  
The treatment infusion in this study lasted for 30 minutes, with some indication of 
reduced effects upon termination, as seen in the AF time and heart rate.  This indicates 
the potential quick action of these agents, which may not require a full 90 minutes to 
diffuse.  Thus future studies are designed to evaluate effects of shorter infusions.  Such 
shorter infusions would also be more readily adopted into cardiothoracic procedures. 
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Conclusions and future work 
Using clinically approved fatty acid emulsions may reduce hurdles to clinical adoption. 
Here we showed that the nutritional supplement Lipovenos can reduce AF and improve 
hemodynamics when administered to the pericardial space.  This may have significant 
impact in cardiac transplant.  Future work will include additional dose-response and 
infusion rate testing.  Tailoring delivery to cardiac surgery may involve reduced infusion 
times, but may improve outcomes in the over one million cardiothoracic surgeries each 
year. 
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Preface 
The experiments in this chapter were performed concurrently and using the same 
protocol at in chapter 6.  The results are divided out here to improve clarity.  The main 
parameter that was adjusted in this chapter was that instead of the 90 minute therapy, a 
30 minute treatment was tested.  While the original application for the pretreating to 
improve outcomes after heart transplantation, where a 90 minute window is feasible, 
pretreating for that length of time before routine cardiac surgery would not be practical.  
After getting feedback from physicians here at the University of Minnesota Fairview 
hospital, it was decided that a 30 minute treatment was much more acceptable when 
time was limited.  For example, such a treatment could be given during preparation for 
bypass. 
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Introduction 
The delivery of omega-3 polyunsaturated fatty acids (ω3PUFA) to the pericardial space 
holds great promise.  The antiarrhythmic and ischemic protection have been 
demonstrated in a swine model of acute myocardial infarction [1].  We have also show 
the potential for reducing atrial fibrillation (AF) in previous studies.   
 
The 90 minute treatment used in previous studies allows ample time for the fatty acid to 
diffuse into the myocardium, but may not be ideal for all clinical applications.  A 30 
minute pretreatment would be much more suitable for most cardiothoracic surgeries.  
For instance, a pericardial infusion could begin while a surgeon is preparing the internal 
thoracic artery for coronary artery bypass grafting.  Such a window may allow for 20-40 
minutes of treatment while the pericardium in mostly intact.   A shorter treatment time 
also decreases the time pericardial access is required.  This can reduce the risk of 
infection [2], [3].  Decreased treatment time also decreases the time in the operating 
room, decreasing procedure cost.   
 
Methods 
Surgical procedure 
A total of 29 healthy, castrated male Yorkshire swine, weighing 83±7.8kg, were used for 
this study.  Anesthesia, instrumentation and measurements were taken as described in 
chapter 6.  For these animals, the heart was given one of three treatments in the 
pericardial space: DHA, Omegaven, or control with saline.  All treatments infused at a 
constant rate of 1mL/min for 15 minutes.  All hemodynamic and electrophysiological 
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measurements were taken for 30 minutes after drug delivery after which the heart was 
removed 
 
In vitro performance 
As in chapters 5 and 6, after excising the heart, it was reperfused with krebs buffer and 
reanimated using Visible Heart® methodologies [4]. Hemodynamic and biomarker data 
were collected as described  previously. 
 
Statistics 
Data are presented as mean with standard deviation.  Significance was determined 
using Student’s t-test or ANOVA, where appropriate.  An α of 0.05 was considered 
significant, with bonferroni corrections when appropriate.  Analysis was done using 
Microsoft Excel 2007 and STATA version 10.1 
 
Results 
A total of 29 pigs were used in this study with no major morbidity or mortality detected 
from the treatments.  There were no significant differences in animal weight or heart 
weight among groups (Table 6b.1).  No differences exist among the groups in cold 
ischemia time, defined as the time between arrest and defibrillation to start reanimation. 
Treatment n 
Animal wt 
(kg) 
Heart Wt        
(g) 
cold ischemia 
time (min) 
Omegaven 10 80.3±8.8 395.8±39.8 77.7±9.4 
DHA 9 84.8±9.0 420.4±33.4 79.7±7.3 
Control 10 85.1±8.0 440.9±52.4 78.7±24.6 
Table 6b.1: Baseline characteristics, including animal weight, heart weight and cold ischemia time. 
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During the explant procedure, time from cross clamp to cessation of electrical and 
mechanical activity was recorded as time to flatline.  Upon reanimation, the number of 
shocks required to restart the heart was also recorded, with no significant differences 
observed (Table 6b.2). 
 
Treatment n 
Time to 
flatline 
(sec) 
number 
shocks to 
re1start 
Omegaven 10 97.8±57.6 1.56±0.73 
DHA 9 58.1±25.8 2.0±1.31 
Control  10 54.8±14.6 2.43±2.38 
Table 6b.2: Time to flatline upon cardioplegia delivery and the number of defibrillation shocks 
required to restart the heart. 
 
Atrial fibrillation  
In this open chest model, pig hearts were induced into atrial fibrillation with a burst pace. 
None of the treatment groups changed from baseline in this short treatment (Figure 
6b.1). 
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Figure 6b.1: change in time in AF from baseline values. 
 
Refractory periods 
There were no significant differences among the groups or significant changes from 
baseline in either the atrial effective refractory periods (AERPs) stayed within 20ms of 
their starting values, with no statistically significant changes.  The ventricular effective 
refractory periods (VERPs) of all groups stayed within 5ms of baseline, with no 
significant changes (Figure 6b.2). 
 
-130
-80
-30
20
70
120
-5 5 15 25
C
h
an
ge
 in
 A
F 
ti
m
e
 (
se
co
n
d
s 
ch
an
ge
 
fr
o
m
 b
as
e
lin
e
) 
Time (min) 
Change in time in AF, 30 min only 
Saline
omegaven
DHA
  146 
 
 
Figure 6b.2: Atrial and ventricular effective refractory periods.  Shown as change from baseline 
refractory period. 
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The heart rate was measured in for each treatment group.  There was a slight increase 
in heart rate for all groups, though no significant differences were observed (Figure 
6b.3). 
 
Figure 6b.3: Heart rate in for three treatment groups remains nearly constant. 
 
Left ventricular pressures 
Prior to heart explant, there was minimal change in blood pressure.  Upon reanimation, 
the maximum left ventricular pressure (LVP) jumped 22% in the DHA group.  The DHA 
treated hearts had significantly higher maximum LVPs at several points throughout the 
four hours of reanimation.  All groups had stable maximum LVPs for the first two hours, 
followed by slight decline.  The saline treated hearts had the lowest maximum pressure, 
which also declined to the lowest value in the last two hours (Figure 6b.4). 
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Figure 6b.4: Maximum left ventricular pressure.  The DHA treated hearts held significantly higher 
function compared to saline controls at several points during reperfusion (*).  The DHA treated 
hearts also contracted with more pressure compared to the Omegaven treated hearts at the 30 and 
60 minute data collection points (ⱡ).  The Omegaven treated hearts had higher maximum pressure 
compared to saline, with a significant difference only found at the four hour collection point (†). 
 
Minimum LVP was also tracked throughout the experiment.  There were 
indistinguishable differences among the three groups, which all rose in pressure 
throughout reperfusion (Figure 6b.5). 
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Figure 6b.5: Minimum left ventricular pressure.  No significant differences were observed among the 
three groups. 
 
Protein levels  
The levels of biomarkers measuring cell injury were also collected.  There was an 
observed buildup in levels of lactate, troponin and myoglobin over the course of the first 
50 minutes of reperfusion (Figure 6b.6). 
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Figure 6b.6: Biomarkers detected in the circulating krebs buffer.  While the levels of each continued 
to rise, there is little difference among the groups for each biomarker. 
 
Discussion 
With over a million cardiac procedures in the US per year, any improvement in outcomes 
or reduction in complications would have significant impact on improving patient heath 
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and lowering healthcare cost.  A simple pericardial treatment while the surgical site was 
being prepared would add minimal time, cost or complication to many cardiothoracic 
procedures.  Previous studies have shown pretreatment with DHA provides excellent 
antiarrhythmic and cardioprotecive effects during acute ischemia in swine[1].   
 
In vivo, there was little impact by any of the treatments.  Previous doses of DHA (chapter 
5) showed non-significant increase in VERPs and a significant reduction in time in AF.  
The main difference was the previous treatments started with a loading dose of DHA 
followed by a steady infusion.  With the thought of simplifying the protocol, the current 
procedure eliminated the loading dose.  The resulting effect was almost no response in 
the refractory periods or time in AF observed in the current study.  Thus it may be 
necessary for higher doses of ω3PUFAs to be administered before electrophysiological 
effects can be observed. 
 
There were, however, significant hemodynamic improvements observed with DHA 
infusion, as well as non-significant improvements in Omegaven treated hearts. These 
improvements with ω3PUFAs may be a result of the anti-inflammatory effects [5], [6] as 
well as anti-apoptotic effects [7].  In addition, ω3PUFAs have been shown to help 
decrease oxidative injury [8].  These effects likely combine to reduce cell damage and 
death, contributing to the cardioprotective properties of PUFA.   
 
Limitations 
Although the Visible Heart® approach provides an excellent model for studying cold 
ischemia and heart function, there are several limitations.  Because the circulating buffer 
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has no oxygen carriers, the working heart undergoes minor global ischemia.  It is thus 
necessary to cycle the heart out of a full working mode into a “resting” right side working 
mode.  In this mode the right side of the heart is pumping little more than the coronary 
effluent. It is also important to note that a transplanted heart would have reduced neural 
connectivity, but it would maintain hormonal responses.  The tissue in the in vitro portion 
of this experiment lacks all neurohormonal influences from the body.  While this differs 
from the in vivo conditions, the Visible Heart® setup makes it possible to isolate cardiac 
responses from other influences. 
 
Conclusions and future work 
We have shown here that an infusion of the ω3PUFA DHA can improve hemodynamic 
function after global ischemia and reperfusion.  Previous experiments with variations in 
delivery protocol have shown slight variations of effect.  Clearly, the dose, delivery rate, 
timing and form of ω3PUFAs impact the cardiac effects.  Future work includes 
refinement of delivery protocol and, ultimately, clinical trials to determine effectiveness in 
humans. 
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Preface  
One of the most common types of ischemia comes as a result of acute myocardial 
infarctions.  Because such an event is often unpredictable, pretreatments are of limited 
use.  To test the effectiveness of fatty acids as a post-treatment therapy, we used a 
similar protocol as with the previous in vitro studies.  Instead of pretreating the animals 
prior to explant, the hearts were treated upon reanimation in the Visible Heart apparatus.  
And while preconditioning with fatty acids has been observed to minimize damage from 
ischemia/reperfusion injury [1], [2], the mechanisms are not clear.  Chapter 7: Influence 
of Supplemental Lipids on Hemodynamic and Metabolic Performance of the Isolated 
Swine Heart provides a summary of the hemodynamic measurement after 
administrations of two different fatty acid formulas during reperfusion of swine hearts. 
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Summary  
Background: In healthy hearts, free fatty acids (FA) are the preferred myocardial 
metabolic substrate. Further, certain classes of FAs have been shown to exhibit 
antiarrhythmic and other cardio-protective properties. The current study utilized isolated 
swine hearts to examine the cardiac effects of an omega-3 polyunsaturated FA 
(Docosahexanoic acid; DHA) and a commercially available triglyceride mixture (Intralipid 
20%; IL). We hypothesized that lipid compounds would increase hemodynamic 
performance, with speculation that DHA would provide a greater improvement.  
Methods: Yorkshire swine (n=40) were anesthetized and hearts were excised via 
median sternotomy. Hearts were then cannulated and reperfused utilizing the Visible 
Heart® methodology. Prior to reanimation, hearts were instrumented for left ventricular 
pressure (LVP) measurement. In vitro, hearts were separated into DHA, IL, and control 
groups and hemodynamic data were collected during each of three perfusion modes 
(Langendorff, right-side working, and full-working) over the course of an hour.  
Results: Hemodynamic benefits from lipid treatment were most evident during full-
working mode. Treatment with IL resulted in significantly higher (p<0.05) maximum LVP 
at several points during the first hour when compared to control, and higher positive LVP 
time-derivative (dP/dtmax) compared to DHA and control. IL also resulted in significantly 
lower (p<0.05) minLVP than DHA and control, and lower dP/dtmin than control.  
Conclusions: Lipid administration conferred a level of cardioprotection manifested as 
improved systolic and diastolic functioning. It is interesting to note, however, that IL 
resulted in greater improvement compared to DHA. It is likely that performance 
enhancement with IL was maintained due to mechanisms other than metabolic.  
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Introduction  
Under normal physiologic conditions, cardiac muscle utilizes high-energy fatty acids (FA) 
as its primary metabolic substrate. However, during heart failure or following myocardial 
infarction, FA metabolism is disrupted, causing a shift to a glucose-based metabolism  
[3–5]. Preconditioning with FA substrates has been shown to minimize subsequent 
ischemic damage, and also to minimize arrhythmias [1], [2]. Even so, the underlying 
cardiac mechanisms responsible for the benefits provided by circulating free FAs are not 
clear. By isolating the heart from the systemic influences present in vivo, it is possible to 
investigate specific cardiac effects of FA administration.  
 
The current study used the global ischemic condition of the isolated heart preparation to 
investigate hemodynamic and metabolic effects of administering Intralipid 20% (IL; 
Sigma-Aldrich, St. Louis, MO, USA) or docosahexanoic acid (DHA; Cayman Chemical 
Co., Ann Arbor, Mi, USA) following an ischemic event. In particular, the isolated swine 
heart maintained with a crystalloid perfusate can be considered globally ischemic; our 
lab has utilized this model extensively for a number of scientific purposes [6–9]. Such 
isolated hearts are able to produce intrinsic electrical activation or can be paced [10]. It 
is generally accepted that swine hearts are anatomically and electrophysiologically 
similar to human hearts, particularly concerning arrhythmia potential [11], [12] With this 
in mind, we hypothesized that the addition of lipid compounds would better preserve 
hemodynamic function of the isolated heart preparation when compared to control 
hearts. We further hypothesized that DHA would improve hemodynamics to a greater 
extent than IL. 
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Methods  
The research protocol was reviewed and approved by the University of Minnesota 
Institutional Animal Care and Use Committee, and was designed to ensure the humane 
treatment of all animals as outlined by the "Guide for the Care and Use of Laboratory 
Animals" (NIH). There was no practical difference in the time of day for each of the 
experiments performed and all animals were handled in a similar manner prior to 
investigation (acclimated for a week prior to the study and fasted for 24 hours). All data 
were collected using a Windows-based analog-to-digital data acquisition system running 
the IOX software (EMKA Technologies, Paris, France).  
 
In situ protocol  
Yorkshire-cross mongrel swine (n=40, 82.9 ± 9.4 kg) were initially anesthetized using 
intravenous midazolam (2-3 mg/kg), then intubated and mechanically ventilated to allow 
administration of isoflurane to maintain a surgical depth of anesthesia (>1.0 MAC). 
Catheter access to the right and left ventricles (RV, LV) of the heart was achieved via 
incisions in the external jugular vein and right common carotid artery, respectively. 
Separate Millar Mikro-Tip® pressure catheters (5 French (Fr), MPC 500, Millar, Houston, 
TX, USA) were inserted into the RV and LV so to allow for continuous pressure 
assessment. Following internal instrumentation and closed-chest hemodynamic data 
collection, a medial sternotomy was performed, exposing the heart. 
 
Isolation and in vitro protocol  
Upon completion of in situ data collection and intravenous heparinization (300 IU/kg), 
hearts were arrested using refrigerated (4°C) St. Thomas' cardioplegia, then excised and 
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cannulated for attachment to the Visible Heart® apparatus following a protocol similar to 
that previously described [6]. The excision and cannulation procedure was typically 
completed in 70-80 minutes.  
 
Isolated hearts were instrumented in a similar fashion to the in situ setup; ventricular 
pressures were measured using Millar catheters placed directly into the RV and LV. The 
first derivative of LV pressures (dP/dt) was calculated in real time, with maximum 
(dP/dtmax) and minimum (dP/dtmin) values reported by the data acquisition software. Flow 
probes were placed at the aortic and pulmonary vein cannulae (Model 8N, Transonic 
Systems Inc., Ithaca, NY, USA). The filling pressures of both the right and left sides were 
held constant throughout each experiment. Furthermore, the resistance to ventricular 
ejection was held constant, therefore providing a constant afterload by attempting to 
match it to the in vivo aortic/systemic resistance.  
 
Following instrumentation, defibrillation patches were placed on the anterior and 
posterior portion of the ventricles, and oxygenated Krebs perfusate was supplied to the 
cardiac chambers. The heart was defibrillated and the experimental protocol initiated. In 
vitro hearts were divided into three treatment groups: a) control (n=14), b) IL (n=10), or 
c) DHA (n=16). Figure 7.1 shows the experimental protocol for lipid administration. In 
each case, the particular compound was circulated for an initial 20-minute period, 
followed by a 30-minute "working" period during which no further lipids were added. 
During the subsequent 10 minutes of the study, the entire circulating volume of perfusate 
was replaced 2-3 times in an attempt to remove all lipid compounds.  
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IL Administration  
Intralipid was delivered continuously (Figure 7.1) in an attempt to maintain a constant 
circulating level of lipids in the isolated heart apparatus. A syringe pump was connected 
directly to the aortic root cardioplegia cannula to minimize compound dilution and to help 
ensure administration of IL into the coronary circulation. The infusion was performed at 
0.5 ml/min for the 20-minute administration time, resulting in 10 ml total administered 
volume, or 2 g of lipids.  
 
Figure 7.1: treatment timeline.  DHA and IL were administered at the times indicated.  Hemodynamic 
data were collected at the times marked by the black triangles.  Buffer changes were performed after 
50 and 55 minute timepoints, as indicated by the black circles. 
 
DHA Administration  
A 0.27 ml bolus of stock DHA (250 mg/ml) was administered at time 0 as shown in 
Figure 7.1. This volume delivered 0.0675 g of DHA, with an approximate resultant 
concentration of 30 µM.  Given the small volume of administered DHA relative to the 
circulating volume of Krebs, the injection was made directly into the largest volume 
perfusate reservoir of the isolated heart apparatus to help ensure uniform dilution within 
the system. This concentration of DHA is similar to that used in other in vitro 
experiments [13], [14]. 
 
  160 
Statistical Analysis  
Statistical analysis of the data employed unpaired ANOVA (analysis of variance) along 
with ttests, employing the bonferroni corrections where appropriate. Comparisons were 
performed across elapsed time of the experiment, and also between treatment groups.  
Statistical significance was inferred if p<0.05. Unless indicated otherwise, all values are 
reported as mean ± standard error.  
 
Results  
A total of n=40 swine (mean weight 82.9 ± 9.4 kg) were use in this study.  No significant 
differences existed in cardiac physiology before explant and start of in vitro protocol.  
Treatment groups were tracked over time as well as compared against each other. In 
this way, each treatment was compared both against the others and against itself over 
the course of the in vitro experimentation as time elapsed.  
 
Time Course Comparison  
As shown in Table 1, for the maximum left ventricular pressure (maxLVP) did not 
significantly decrease from baseline with any of the treatments.  The minimum LVP 
(minLVP) increased from baseline only in the DHA, starting at 40 minutes in right sided 
mode (RtSide) and at 50 minutes in Langendorff mode.  The maximum contractility as 
measured by the time derivative of pressure (dP/dtmax) decreased in the control group at 
40 and 50 minutes in right sided and Langendorff modes, respectively.  The contractility 
decreased in the DHA treated hearts at both the 50 and 55 minute times, but not at 60 
when the hearts were in working mode.  These hearts also significantly decreased in 
right sided and langendorff modes at 12 minutes. The increase in relaxation rates was 
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measured by the minimum time derivative of pressure (dP/dtmin).  Similar to the 
contractility, the control hearts significantly increased relaxation rates in both the right 
sided and Langendorff modes, but no in working mode.  The DHA treated hearts also 
increased their relaxation rates in each of the three modes as seen in Table 1.  The IL 
treated hearts had no significant changes in any of these four parameters when 
compared to baseline. 
 
maxLVP Control IL DHA   minLVP Control IL DHA 
work n/a n/a n/a   work n/a n/a n/a 
RtSide n/a n/a n/a   RtSide n/a n/a 40 
Lang n/a n/a n/a   Lang n/a n/a 50 
         dP/dtmax Control IL DHA   dP/dtmin Control IL DHA 
work n/a n/a 50,55”   work n/a n/a 55 
RtSide 40 n/a 12   RtSide 40 n/a 35 
Lang 50 n/a 12   Lang 55 n/a 50 
Table 7.1: Time of observed significant parameter decline. Data resulting from comparisons between 
in vitro data measured at time 0 (reperfusion) and subsequent time points over the course of an 
hour. Listed in the table above are the time points after which a significant difference was observed 
when compared to time 0. A shorter time indicates that performance declined more quickly, while a 
later time point indicates that performance was better maintained. The case where the difference 
was observed only at the particular time (as opposed to the indicated time and all times following) is 
indicated (") Significance was considered where p<0.005 (Bonferroni correction with ten 
comparisons). MaxLVP = maximum left ventricular pressure; DHA = docosahexanoic acid group; IL = 
IntraLipid group; work = full-working mode; rtside = right-sided working mode; lang = Langendorff 
mode; minLVP = minimum left ventricular pressure; dP/dtmax  = maximum left ventricular pressure 
time derivative; dP/dtmin = minimum left ventricular pressure time derivative. 
 
Between Group Comparison 
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Figure 7.2: Maximum (left) and minimum (right) left ventricular pressures in working mode (top) right 
side working mode (middle) and Langendorff perfusion mode (bottom).  MaxLVP = maximum left 
ventricular pressure; and minLVP = minimum left ventricular pressure. The * indicates significant 
difference between IL and control; the † indicates significant differences between IL and DHA; the ⱡ 
indicates significant differences between IL and both DHA and control 
 
Figure 7.2 shows plots of maxLVP and minLVP for each treatment group, as recorded 
during A) working mode, B) right sided working mode, and C) Langendorff perfusion 
modes. In working mode, IL reached a higher maximum pressure compared control for 
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the last ten minutes.  The IL also had significantly lower minimum LVP throughout the 
hour compared to both control and DHA groups.  In the right sided mode, there is little 
difference among the maxLVP at each point.  The IL treated group had lower minLVP at 
most points compared to both control and DHA, marked in Figure 7.2.  In Langendorff 
mode when the only flow in the heart was the coronary flow, there were no significant 
differences in the maxLVP.  However, IL treated hearts had significantly lower minLVP at 
several points, as marked in Figure 7.2. 
 
Figure 7.3 shows in vitro dP/dtmax and dP/dtmin values as recorded for the same time 
points during the same three perfusion modes. In working mode, IL treated hearts 
contracted and relaxed faster than control or DHA hearts, with statistical significance at 
the times marked in Figure 7.3.  In the right sided working mode The IL hearts had 
higher contraction when compared to DHA hearts, with significantly better performance 
at 20, 30 and 40 minutes post reanimation, as noted.  There were no significant 
differences observed in Langendorff mode. 
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Figure 7.3: Maximum and minimum contractility. The * indicates significant difference between IL 
and control; the † indicates significant differences between IL and DHA; the ⱡ indicates significant 
differences between IL and both DHA and control 
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Discussion  
Based on previous experimentation, it is assumed that cardiac performance declines 
over the course of the experiment. While no significant changes were found in maxLVP 
over time (Table 7.1), this in itself is significant. It should be noted in Figure 7.2 that the 
control group continued to exhibit a decline in maxLVP as the experiment progressed, 
while IL actually showed a further increase to values similar to those at time.  Overall, 
administration of lipid compounds was found to better maintain cardiac performance with 
significant improvements seen in IL treated hearts. In general, IL treatment tended to 
result in improved cardiac performance over the DHA group. In particular, minLVP was 
markedly lower over the entire course of the experimentation. In examining the perfusion 
modes, it can be seen in Figure 7.2 and Figure 7.3 that the most pronounced benefits 
were observed during work.  
 
The main advantage of performing this study in the isolated heart preparation was the 
ability to remove systemic influences (neural, hormonal, etc.) and study strictly cardiac 
effects of the investigational compounds. Full-working mode provides the most accurate 
basis for comparison given the physiological functioning of the left ventricle. It is in this 
mode that the Krebs perfusate is circulated in a manner similar to that found in situ. 
Consequently, the LV is actively filling and ejecting, which allows for better assessment 
of pressure and contractility measures.  
 
Supplemental Lipids  
According to the manufacturer, IL is a phospholipid-stabilized soybean oil compound. 
Van de Velde and colleagues further identified the major components in this 
  166 
triglyceridebased lipid emulsion as five different long-chain free fatty acids: linoleic acid 
(C18:2n6), linolenic acid (C18:3n3), oleic acid (C18:1n9), palmitic acid (C16:0), and 
stearic acid (C18:0). These compounds (and some others in smaller amounts) are 
emulsified in 1L of water using 12 g/L of an egg-yolk-derived phospholipid emulsifier 
consisting mainly of phosphatidylcholine [15].  The recommended dosage when used as 
a nutritional supplement is approximately 2 g of fat/kg body weight/day. 
  
The healthy "normal" heart can metabolize a wide variety of substrates including fatty 
acids, glucose, lactates and ketone bodies. Long-chain nonesterified free fatty acids and 
glucose are often the main energy sources for myocardium. Under normoxic conditions, 
metabolism is mainly oxidative. Fatty acid metabolism, which occurs predominantly via 
beta oxidation, is very similar for short-or long-chain fatty acids except that long-chain 
FAs produce more C2 units in form of acetyl-CoA. The energy production from a 
molecule of a fatty acid is dependent on the length of its molecular chain. As such, the 
energy yield from a molecule of a longer-chain fatty acid is higher; however, beta 
oxidation of unsaturated fatty acids requires special enzymes. Intralipid is comprised of 
several saturated and unsaturated fatty acids all with shorter chain-lengths than that of 
docosahexanoic acid (DHA, 22C:6n-3).  
 
Limitations  
DHA was supplied in concentrated form, unbound to any carrier molecules. It has been 
shown that DHA uptake is enhanced in the presence of albumin or another similar 
molecule. It is not known how the addition of an albumin substrate would have affected 
the results of the current study.  
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Translating the proper dosage of IL was unclear given that it is clinically administered 
into a patient's systemic circulation. It is possible that a lesser amount would have similar 
functional effects. The choice of delivering 10 ml of IL was made based on work 
previously published using the same compound to treat isolated hearts [15]. 
 
The isolated heart preparation subjects the heart to mild global ischemia. The amount of 
dissolved oxygen supplied by the Krebs perfusate is considered to be inadequate to 
support full aerobic metabolism. Consequently, and in conjunction with other factors, 
hemodynamic performance is known to degrade over the duration of the prep. Further, 
we were unable to study long-term (> 1 hr) effects due to the necessity of fully utilizing 
the isolated preparation for other experiments. A wide range of other investigations of 
was generally carried out following the current study, making it difficult to obtain 
consistent hemodynamic data from the isolated heart preparation late in the day.  
 
Conclusions  
Hemodynamic performance tended to be better preserved with both DHA and IL 
treatment when compared to control hearts. Overall, IL tended to result in greater 
improvement in cardiac function; IL increased diastolic performance to a greater degree 
than systolic, and also to a greater degree than DHA. Given the difference in molecular 
chain length between DHA and the components of IL, it is unlikely that the benefits of IL 
administration were due to metabolic reasons. We postulate that the observed 
hemodynamic benefits were due to integration of lipid compounds into the cellular 
membrane, thereby modifying the fluidity of the phospholipid bilayer.    
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Preface 
As part of the design of the previous animal experiments, great consideration was given 
to the clinical application of the therapies.  With the help of Eric Richardson, I designed a 
delivery catheter for use during and after cardiac procedures.  This idea stemmed from 
methods of delivery and access, which was trivial with an open chest procedure, but 
eliminated upon closure.  Chronic delivery with an implanted pump seems possible, but 
has shown problems in previous studies.  In swine, after a soft catheter was left in for six 
months, the myocardium showed moderate inflammation and scarring [1].  Thus the idea 
for acute delivery was more suitable.  The prototypes we developed are designed to be 
placed in the pericardial space upon closure after cardiac surgery along with chest 
drainage tubes.  The different interactions of this catheter lead up to a model with 
multiple lumens for clearing pericardial effusions as well as delivering drugs.  An 
incorporated temporary pacing lead allowed for increased control of heart rate.  This 
work is summarized in Chapter 8: Multifunction pericardial drainage catheter, which was 
presented at the Design of Medical Devices conference in 2011. 
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Summary 
A longstanding controversy in the field of cardiac surgery is whether or not to repair the 
pericardium on completion of open heart surgery. The device proposed is a multi-lumen 
catheter that will allow for delivery and removal of fluids to and from the pericardial 
space. In more detail, the main lumen will allow for gentle suction. A second lumen will 
allow for targeted drug delivery if desired. Targeted drug deliver can be especially 
important in the case of adverse events such as infection or postoperative atrial 
fibrillation. A temporary pacing lead through the catheter will allow for increased rate 
control by means of anti-bradicardic pacing. The catheter can help reduce the 
complications involved with closing the pericardium, and thus encouraging more 
surgeons to complete this task in more procedures in order to reduce complications 
among the ever-increasing number of repeat operations. 
 
KEYWORDS 
Pericardium, Targeted Drug Delivery, Atrial Fibrillation 
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Introduction 
The pericardium provides a controlled environment for the heart.  The seemingly double-
layered membrane is actually one single layer of tissue folded on itself.  The inner layer, 
or serous pericardium, is fused to the epicardium, but the tough outer layer, or parietal or 
fibrous pericardium, can be almost 0.5mm thick surrounding the heart.  The outer layer 
is the most visible and by itself is often referred to as the pericardium.  Between the 
layers is 15-25mL of pericardial fluid that lubricates the heart as it beats within the 
mediastinum. 
 
Open heart surgery, which requires the surgical opening of the pericardium, carries 
inherent risks including infection.  Because the pericardium is a contained space, any 
buildup of fluid that may accompany an infection will cause cardiac tamponade; a 
condition in which the heart is prevented from filling effectively as a result of the fluid 
buildup in the pericardium.  In order to avoid this risk, many cardiac surgeons will leave 
the sac open rather than attempt to close it.  Leaving the pericardium open lowers the 
risk of cardiac tamponade, but can lead to other issues.  Without the pericardial barrier 
separating the two, scarring between the myocardium and sternum can occur, effectively 
fusing the ventricles to inside of the sternum. In other words, the pericardium that 
remains open will often not provide the same protection as the pericardium that is 
sutured together.  This barrier is especially important since an increasing number of 
patients are undergoing a second or third cardiac procedure, and separating the heart 
from the sternum carries significant risks such as damage to myocardium itself and 
increases the overall surgical time.  In 2001 it was estimated that 5% of all cardiac 
surgeries in the UK were redo operations, the second or third on a single patient [1].   
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Currently, most cardiac surgeons do not attempt to close the pericardium because they 
feel that the benefit of removing the pericardium outweighs the drawbacks.  However, a 
minority of surgeons still argue that the benefits closing the pericardium warrant closure.  
Clearly either approach has disadvantages and benefits to the patient; the device 
proposed here removes and reduces some of the risks incorporated with pericardial 
closure thus encouraging more frequent closure.  
 
Another complication with cardiac surgery is the high rate of arrhythmias such as atrial 
fibrillation, which occurs post-operatively: such occurrence has been reported to be as 
high as 18-34% in post-surgical patients, depending on the procedure [2].  As a result, it 
has become common to administer prophylactic antiarrhythmic drugs [3], but this also 
does not come without risks.  While preemptive treatments have proven effective [4], 
most antiarrhythmic agents also have inherent side effects that make prophylactic 
treatment not suitable for all patients.  Intrapericardial delivery of antiarrhythmics has 
been shown to produce similar or greater tissue concentrations compared to intravenous 
delivery [5, 6], while reducing drug levels throughout the rest of the body.  Such an 
increase in tissue concentration achieved through pericardial delivery should have 
similar effects to delivery by other means. 
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Figure 8.1: The pericardial drainage catheter inserted into the pericardium of a pig.  Here a suture 
around the shaft holds the catheter in place.  Other options to hold the catheter in place include 
inflating a balloon to hold it in place.   
 
Device Description 
The device proposed (Figures 8.1 and 8.2) can either incorporate double or triple lumen 
catheter that will allow for delivery and removal of fluids to and from the pericardial 
space. In more detail, the main lumen will allow for gentle suction.  Because of this 
vacuum, the catheter must remain rigid enough to prevent collapse while at the same 
time remaining soft enough so as not to irritate the epicardial surface of the heart.  The 
catheter shaft should employ a higher durometer (or could be reinforced with a mesh) 
while the tip and portion inserted into the pericardium (and against the heart) would best 
to be a softer material such as silicone.  The distal tip should also have multiple 
openings to reduce the chance of clogging while suction is applied.  From early 
prototype design feedback, we approximate that the main lumen should be 
approximately 9 Fr (3mm) in diameter.  This would be of sufficient size to clear typical 
amounts of pericardial effusion in such surgical cases.   
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A second incorporated lumen will allow for targeted drug delivery as desired.  Such 
targeted drug deliver could be especially useful in the surgical cases of adverse events 
such as infection or postoperative atrial fibrillation.  As such, the second lumen would 
provide for bolus or continuous delivery of antibiotics or antiarrhythmic agents.  In those 
cases in which the pericardium was repaired, the delivered drug will remain within the 
contained space and decrease systemic side-effects of the selected drug. 
In order to keep the catheter in place post-surgically and also allow for enhanced 
removal, an optional third lumen could be connected to a balloon near the distal tip of 
the catheter.  This would enable the surgeon to cut or suture a small hole, insert the 
catheter and inflate the balloon just inside the pericardial space.  The balloon would 
anchor the catheter and, when deflated, would allow for easy removal.  Another option to 
prevent the catheter from slipping would be to add a small hook or attach it to a 
temporary pacing lead. 
 
A temporary pacing lead through the catheter (or attached to the outside) will allow for 
increased rate control by means of anti-bradicardic pacing.  A patient may have irregular 
heart rhythm after surgery, or may even have a sensitive reaction to certain 
antiarrhythmics, such as beta blockers, which will result in a slower heart rate.  This 
pacing lead could travel through the skin on or in the catheter, or could remain as a 
separate entity.  The pacing lead could also be sewn into the epicardium, and this may 
also provide a means to hold the catheter assembly in place. 
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Figure 8. 2: Catheter tip with balloon.  Main lumen is used for drainage while smaller lumen (visible 
at distal tip) is used for drug delivery.  The optional balloon shown would help keep the catheter in 
place. 
 
The delivery/drainage/pacing device designs described here could allow the given 
cardiac surgeon to close the pericardium while reducing the risk and consequences of 
infections.  The risks of tamponade would be greatly reduced with the drainage function.  
In the case of infection or arrhythmia, the catheter would also provide a conduit to target 
antibiotic or antiarrhythmic treatment directly onto the heart.  In addition to 
pharmacological rate control, the accompanying pacing lead allows the addition of 
pacing, granting greater post-surgical control of heart rate. It is considered that these 
catheters would remain in place for a short period of time, with the idea to remove at the 
same time as a chest tube, typically less than 48 hours.   
 
Limitations And Conclusions 
One limitation to pericardial closure is that it slightly reduces initial cardiac index and 
stroke work.  Rao et al. found that these functions were reduced one hour 
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postoperatively in patients who had pericardial closure (P<0.001).  However, they found 
no significant difference in function at 4h or 8h postoperatively [7]. 
 
In the cases of severe bleeding into the pericardial space, the catheter may not be large 
enough to keep up with blood loss.  Yet, in these types of cases, where the patient is 
bleeding several hundred mL/hr, additional intervention would be likely warranted.   
It should be noted that since the pericardial barrier would remain primarily intact, this 
catheter would not be a replacement for, but rather a supplement to, a typical chest tube 
placement.  The additional transcutaneous tube increases the risk of irritation and 
infection, however, current practices minimize these risks. 
 
Overall, the catheter systems proposed here could help reduce the known complications 
involved with closing the pericardium.  We propose that by making the closure of the 
pericardium safer procedure, it would be possible to encourage more clinicians to 
complete this task in more surgical cases.  In addition to the targeted drug delivery, a 
closed pericardium will have the benefit of reducing complications in future surgeries.   
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Figure 8.3: Heart rate through a pilot study exhibiting the properties of the catheter, which is placed 
in the pericardial space in a swine model.  At time t=0, the heart rate has been elevated with 
isoproterenol to induce sinus tachycardia.  At the marked time, a bolus of metoprolol is given to the 
pericardial space.  After a slight bump, the heart rate drops and levels off 40bpm lower to 110bpm.  
To illustrate further control, at minute 12, the heart is paced at 120bpm 
 
  
Figure 8.4: A version of the drainage catheter that contains a pacing lead and adequate size for 
withdrawing pericardial effusions.  This version also contains a wick (gauze as pictured) that will aid 
in keeping treatment next to the myocardium and might be necessary in cases where the 
pericardium is not closed. 
 
Figure 8.5: (below) Poster exhibited at the Design of Medical Devices conference in 2011 
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Preface 
In addition to the pre- and post-treatments to improve function of the heart, the cold 
ischemic time during a typical heart transplant provides another opportunity for 
cardioprotective treatments.  To investigate treatment during this time, I helped Robin 
Brusen, an MD/MS student, design and test a continuous perfusion cold storage 
apparatus, which is described in Chapter 9: A device and methodology for continuous 
hypothermic perfusion of explanted large mammalian hearts, followed by in-vitro 
langendorff reanimation: pilot studies, published in the Journal of Medical Devices.  In 
the pilot studies, several additives were included in the cold perfusate: albumin, DHA, 
DADLE (a δ-opiod agonist), lidocaine as well as a mid-thermic interval.  In these pilot 
studies, the hearts were ischemic for 15-24 hours, and while hemodynamic function was 
below normal levels, the results were superior to those from static cold storage.  
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Summary 
The current methodologies of clinical heart transplantation limit the ischemic window to 
4-6 hours. Periods longer than this can induce dysfunction in the organ and lead to 
increased patient morbidity and mortality. An alternative to the current methods of static 
cold storage (CS) is continuous hypothermic perfusion (CHP), where a hypothermic 
oxygenated crystalloid solution is mechanically perfused through the coronary arteries. 
This has been shown to preserve function for up to 72 hours, but the techniques have 
yet to be optimized. We have developed an apparatus and methodology for performing 
CHP on large mammalian hearts, followed by reanimation in our in vitro Langendorff 
apparatus (Visible Heart™). We are also investigating the utility of the cardioprotective 
agents docosahexaenoic acid (DHA) and [D-Ala2, D-Leu5] enkephalin (DADLE), both of 
which have shown cardioprotective effects in our laboratory; we believe that their 
addition to the preservation solution can further extend the transplant window. A series 
of pilot studies have been performed to date, with modestly successful results. Hearts 
preserved with CHP seem to show better functionality than CS hearts, but far worse 
functionality and higher release of biochemical injury markers than hearts reanimated 
immediately after explant. We hope to use this system to optimize CHP methodology 
and eventually develop a system for prolonging the window for heart transplantation. 
 
  
  182 
Introduction 
The advent of heart transplantation in 1967 [1] brought hope for millions of patients with 
late-stage heart failure. The complete exchange of a diseased heart for a healthy one 
has the potential to prolong life for many years, especially in individuals who otherwise 
would likely have died in several months or would have required support on a ventricular 
assist device. Nevertheless, even in best-case scenarios the heart transplant procedure 
presents complications, difficulties, and an average longevity of 10 years post-transplant.  
 
It is the relative degree of ischemic injury associated with the transit of the heart from 
donor to recipient that lies at the core of many complications attributed to the heart 
transplantation procedure. In general, all transplanted organs/tissues undergo some 
amount of ischemic damage, but cardiac tissue seems to be particularly susceptible. 
More specifically, the kidney and liver can be transplanted reliably and safely for a cold 
ischemic time of up to 24 hours, whereas for the heart this period is currently clinically 
limited to 4-6 hours. Importantly, ischemic times beyond these considered limits have 
been shown to increase the relative risks of recipient mortalities at 1 year [2].  
 
The current standard of heart preservation for transplantation is static cold storage (CS) 
where the donor heart is arrested with a cardioplegic solution and placed in a simple ice-
filled cooler. This is primarily based on the principle that metabolic activity will be 
suppressed by hypothermia, thus reducing enzymatic rates. The generally accepted rule 
is that metabolic rate is reduced by a factor of 2 for every 10°C decrease in temperature, 
yielding a remaining 10-12% of basal metabolic rate at 4°C. It is important to note that 
this residual metabolic activity continues during the CS transportation and, in the 
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absence of oxygen and a supplied energy source, leads to anaerobic metabolism and 
gradual decreases in both tissue ATP levels and pH. Ultimately this sustained 
metabolism leads to ischemic myocardial damage and primary graft dysfunction [3]. This 
clinically translates to decreased cardiac contractility after transplant, typically requiring 
additional inotropic and/or mechanical support; the current estimate is that this will occur 
in 10-25% of recipients even with the current standards concerning donor quality and 
ischemic times [4]. It should be noted that previous studies in our lab, in which we 
attempted 17 hours CS preservation followed by in vitro reanimation, yielded minimal or 
no contractile and/or sustained electrical functionality [5]. 
 
One potential method of prolonging the window of heart viability and reducing ischemic 
damage is continuous hypothermic perfusion (CHP). This procedure is relatively simple 
and involves continuous perfusion of the coronary arteries with a hypothermic 
oxygenated crystalloid preservation solution to support residual metabolic activity and 
thus limit global ischemic damage. More specifically, in one study the use of this 
technique was shown to shift metabolic activity from anaerobic to aerobic and maintain 
cell integrity and functionality [6]. CHP as a research method was first reported for 
application in dog hearts, only a year after the first successful human heart transplant. 
Importantly in this study, these hearts were shown to maintain contractility for up to 72 
hours [7]. Subsequently, this approach was employed to preserve both baboon and 
swine hearts for up to 48 hours before implantation into recipients [8]. Furthermore in an 
additional report, CHP was shown to be superior to CS with 6-hour preservation times; 
CHP resulted in better function upon reanimation, preserved high tissue ATP 
concentrations, and lowered levels of several markers for oxidative damage, apoptosis, 
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vascular dysfunction, and DNA damage [9]. Taken together, these results suggested 
that not only could CHP lengthen the transplant window, but it could also decrease 
primary graft dysfunction associated with short ischemic times. 
 
To date, CHP has been relatively well received by the kidney transplantation community, 
and several commercial devices for renal transplantation are currently available [10]. 
Interestingly, CHP for clinical heart transplantation has yet to be adapted, despite the 
fact that it has been shown advantageous over CS preservation in animal models. On 
the other hand, one can identify several issues with using CHP for extending the window 
of heart transplantation, the main disadvantage being its potential for the induction of 
myocardial edema and associated diastolic dysfunction. In previous studies, this edema 
has been reported to increase the weight of hearts up to 5-fold compared to those 
recovered with CS for the same time interval, despite using preservation solutions with 
high oncotic pressure [11]. This, combined with low numbers of clinical trials, a lack of 
consensus on methodology in preclinical experiments, and long length and high cost of 
the experiments has led to a lack of clinical acceptance. Thus more research must be 
performed on such techniques to perfect or enhance them before they will become a 
clinical reality. 
 
It is proposed by our laboratory that improved formulations of the preservation solution 
could lead to better function of hearts preserved with CHP. More specifically, we 
postulate that the addition of docosahexaenoic acid (DHA), an ω-3 fatty acid and/or [D-
Ala2, D-Leu5] enkephalin (DADLE), a δ-opioid agonist could be employed to further limit 
ischemic damage to the heart. For example, there are numerous known actions of DHA, 
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including increased fluidity of cell membranes, ion channel blockade, and inhibition of 
eicosanoid pathways [12]. Furthermore, our laboratory has previously shown that 
intrapericardial administration of DHA followed by coronary artery occlusion can reduce 
associated infarct sizes and incidences of ventricular tachycardia relative to controls 
[13]. It should also be noted that δ-opioid agonists have been shown to induce the 
hibernating state in mammalian tissue, leading to more stable membrane potentials, 
stabilized ion gradients, altered channel activity, decreased arrhythmia propensity at low 
temperatures, reduced vascular dysfunction, and/or inhibition of oxidative damage [14]. 
As such, we hypothesize here that both of these compounds can be used to reduce 
ischemic damage when combined with the CHP methodology.  
 
In this paper, we describe our novel device for performing CHP on swine hearts, the in 
vitro apparatus for reanimation, a series of pilot studies to assess currently reported 
CHP methodology, and plans to develop it further. 
 
Methods 
Swine (70-100 kg) were used for such investigations following approval from the 
University of Minnesota’s Animal Care and Use Committee. Intramuscular telazol (5 
mg/kg) was used to preanesthetize the animals, followed by intravenous administration 
of thiopental (5 mg/kg) via an ear vein. The animals were intubated with a 7- or 7.5-mm 
inner diameter endotracheal tube and mechanically ventilated with 65% air and 35% O2. 
Subsequently, general anesthesia was maintained using isoflurane (~1.5 minimal 
alveolar concentration); end-tidal CO2 and exhaled isoflurane levels were monitored 
continuously and adjusted to maintain sufficient anesthetic depth. The animals’ hearts 
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were then exposed via median sternotomy. In several of the pilot studies, incisions into 
the pericardial sac were made and then a soft infusion catheter was inserted to allow for 
the continuous infusion of DHA (45 mg dissolved in 20 mL saline solution, infused over 
45 minutes). After heart exposure and/or DHA pretreatment, cardioplegia cannulae were 
sewn into the aortas and St. Thomas II Cardioplegia solution (1 L) was infused into the 
cannulae with a perfusion pressure of 150 mm Hg. After contractile and electrical 
activities ceased, the hearts were excised, the great vessels were dissected, and plastic 
cannulae were tied into the aorta proximal to the innominate artery and distal to the 
coronary artery ostia. The heart chambers were flushed with St. Thomas II Cardioplegia 
solution (~1 L) to remove residual blood and the hearts were weighed. The hearts were 
then connected to the perfusion apparatus and suspended within the lower reservoir. 
 
The perfusion apparatus is shown in Figure 9.1. A circulator-chiller (RM6, Lauda-
Brinkmann, Lauda- Konigshofen, Germany) was used as the pump, refrigeration unit, 
and reservoir for the preserved hearts. This device has proven efficacious and safe for 
supporting muscle tissue in our laboratory. The fluid was pumped to an upper reservoir 
to prevent air bubbles from entering the grafts. Auxiliary tubing connecting the upper to 
the lower reservoir prevented overflow. The upper reservoir drained into a 27 μm blood 
filter (Affinity, Medtronic, Inc., Minneapolis, MN, USA) and a hollow fiber oxygenator 
(Affinity, Medtronic, Inc. Minneapolis, MN, USA) before draining into the cannulated 
aortas of the hearts suspended in the lower reservoir within the circulator-chiller. 
Surgical tubing (Nalgene Labware, Rochester, NY, USA) was used to connect the 
elements of the system. The height of the upper chamber and screw clamps (Nalgene 
Labware, Rochester, NY, USA) were used to control the perfusion pressures. A Luer 
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taper connector between the oxygenator and the heart was used to monitor pressure 
(Uniflow, Baxter Healthcare, Irvine, CA, USA) and oxygenation (ISO2, World Precision 
Instruments, Sarasota, FL, USA) of the perfusate. 
 
The durations of the preservation were variable between the preliminary studies 
described here. The temperatures of the perfusate were either held at a constant 9°C for 
the duration of the preservation interval or elevated to 25°C for the first 30 minutes of the 
preservation, then lowered to 9°C for the remainder of the preservation (midthermic 
interval). The perfusion pressures were set to 15-20 mm Hg at the beginning of the study 
and no attempt was made to modify them afterwards. Carbogen (95% O2/5% CO2) was 
infused into the oxygenator at a rate of 1 L/min. Samples of the preservation solutions 
were taken at approximately 3, 6, and 12 hours into the preservation intervals and stored 
for later biochemical analyses. 
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Figure 9.1: diagram of preservation apparatus, showing the circulator/chiller pumping fluid into the 
upper reservoir, filter, oxygenator, and eventually into the aorta of the preserved heart in the lower 
reservoir 
 
To date, it should be noted that there is no consensus regarding the best organ 
preservation solution to use for CHP. For the present studies, we employed 6 L of 
modified Celsior solution. The solution modifications included: 1) addition of albumin 
toincrease oncotic pressure and reduce tissue edema; 2)  reduction in potassium 
concentrations or addition of lidocaine to reduce vascular dysfunction during 
preservation; and 3) addition of DHA or DADLE as preconditioning protective agents.  
 
At the end of each preservation interval, each heart was reanimated using the in vitro 
Langendorff (Visible Heart™) methodologies which employ a modified Krebs-Henseleit 
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Buffer (KHB, ~8 L) for approximately 1 hour. The KHB was supplemented with 
nitroprusside (40 mg) before reanimation to induce vasodilation of the already 
constricted vasculature as well as dobutamine (~ 0.2 mg/l) to improve contractility. This 
apparatus and methodology have been previously validated as a method to reanimate 
large mammalian hearts and assess physiology and functionality [15]. To date, our lab 
has reanimated and assessed the function of over 700 swine and 39 human hearts 
using this approach, thus this technique was used in this experimental model as a 
means for appropriately assessing viability of these potentially preserved hearts. 
Additionally, ventricular pressures (MDE Escort, Viasys Healthcare Technology, 
Conshohocken, PA, USA) and surface EKG (101 Patient Monitor, IVY Biomedical 
Systems, Branford, CT, USA) were monitored during reanimation. Further, for the final 
two pilot studies, an infusion catheter was placed in the coronary sinus for sampling of 
the KHB at 0, 20, and 40 minutes after reanimation for biochemical analyses; note that 
similar samples were drawn from hearts reanimated immediately after explant (within 1 
hour) for comparisons. 
 
The preservation solutions and KHB samples were stored at -4°C. After all experiments 
were completed, the samples were thawed by allowing them to return to room 
temperature, and 7 mL aliquots of each sample were sent to the Department of 
Laboratory Medicine for myoglobin and troponin quantification (via radioimmunoassay). 
Oxidative stress was quantified using a fluorometric thiobarbituic acid reactive substance 
(TBARS) assay (Cayman Chemical Company, Ann Arbor, MI, USA). Note that 
malondialdehyde (MDA) is a product of lipid peroxidation that reacts with thiobarbituic 
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acid (TBA) to form an adduct that can be measured colorimetrically at 530-540 nm, and 
the degree of absorbance correlates to the degree of oxidative damage [16].  
 
The data were plotted using Microsoft Excel. Statistical analyses (inference value 
calculations) were performed using the statistical package R (http://www.rproject.org). 
Biochemical values were reported as mean ±SE and inferences were performed using 
Student’s Ttests. Regression line parameters were reported as mean ±SE, and P-values 
were based on the 2-sided alternative model, i.e., slope ≠ 0. Regression models were 
compared using ANCOVA (F- and P-values reported). Values are reported as significant 
if P < 0.05. 
 
Results 
To date, we have performed numerous control and pilot studies employing the system 
described. Table 9.1 summarizes these preliminary data.  
 
The carbogen delivery rate of 1 L/min saturated the perfusate oxygenation to 95% of 
atmospheric pressure. Given the small number of studies performed to date and that 
none had identical conditions, no specific conclusions can be drawn about the relative 
differences identified in our studies. It is noted, however, that these hearts developed far 
lower contractility and pressure than those reanimated within one hour after explant, yet 
they seemed to develop better contractility and pressure compared to hearts reanimated 
after 17 hours of CS preservation. It was observed that the addition of albumin to the 
perfusate did not seem to reduce edema, and the degree of edema appeared to be 
related more strongly to the preservation duration. Interestingly, the addition of DHA 
  191 
seemed to improve contractility relative to the control studies. Also noted, the pilot study 
with the lidocaine additive seemed to be more susceptible to ventricular fibrillation upon 
reanimation. Nevertheless, these statements need be considered as anecdotal and merit 
further controlled studies to draw definitive conclusions. However we can be reasonably 
certain that hearts preserved via the methods described have significantly diminished 
function compared to control hearts (~1 hour ischemic time). 
 
The KHB myoglobin and MDA concentrations in the preserved and immediately 
reanimated (nonpreserved) hearts are compared in Figure 9.2. There was significantly 
higher myoglobin (P = 0.002) and troponin (P = 0.022) released by the preserved hearts 
compared to non-preserved hearts, but there were no significant differences in MDA 
concentrations (P = 0.111) between the 2 groups. 
 
 
Figure 9.2: comparison of biomarkers in the khb from preserved and nonpreserved hearts, displayed 
as mean ± se. Student’s ttest: mda p-value = 0.111; myoglobin p-value = 0.002; troponin p-value = 
0.022. 
 
Of interest, troponin was generally undetectable in the preservation solution. The MDA 
concentrations of the preservation solution are shown in Figure 9.3 (A); note that a linear 
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relationship was assumed between MDA concentration and time. The data were 
separated into studies with and without the DHA additive. The residuals of each 
regression model were approximately normal with means centered at 0 (not shown). For 
the studies with the DHA additive in the preservation solution, the regression line had a 
slope of 0.025 ± 0.063 (P = 0.695) and R2 = 0.023. For the studies without the DHA 
additive, the regression line had a slope of 0.979 ± 0.512 (P = 0.152) and R2 = 0.550. 
The ANCOVA comparing the 2 regression lines yielded F = 0.165, P = 0.696. 
 
The myoglobin concentrations of the preservation solutions are shown in Figure 9.3 (B). 
A linear relationship was assumed between myoglobin concentration and time. The data 
were separated into studies with and without the DHA additive. The residuals of each 
regression model were approximately normal with means centered at 0 (not shown). For 
the studies with the DHA additive to the preservation solution, the regression line had a 
slope of 38.43 ± 17.23 (P = 0.06) and R2 = 0.41. For the studies without the DHA 
additive, the regression line had a slope of 260.56 ± 58.75 (P = 0.02) and R2 = 0.87. The 
ANCOVA comparing the 2 regression lines yielded F = 4.974, P = 0.06. 
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Figure 9.3: mda (a) and myoglobin (b) concentrations of the preservation solution. 
 
Discussion 
The pilot studies performed and described here show promise as: 1) an experimental 
means to assess the outcomes relative to optimizing CHP or the heart for long-term 
storage; and 2) providing novel pharmacological approaches to precondition the heart to 
enhance the potential benefits of CHP. Nevertheless, many more studies are needed to 
validate and build on these aforementioned statements. 
 
Within the pilot studies described here, in all cases we saturated the preservation 
solution with oxygen (~95%), which is higher than what would be required to maintain 
the organ at 10°C assuming 100% oxygen extraction. This was done because it remains 
unknown as to exactly what the oxygen extraction capabilities of the organ are in the 
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hypothermic arrested state. Nevertheless, given the inhibition of enzyme and 
hemoglobin function, it was assumed they would be compromised. It is believed that 
higher oxygen concentrations would be required to support aerobic metabolic activity 
than if the organ had the same oxygen consumption at normothermia. The oxidative 
effects of oxygen should also be determined, as the preserved organs are much more 
susceptible to oxidative damage in the absence of functional antioxidant enzymes. One 
should note that a higher than necessary oxygen concentration could thus be 
detrimental to the organ via exacerbating oxidative damage. Furthermore, no studies to 
date have included glucose or insulin, although previous studies suggest that glucose 
utilization is minimal during CHP [17]. As such, the effects of various levels of 
oxygenation should be explored further, perhaps by looking for markers of oxidative 
damage at varying levels of oxygen concentration. 
 
 
Table 9.1: Summary of pilot study results 
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It should be noted that our Visible Heart™ methodology used for reanimation does not 
perfectly simulate the functional and metabolic state of a transplanted heart. Importantly, 
the KHB circulated throughout our apparatus does not contain an oxygen carrier, thus 
the reanimated hearts continue to be globally ischemic. This contrasts to transplanted 
hearts, where the high O2 content of the blood allows for better metabolic support of the 
already ischemic organ. Thus, we would expect metabolically stressed hearts 
reanimated in our system to perform less well than a transplanted heart. 
 
Biochemical comparisons of the KHB collected from the coronary sinus of preserved and 
control hearts suggest significantly higher myolysis in the preserved hearts than controls, 
as evidenced by the myoglobin and troponin concentrations. These proteins are 
commonly used biomarkers for cardiac injury clinically, and are typically part of the 
diagnostic criteria for identifying acute myocardial infarction. Since the myoglobin and 
troponin seemed to correlate well to the perceived function of the reanimated heart, it 
suggests that these markers could also be used to assess general organ viability. 
Further, these biomarkers have a distinct advantage over mechanical and hemodynamic 
indicators in that they are independent of preloads, afterloads, and/or addition of 
inotropic agents to the KHB solution. Yet, the lack of difference in the MDA concentration 
may suggest that there is not increased oxidative damage incurred during reanimation of 
the preserved hearts compared to controls, and that the difference in function is not due 
to increased oxidative damage during reanimation. 
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The biochemical analyses described above may also be interpreted to suggest both 
cardioprotective and antioxidant effects of DHA when added to the preservation solution. 
However, since there are other differences between these pilot studies, including colloid 
and lidocaine addition, it is unknown which of the additives may be eliminating or 
inducing oxidative damage. The fact that pilot study #4 had similar observed function 
upon reanimation as hearts preserved for longer durations and that it seemed to be 
more susceptible to ventricular fibrillation suggests that the either the addition of 
lidocaine or the absence of albumin, DHA, or DADLE could have been considered as 
proarrhythmic or anti-protective. Yet we acknowledge here that in these pilot studies, the 
lack of replicates makes it impossible to know which one induced this effect; more 
studies are planned to better identify such potential interactions. 
 
It is important to consider that given the high cost of performing the described 
experiments and the modest results to date, it may be worth moving a step back 
experimentally from whole organ preservation to tissue preservation, e.g., where 
dissected cardiac muscle bundles are preserved under various CS conditions and 
subsequently tested for resultant recoverable force productions. Additionally, this would 
allow for optimization of preservation conditions such as temperature, oxygenation, and 
preservation solution composition without expensive and labor intensive total heart 
reanimations. Nevertheless, this tissue bath approach may have a foreseeable confound 
in that it does not recapitulate the perfusion of the organ, and the potential edema often 
associated with CHP may not be observed. In such experiments at least the effects of 
the parameters and additives could be more efficiently estimated than with total heart 
reanimation. 
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Conclusion 
We report a reproducible experimental approach to assess the outcomes of CHP for 
optimizing heart preservation. To date, we have observed modestly successful 
reanimation of swine hearts after extended preservation beyond current clinical 
methods. In each pilot study, cardiac function was severely diminished in the CHP 
preserved hearts, and these preserved hearts released higher amounts of troponin and 
myoglobin into the KHB solution, indicating more cellular damage. However, CHP-
preserved hearts exhibited better function than the absent or near absent functionality 
seen in CS preserved hearts. The addition of various pharmacological pretreatments 
along with CHP may help to further support subsequent functionalities, e.g., the addition 
of DHA may induce additive positive effects on cardiac function, biomarkers of cardiac 
injury, and oxidation. This suggests that our current device and methodology has the 
potential to extend the duration of heart transplant, but more studies are needed to verify 
optimization including randomized controlled trials. 
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Thesis summary 
Through the course of this thesis I have investigated cardioprotective treatments with 
particular focus on the pericardial delivery of antiarrhythmic agents.  Through the studies 
contained herein, it is clear that pericardial delivery provides a unique delivery route that 
can increase the effects of certain antiarrhythmic agents while decreasing systemic 
levels and ensuing side-effects. 
 
In order to come to this conclusion, I began with much of the necessary background 
research, including anatomy and physiology of atrial fibrillation, written up in chapter 
one.  This study of the anatomy compared perfusion fixed hearts with AF to controls, and 
demonstrated the remodeling that occurs with the disease.  I continued on with 
investigating many different types of targeted drug delivery, in a chapter authored for the 
textbook Thoracic Surgery.  This is reproduced here in chapter two. 
 
The localized delivery of drugs during cardiac surgery and heart transplant posed a 
unique opportunity for treatment.  I began to investigate such deliveries by developing a 
swine model of AF, first comparing pericardial delivery of metoprolol to IV delivery, then 
studying the effects of pericardial omega 3 fatty acids with various formulations. 
 
Through this work, I have come to the conclusion that intrapericardial delivery can 
increase the effectiveness of certain drugs.  The enclosed pericardial space increases 
concentrations of drugs at the targeted site and reduces peripheral exposure. The 
included experiments were designed to translate into surgical clinical situations where 
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pericardial access can be easily obtained.  The protocols were kept simple to add 
minimal complexity to heart surgery and transplantation.  The timing of the 90 minute 
treatment was intended to be incorporated into heart transplant procedures, where 
treatments such as DHA or Lipovenos delivered to the pericardial space during 
preparation and peripheral organ harvest could help improve hemodynamic performance 
and reduce postoperative AF in the heart recipient.   
 
Omega-3 polyunsaturated fatty acids have anti-inflammatory and antiapoptotic effects 
that may contribute to the improved performance observed upon reanimation.  This may 
translate to improved performance of donor hearts upon implantation.  With the 
reduction of tissue damage throughout the transplant procedure, transportation time 
between donor and recipient may be increased.  This would relieve the stress on the 
logistics of transplantation and allow for increased transport times, likely increasing the 
number of possible transplants. 
 
The 30 minute timing was designed to fit in with cardiac surgeries that may require some 
preparation time prior to arresting the heart.  For instance, the internal thoracic artery is 
often used as the donor vessel in a coronary bypass procedure, and this may take 30 
minutes to isolate and prepare.  This time could be used for treatment with DHA, which 
was shown in the above experiments to improve function upon reanimation. 
 
These studies are performed in swine, and several steps must take place before 
widespread clinical application proliferates.  Clinical methods for pericardial delivery will 
require surgical or novel minimally invasive protocols for delivery.  To accomplish this, 
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modifications may need to be made to common surgical techniques and custom tools, 
such incorporating as the pericardial catheter variations outlined herein.  Future steps 
would include clinical studies to confirm the effective translation into humans prior to 
use.  Such treatments described in detail in this thesis may improve outcomes and 
increase the total number of heart transplants that are possible. 
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Appendix A: Preface 
As I started my PhD research, I initial focused on ischemia/reperfusion injury.  As the 
leading cause of morbidity and mortality in the U.S., ischemic heart disease is usually 
caused by coronary artery disease and myocardial infarction.  Ischemia due to reduced 
blood flow includes a reduction in oxygen, a drop in the availability of nutrients and 
metabolic substrates, as well as a decrease in waste clearance.  
 
Reperfusion, or the restoration of blood flow, is necessary to minimize cell death due to 
lack of oxygen, or infarct, and to restore cardiac function.  Paradoxically, reperfusion is 
associated with a host of mechanisms that can lead to further myocardial injury.  
Mechanisms such as oxygen free radicals, intracellular calcium overload, microvascular 
and endothelial dysfunction as well as altered metabolic function are mediators of 
reperfusion injury, and steps taken to mitigate these may reduce damage caused during 
reperfusion.  One such agent that may influence metabolic function is glucagon-like 
peptide-1 (GLP-1).  This appendix contains background and experimental data on 
certain cardiac effects of GLP-1.  This early work served to form much of my foundation 
of cardiac physiology and pharmacologic treatment.  Below is a brief review of GLP-1 
and its cardiac effects, as well as a scientific report of the experimental treatments with 
GLP-1 during cardiac ischemia, which is in preparation for publication. 
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Glucagon-line peptide-1: Introduction  
Glucagon-like peptide 1 (GLP-1) is a naturally occurring incretin hormone secreted by 
intestinal L-cells in response to ingested nutrients.  It stimulates glucose-mediated insulin 
release,  increases insulin sensitivity, mimics response to insulin and inhibits glucagon 
secretion [1].  Since the insulinotropic actions of GLP-1 are dependent on circulating 
glucose levels, a major advantage is the reduced risk of hypoglycemia compared to 
direct injections of insulin.  Because of these effects, GLP-1 has been the subject of 
intense investigation as a therapy for diabetes mellitus, resulting in multiple synthetic 
versions available for therapy today.  
 
The GLP-1 receptors are widely distributed, located in the stomach, intestinal tract, 
brain, kidney and heart [1].  Initial studies of the cardiac GLP-1 receptors, along with the 
classification of a GLP-1 receptor knockout mouse [2], incited interest in the 
cardiovascular effects of GLP-1.  The GLP-1 receptor deficient mice show reduced heart 
rate and elevated left ventricular (LV) pressures compared to controls at age 2 months.  
By 5 months of age, the mice lacking the receptor have increased LV wall thickness 
compared to controls, as well as a lack of a response to intravenous insulin [2].  Thus it 
is hypothesized that GLP-1 has cardiovascular effects via two routes: cardiac effects 
mediated through increase insulin secretion and sensitivity as well as direct effects on 
the myocardium.  To that end, GLP-1 has been demonstrated to have its own effects in 
isolated rodent heart preparations [3–5].  The exact mechanism is not known, but it has 
been shown that the beneficial effects are abolished by the inhibitors of PI3K, mitogen-
activated protein kinase, and cyclic AMP (cAMP), suggesting that these pathways are 
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involved in the protective response of GLP-1 [4].  The effects can also be blocked by the 
GLP-1 receptor agonist exendin 9-39.  
 
One of the difficulties with GLP-1 therapy is the short half-life of 1-2 minutes, as the 
peptide is quickly broken down by dipeptidyl peptidase-IV (DPP-4) [6].  Because of this, 
several methods for prolonging GLP-1 exposure have been used, including continuous 
intravenous infusion, subcutaneous delivery, DPP-4 inhibitors and long acting GLP-1 
analogs.  One such analog was extracted from gila monsters (which eat 5-10 times 
annually) is Exendin-4, commercialized in synthetic form as Exenatide (Byetta, Amylin 
Pharmaceuticals), which is injected subcutaneously for diabetic therapy. 
 
Cardiovascular Effects 
GLP-1 has been widely studied for its physiological effects on the cardiovascular system 
and for its therapeutic potential in ischemia and heart failure. GLP-1 and its analogs 
have been shown to be cardioprotective in rodent [3–5], [7], [8], swine [9], and canine 
[10] models of ischemia-reperfusion injury.  
 
However, many of the results found in the literature are inconsistent, such as the 
inotropic effects of GLP-1.  Zhao et al. showed that GLP-1 treatment resulted in a 
decrease in left ventricular developed pressure (LVDevP) as well as a decline in LV 
change in pressure over time (LV dP/dt) in the non-ischemic isolated rat heart [5].  
However, when subjected to ischemia/reperfusion injury, GLP-1 improved recovery of 
LVDevP [5].  Other studies have corroborated these improved hemodynamics after 
ischemia/reperfusion injury in mice (Ban et al., 2008) and dogs (Nikolaidis et al., 2005) as 
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well as showing increased cardiomyocyte viability when delivered at reperfusion and/or as 
a preconditioning mimetic [8], [12].  And Ban and colleagues went on to show that many of 
these effects are independent of the GLP-1 receptor by producing similar results in a GLP-
1 receptor knockout mouse [8], [12]. Ossum and colleagues reported that GLP-1 has a 
small, non-significant effect on contractility in an ischemia/reperfusion model of the rat 
heart [13], which could be explained by the cardioprotective property of the treatment. 
GLP-1 infusion has also demonstrated a significant inotropic effect in a canine model of 
heart failure [14], [15].  
 
When studied in acute infarction models, GLP-1 has been suggested to reduce tissue 
damage when administered as a preconditioning agent or at reperfusion.  Bose et al. 
showed GLP-1 was effective at reducing infarct size when co-administered with the 
DPP-4 inhibitor valine pyrrolidide (VP), both as a preconditioning mimetic and during the 
first 15 minutes of reperfusion in isolated rat hearts[3], [4], [7] and in vivo [4], but did not 
reduce infarct size in the absence of the DPP-4 inhibitor [3].  Kavianipour et al. [16] 
reported no effect on hemodynamics or infarct size when GLP-1(7-36) amide was 
administered intravenously in pigs before and during ischemia/reperfusion.  But Timmers 
et al. demonstrated in a swine model that injections of Exenatide  five minutes prior to 
reperfusion and on the subsequent two days reduced the infarct size and deterioration in 
cardiac function observed in the control group [9].   
 
In addition to GLP-1 in its entirety, more specifically known as GLP-1(7-36), the effects 
of the initial breakdown product, GLP-1(9-36), have also been studied.  Cardioprotective 
effects of GLP-1(9-36) remain controversial with observed reduced infarct size in mouse 
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hearts [17] but no effect seen in rat hearts [13].  Additionally, GLP-1(9-36) has negative 
inotropic effect on the isolated rat heart [13], but positive inotropic effects in dogs with 
dilated cardiomyopathy [15].  Another study showed pretreatment with the metabolite 
GLP-1(9-36) amide actually worsened the hemodynamics compared to controls, while 
administration on reperfusion had a positive effect on both hemodynamics and infarct 
size [8].  Reports such as these in the literature suggest that GLP-1(9-36) amide may act 
independent of the GLP-1 receptor to produce cardioprotective effects when delivered 
initially upon reperfusion [8], [12], [18].  Unless otherwise noted, the use of “GLP-1” 
refers to the GLP-1(7-36) moiety.  Throughout the study of GLP-1, the particular analog 
chosen, administration with or without inhibitor, timing, dose and duration of delivery, 
and the species and model used to evaluate the peptides for their therapeutic potential 
are all have great influence on the observed response.  
 
In vitro trabeculae model  
In order to study the direct effects of GLP-1 on contractility in a time and cost efficient 
manner, I use an in vitro trabeculae model for some of the studies in Chapter 1.  This 
model uses trabeculae carnae dissected off the endocardial surface of porcine (or other 
large mammalian) hearts.  This model has numerous advantages over in vivo studies, 
such as the isolating the effects of GLP-1 from other systemic effects including insulin 
release and sensitivity, as well as other hormonal and autonomic responses.  This is 
beneficial since GLP-1 is hypothesized to have direct effects on cardiac function, 
independent of its insulinotropic effects [3]; however, when delivered intravenously or 
subcutaneously in vivo, all systemic effects of the treatment will be generated.   
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Other advantages of this model include reduced time and cost.  The equipment in our 
lab allows a single heart to be used in up to 22 studies to be performed simultaneously.  
Thus, tissue from a single animal can be used in several unique treatments as well as 
serve as its own controls.  The in vitro approach also uses only a small amount of buffer.  
This allows precise control over dosing as well as requiring only a small amount of drug 
compared to a whole animal or Visible Heart®  preparation [19]. 
 
Another advantage specific to the use of GLP-1 in the isolated trabeculae model is its 
increased half-life.  When administered intravenously in vivo, GLP-1 has a half-life of 1-2 
minutes, as the peptide is quickly broken down by DPP-4 [10].  When administered in 
the isolated tissue model, in the absence of DPP-4, the half-life is significantly extended, 
thus removing the need for a continuous infusion. In pilot studies, the half-life was 
measured to be over 35 minutes. 
 
The drawbacks to this model include the artificial environment that the bundles are 
placed in.  Additionally, the tissue necessarily goes through a short period of hypoxia 
before the bundles are hung.  The damage is minimized by cooling the tissue and 
removing any form of stimulation to help reduce metabolic demand. 
 
Ventricular trabeculae were chosen for convenience and consistency.  In addition to 
being appropriately sized, each trabecula is easy to dissect from the endocardium with 
minimal damage to the myocytes.  Additionally, fiber orientation within the myocardial 
wall is not always clear and changes with depth.  Using trabeculae maximizes 
longitudinal fiber orientation, which is desirable for maximum contractility. 
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This model also allowed for the measurements of the direct effects on human 
myocardium.  Using a unique connection with the University of Minnesota Fairview 
hospital, we were able to acquire human ventricular tissue from heart transplant 
recipients.  This provided a unique opportunity to translate protocols to human 
myocardium in heart failure.  Combined with our isolated trabeculae model, we were 
able to efficiently evaluate the effects of GLP-1 on swine and human tissue. 
 
This trabeculae model was used to investigate the inotropic effects of GLP-1 and 
Exendin-4, as well as any protective effects during hypoxia/reperfusion injury by 
measuring contractility effects on swine tissue.  After 11 pig hearts and 178 trabeculae 
(63 non-hypoxic, 115 hypoxic), no inotropic effect was seen in the non-hypoxic model 
and no improvements in tissue function after hypoxia/reperfusion injury were seen at two 
dosing levels of each GLP-1 or exendin-4 (details in chapter 1). 
 
During the course of this study, we received 4 human heart biopsies and were able to 
test 34 trabeculae.  The failing heart dropped in function in throughout the experiments, 
losing 80% of its function regardless of treatment level or even exposure to 
hypoxia/reperfusion (Figure A.1).  This is likely due to the severe heart failure of the 
individual hearts. Not only did GLP-1 not have an effect at either dose tested, the 
hypoxia/reperfusion protocol did not damage tissue any more than being in vitro for four 
hours as seen by comparing to the non-hypoxic trabeculae.  This same 
hypoxia/reperfusion protocol reduced function approximately 30% compared to non-
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hypoxic porcine tissue (see study, below).  The dramatic drop in function in all contractile 
force makes it difficult to draw conclusion from this human model.   
 
 
Figure A.1: peak forces of human LV trabeculae.  Peak forces dropped throughout the experiment to 
approximately 20% original function. 
 
Delivery method 
While most studies using GLP-1 deliver intravenously (IV) or directly to the coronary 
arteries in isolated in vitro models, subcutaneous (SC) delivery offers a slower 
absorption rate.  In fact, the clinically approved analogs, Byetta and Bydureon, are 
administered SC for diabetic therapy.  For SC delivery, pigs are most similar to humans in 
terms of skin and subcutaneous fat.  In contrast to rats and dogs, pigs exhibit similar 
absorption rate of insulin into the plasma after SC delivery compared to humans [20].  The 
possibility of SC delivery of GLP-1 was explored in comparison to IV delivery in a pilot 
study in our lab.  The main advantage of a SC bolus upon reperfusion compared to 
continuous IV infusion is the potential to simplify the delivery method in a clinical setting. 
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For our studies, we used the GLP-1(7-36)amide, as there is more evidence of clinical 
relevance compared to the breakdown product GLP-1(9-36)amide.  Henceforth, any 
reference of GLP-1 is to the GLP-1(7-36)amide, unless otherwise noted. 
 
The objectives of this pilot study were to compare the pharmacokinetic actions of GLP-1 
delivered IV vs. SC.  The specific delivery protocols are outlined below 
A) Continuous IV Dose-Escalation:  Three doses (1.5, 3.0, 4.5 pmol/kg/min) of 
GLP-1 were delivered consecutively via continuous IV infusion for 30 min 
each, followed by a 60-min washout period.  (n=2) 
B) Continuous SC Dose-Escalation: Three doses (1.5, 3.0, 4.5 pmol/kg/min) of 
GLP-1  were delivered consecutively via continuous SC infusion for the same 
duration, followed by a second washout period.   (n=2). 
C) Bolus SC injections at two increased doses (0.27 and 2.7 nmol/kg/min) with 
appropriate washout between.  (n=2) 
D) Continuous IV infusion at the lowest dose (1.5 pmol/kg/min) for twice the 
duration (60 min)  (n=1) 
 
Because of the short half-life of GLP-1 in the blood, it was decided that delivery 
protocols A and B could be performed in the same animals with the included 60 minute 
wash out period. Both protocol A and B were performed in pig 1 and pig 2.   After 
inconsistent results with SC delivery (see Figure A.3), modifications in the protocol were 
made in an attempt to troubleshoot the lack of a dose-escalation response.  Possible 
explanations for ineffective delivery included inappropriate site and too small of a dose.  
Saline was used as buffer in the first two experiments, and the Amylin buffer was used 
for subsequent experiments.  In addition to the increased dosing for part C, the site was 
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changed based on the literature [20].  Subcutaneous delivery was simplified by doing 
bolus injections rather than infusions.  In addition, a longer infusion was added (protocol 
D) to confirm stability, which was performed in the last animal prior to SC delivery. 
 
Four male Yorkshire swine weighing 72.2 – 99.8 kg were anesthetized for these 
pharmacokinetic experiments.  A femoral artery was cannulated for measurement of 
blood pressure and withdrawal of blood samples, which were drawn every 10 minutes and 
processed via ELISA (LINCO Research, St. Charles, MI) to measure active GLP-1 
plasma levels.    
 
For intravenous delivery, GLP-1 was infused through the Swan-Ganz catheter into the 
right ventricular outflow tract.  For subcutaneous delivery, a 25-gauge needle was 
inserted at a 45-degree angle to pinched skin at the sites shown in Figure A.2. 
 
Figure A.2: Sites for subcutaneous delivery site in Pigs 1-4.   After no plasma GLP-1 was detected in 
the first experiment, the site was changed to avoid regions of deep subcutaneous fat (the abdomen) 
to optimize delivery.  The targeted regions were the neck/shoulder [20], [21] in Pig 2 and behind the 
ears in Pig 3 and 4.  
 
Pilot Results 
  
Pig 2 Pig 1 
  
- 
  Pig 3 & 4   
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A repeatable dose-dependent elevation in plasma levels were observed during 
intravenous infusion in the dose-escalation experiments (Pigs 1 and 2, Figure A.3).  With 
subcutaneous infusions, however, there was moderate but inconsistent elevation in Pig 
1, and no appreciable elevations in Pig 2. 
 
 
 
Figure A.3  Plasma levels of intact GLP-1 in Pigs 1 and 2 over time in a dose-escalation study at 
three doses (1.5, 3.0 and 4.5 pmol/kg/min) delivered 30 minutes each with a 60-minute washout 
period between IV and SC delivery. 
 
Figure A.4 shows active GLP-1 plasma levels in Pigs 3 and 4 over time.  In Pig 3, two 
bolus injections were given at 0.27 and 2.7 nmol/kg.  Elevated levels of GLP-1 were 
detected in the plasma for both injections at two doses.  For the 0.27 nmol/kg dose, the 
maximum plasma level was reached at 10 minutes and showed an exponential decay to 
baseline shortly after injection.  The 2.7 nmol/kg dose shows a more gradual decay with 
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a sudden spike 50 minutes post-injection, and plasma levels remained elevated at the 
conclusion of the experiment 60 min post-injection.   In Pig 4, stable plasma levels were 
achieved with intravenous infusion.  No elevation was seen with the low dose bolus, and 
compared to Pig 3, the plasma levels decayed more quickly with the high dose bolus.   
 
Figure A.4:  Plasma levels of intact GLP-1 in Pigs 3 and 4 over time with 60 minutes of IV infusion at 
1.5 pmol/kg/min and a 30-minute washout period in Pig 4 only and two SC bolus doses with a 60-
minute washout period between boluses in both Pigs 3 and 4.  
 
Interpretation 
In these experiments, plasma GLP-1 concentrations at expected levels were consistently 
achieved with intravenous administration, while subcutaneous administration yielded 
inconsistent or undetectable results with both infusion and bolus delivery.  In light of 
these results, further work completed with GLP-1 in swine was delivered IV.  It was 
decided that the consistency and predictability afforded by IV delivery outweighed the 
potential clinical benefits of SC delivery. 
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The study in Chapter 1 makes use of the in vitro trabeculae preparation to efficiently 
evaluate the inotropic effects of GLP-1 and Exendin-4 in the absence of systemic 
effects.  A corresponding trabeculae study tests the preconditioning and cardioprotective 
effects of GLP-1 and Exendin-4 in tissue subjected to hypoxia/reperfusion injury.  The 
lack of effect seen in vitro suggests that there is little to no direct effect in this model.   
 
An accompanying swine in vivo model of acute myocardial infarction was also used.  In 
this open-chest model, the left anterior descending coronary artery was occluded for 45 
minutes followed by reperfusion for 180 minutes. Either GLP-1 or Exendin-4 was infused 
for the first 30 minutes of reperfusion.  The main finding was that Exendin-4, but not 
GLP-1, significantly reduced the size of induced infarct. 
 
Pigs were chosen for this study based on their cardiac and coronary anatomy.  Pigs are 
a good model since their coronary vasculature is similar to humans.  The open chest 
model provides a reliable and repeatable model that ensures proper occlusion and 
reperfusion.  
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Summary 
Background:  GLP-1 (glucagon-like peptide 1) is an incretin hormone secreted by 
intestinal L-cells in response to ingested nutrients.  It stimulates insulin release, 
increases insulin sensitivity, mimics response to insulin, inhibits glucagon secretion, 
decreases norepinephrine, and improves cell survival.  GLP-1 has been widely studied 
for its physiological effects on the cardiovascular system and for its therapeutic potential 
in ischemia and heart failure. GLP-1 and its analogs have been shown to be 
cardioprotective in rodent [3–5], [7], [22], swine [9], and canine [10] models of ischemia-
reperfusion injury. The long-acting analog exendin-4 has the potential to provide similar 
benefits in a more stable form. 
 
Methods:  In vitro experiments were performed with isolated trabeculae from porcine 
hearts.  GLP-1 and exendin-4 were administered to test direct effects on contractility and 
performance after hypoxia/reperfusion injury.  A model of acute myocardial infarction 
(AMI) was used in eight Yorkshire swine divided into two treatment groups receiving 
GLP-1(7-36) or exendin-4.  Historical controls from previous infarct experiments [23] at 
the same laboratory were used as controls for this study.  After median sternotomy and 
stabilization, the left anterior descending (LAD) coronary artery was occluded for 45 
minutes.  Therapy was started two minutes prior to reperfusion and continued 30 
minutes into the 180 minute reperfusion period.  Blood samples were drawn for 
metabolic assessment of myocardial glucose and lactate, insulin, and the administered 
peptides throughout reperfusion.  At the end of reperfusion, the LAD was re-occluded 
and patent blue dye injected into the right ventricle to differentiate the area subjected to 
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ischemia.  The heart was harvested, frozen, sectioned and stained with 
triphenyltetrazolium chloride to determine area at risk and infarct areas.  
 
Results: In isolated trabeculae, neither GLP-1 nor exendin-4 had significant effects on 
contractility in either the non-hypoxic or hypoxic model.  In vivo, intravenous 
administration of Exendin-4, but not GLP-1(7-36) amide, significantly reduced infarct size 
in this small investigational study (55.4 ± 15.2% for GLP-1; 48.7 ± 19.7% for Control; 
18.3±12.4% for exendin-4).  Either GLP-1 or Exendin-4 was detected in the plasma of 
the respective treatment groups, confirming efficacious delivery of the peptides.  One or 
more episodes of ventricular fibrillation occurred in 50% of the Exendin-4 group, 25% of 
the control group, and 0% of the GLP-1 group.  There were no mortalities in either 
treatment group, while the control group experienced 17% mortality [23].   GLP-1 had no 
significant effect on hemodynamics, but exendin-4 increase arterial mean and diastolic 
pressures.  Plasma insulin increased during the treatment period in 2 of the 3 animals 
tested, one in the GLP-1 group and one the Exendin-4 group, which may be due to 
administration of these insulinotropic peptides 
 
Conclusions: Exendin-4 but not GLP-1 reduced infarct size in this small study.  
Beneficial effects may in part be explained by the increase in arterial pressure in the 
exendin-4 animals.  Further preclinical studies are warranted to determine dose, analog, 
and heart failure population best served by continuous infusion of exendin-4. 
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Introduction  
Glucagon-like peptide 1 (GLP-1) is a naturally occurring incretin hormone secreted by 
the gut after meals and is responsible for glucose-mediated insulin release [1].  Because 
of its insulinotropic and insulinomimetic properties, as well as evidence of GLP-1 
receptors on the heart, GLP-1 has been investigated for its cardioprotective effect and its 
role in cardiac physiology [1–4], [11].  
 
In various animal and clinical studies, numerous administration protocols have been 
employed.  Because the active form of GLP-1 (7-36)amide is quickly broken down by 
dipeptidyl peptidase-4 (DPP-4), several methods for prolonging GLP-1 exposure have 
been used, including continuous infusion, DPP-4 inhibitors and long acting GLP-1 
analogs such as Exendin-4. 
 
The hemodynamic and cardioprotective effects of GLP-1 are not consistent in the 
literature.  Delivery of GLP-1(7-36) amide has resulted in improved hemodynamics after 
ischemia/reperfusion injury [8], [10], [11] and increased cardiomyocyte viability when 
delivered at reperfusion and/or as a preconditioning mimetic [8], [12].  Ferthermore, Ban 
and colleagues went on to show that many of these effects are independent of the GLP-
1 receptor by producing similar results in a GLP-1 receptor knockout mouse [8], [12].  
  
Bose et al. [7] showed GLP-1(7-36) amide was effective at reducing infarct size in 
isolated rat hearts when co-administered with the DPP-4 inhibitor valine pyrrolidide (VP), 
both as a preconditioning mimetic and during the first 15 minutes of reperfusion.  When 
delivered during stabilization and throughout ischemia/reperfusion, GLP-1 reduced 
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infarct size in rat hearts when co-administered with VP both in vivo [4] and in isolated rat 
hearts[3], [4] but did not reduce infarct size in the absence of the DPP-IV inhibitor[3].  
Kavianipour et al. [16] reported no effect on hemodynamics or infarct size when GLP-1 
was administered intravenously in pigs before and during ischemia/reperfusion.  But with 
the synthetic Exendin-4, Exenatide, Timmers et al. demonstrated in a swine model that 
injections 5 minutes prior to reperfusion and on the subsequent 2 days reduced the 
infarct size and deterioration in cardiac function observed in the control group [9].  
Clearly, the particular analog chosen, administration with or without inhibitor, timing, 
dose and duration of delivery, and the species and model used to evaluate the peptides 
for their therapeutic potential are variables affecting the observed response. 
 
This study measures the effects of GLP-1 and exendin-4 on two porcine 
ischemia/reperfusion models.  The direct inotropic and preconditioning effects are tested 
in vitro using porcine myocardial tissue, while the cardioprotective effects are studied in 
an open chest swine model of acute myocardial infarction. 
 
Methods  
Peptide preparation 
Lyophilized GLP-1 and Exendin-4 were obtained in 1 mg quantities from Bachem 
Americas, Inc. (Torrance, CA).  Dry peptides were reconstituted and aliquoted into 2 mL 
quantities for long-term storage at -20C.  Two solvents were used for this purpose: 1) 
modified Krebs solution, and 2) “Amylin” solution. The compositions of these solvents 
are described in Table A.1. 
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Krebs solution Amylin solution 
Ingredient Quantity   Ingredient 
Unit Formula 
(mg/mL) 
Function 
NaCl 118 mM   Mannitol 50.7 mg 
Osmotic 
Agent 
D-Mannitol 16 mM   Glacial Acetic Acid 0.38 mg Buffer 
D-Glucose 5.75 mM 
  Sodium acetate 
trihydrate 
0.49 mg Buffer 
NaHCO3 20 mM   Water for Injection qs to 1.0 mL Solvent 
2Na-EDTA . 2H2O 0.32 mM    
KCl 4.5 mM    
MgCl2 
.
 6H2O 1.455 mM    
NaH2PO4 
.
 H2O 1.2 mM    
CaCl2 
. 2H2O 1.81 mM    
1% Bovine Serum 
Albumin 
    
Table A.1:  Contents of the Krebs and Amylin solutions used as solvents for drug compounds 
 
Isolated trabeculae model 
Swine hearts were harvested within 10 minutes of sacrifice from animals used for other 
non-phamacological studies and prepared as previously described [24].  Briefly, 
trabeculae carnae 1-2 cm in length and 2-3 mm in diameter were dissected off the 
endocardium and hung on a calibrated force transducer, then mounted in an 
experimental chamber kept at 37˚ C.  The chamber was filled with a krebs henseleit 
buffer and gassed with carbogen (95% O2, 5% CO2).  The buffer composition consisted 
of: NaCl (118.0mM), D-Mannitol (16.0mM), D-Glucose (5.75mM), NaHCO3 (20.0mM), 
2Na-EDTA·2H2O (0.32mM), KCl (4.5mM), MgCl2·6H2O (1.46mM), NaH2PO4·H2O 
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(1.2mM), and CaCl2 (1.81mM). The trabeculae were stimulated with a 1ms 15V pulse 
(pulse width of 1ms) at  0.1 Hz The transducer signal was amplified and recorded in a 
LabView program (National Instruments, Austin TX).   They were subjected to a 
hypoxia/reperfusion protocol outlined in Figure A.5, and dosing in Table A.2. 
 
    Hypoxia/Reperfusion Non-Hypoxic 
  Hearts 3.0nM 0.3nM Control 3.0nM 0.3nM Control 
GLP-1 7 26 28 27 11 12 13 
Exendin-4 4 13 11 10 10 9 8 
Table A.2: Total number of swine and human hearts studied, as well as the number of trabeculae at 
each dose.  
 
Figure A.5: Hypoxia study timeline. Buffer samples are drawn for analysis at points marked a-e. 
 
Acute Myocardial infarction  
Animals  
Approval for these animal experiments was granted from the Institutional Animal Care 
and Use Committee of the University of Minnesota.  Eight Yorkshire swine weighing 44.3 
± 3.2 kg were divided into two treatment groups to receive either GLP-1(7-36) amide (n=4) 
or GLP-1 receptor agonist exendin-4 (n=4).  Historical controls from previous infarct 
experiments [23] at the same laboratory were used as controls for this study (n=6). 
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Surgical Procedure 
The anesthesia and surgical procedures are very similar to those described previously in 
the papers of Xiao [23] and Sigg [23], [25], [26].  Briefly, Yorkshire swine weighing 44.3 ± 
3.2 kg were anesthetized and instrumented.  Two Millar Mikro-Tip pressure sensor 
catheters (5 Fr, model MPC-500) were placed, one in each ventricle.  A Swan-Ganz 
thermodilution catheter (Edwards Lifesciences; Irvine, CA) was placed in the pulmonary 
artery and connected up to a Q2 Continuous Cardiac Output Computer (Abbott 
Laboratories; Abbott Park, IL) to monitor continuous cardiac output.  Blood pressure and 
samples for blood gas analysis were drawn through a cannulated femoral artery. 
 
A median sternotomy was performed and the heart suspended via a four-suture 
pericardial cradle.  A 2- to 3-mm segment of the LAD coronary artery was dissected 
distal to the first diagonal branch (between second and third branch) for occlusion.  The 
azygos vein was clamped and the coronary sinus cannulated for venous blood sampling.   
 
The animal was heparinized (300 IU/kg IV bolus of heparin followed by an infusion of 67 
IU/kg/hr) and allowed to stabilize for one hour before starting the experimental protocol.  
To induce ischemia, a vessel clamp (Sklar Vascular Size 2 Single Clamp) was placed on 
the LAD between the second and third branch for 45 minutes.  Treatment was started 2 
min prior to reperfusion according to one of the three dosing schemes illustrated in 
Figure A.6 and summarized in Table A.3.   Peptides were delivered into the right 
ventricle at 1.0 mL/min through the proximal port of a Swan-Ganz catheter connected to 
a Harvard syringe pump.  The reperfusion period lasted for 180 min.   
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Figure A.6: Timeline of the experimental protocol, blood draws, and dosing schemes. c.i.v: 
continuous IV delivery.  Bolus: SC bolus 
 
 
Table A.3:  Summary of GLP-1 analog, formulation, and dosing scheme for each animal 
 
Electrocardiograms, right and left ventricular pressures, ascending aortic flow, and 
arterial blood pressure were recorded simultaneously with IOX software (EMKA 
Technologies, Falls Church, VA) and BIOPAC MP150 (BIOPAC Systems, Inc., Goleta, 
CA) data acquisition systems.  Derived parameters heart rate, LV dP/dt max, LV systolic 
pressure, LV end-diastolic pressure, LV developed pressure, relaxation time constant, 
and mean arterial pressure were also calculated.  Blood samples were acquired at the 
time points shown in Figure A.6.  Arterial samples were analyzed for blood gases and 
plasma levels of insulin, glucose, lactate, GLP-1, its primary metabolite GLP-1(9-36) and 
Exendin-4.  Venous samples were also analyzed for blood gases, glucose, and lactate. 
Reperfusion
180 min
Ischemia
45 min
Stabilization
60 min
A
B
C
c.i.v.
c.i.v.
bolus
c.i.v.
Dosing 
scheme
-45 -5 5 15 30 45 60 90 120 150 180
Analog Formulation
Total dose 
(pmol/kg)
Dosing 
protocol
Loading dose 
(pmol/kg)
Infusion rate 
(pmol/kg/min)
Duration 
(min)
1 GLP-1(7-36) Saline 45 A - 1.5 30
2 GLP-1(7-36) Saline 45 A - 1.5 30
3 GLP-1(7-36) Saline 45 A - 1.5 30
8 GLP-1(7-36) Amylin 450 C - 2.5 180
4 Exendin-4 Amylin 45 A - 1.5 30
5 Exendin-4 Amylin 45 A - 1.5 30
6 Exendin-4 Amylin 45 B 30 0.5 30
7 Exendin-4 Amylin 45 B 30 0.5 30
Treatment
Animal 
#
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Continuous cardiac output was recorded via the thermodilution catheter at regular 
intervals and at the time of blood draws.  Arrhythmia assessment occurred throughout 
ischemia and during the first 45 minutes of reperfusion. 
  
Determination of Infarct Size and Risk Area 
At the conclusion of the 180-minute reperfusion period, the LAD was reoccluded and 
patent blue dye injected into the right ventricle to differentiate the ischemia area (area at 
risk) from the non-ischemic area.  Immediately following sacrifice, the heart was 
harvested in toto, rinsed, and stored at -20°C for 14-18 hours.  The frozen hearts were 
sliced into 4-mm transverse sections and stained with 1% triphenyltetrazolium chloride 
(TTC).  Slices were photographed and analyzed to determine relative sizes of infarct 
size and area at risk.  
 
Arrhythmia Assessment 
Blinded analysis of arrhythmias was performed by the same person who performed the 
assessment in historical controls using the following scoring system:  0 = ≤ 10 premature 
ventricular contractions (PVCs) in 9 min; 1 = 11–50 PVCs in 9 min; 2 = > 50 PVCs in 9 
min; 3 = 1 episode of ventricular fibrillation (VF) in 9 min; 4 = 2–5 episodes of VF in 9 
min; and 5 = >5 episodes of VF in 9 min. When VF was elicited, cardioversion was 
attempted using 30-J shocks administered via internal paddles and repeated as 
necessary.   
 
Plasma Sampling and Analysis 
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Blood samples were collected in ice-cooled Vacutainer EDTA-plasma tubes containing 
10 μl of 10 mM DPP-IV (Millipore Corporation; St. Charles, Missouri) per mL of blood 
when necessary.  Within the hour, samples centrifuged and analyzed for plasma glucose 
and lactate (Yellow Springs Instruments Model 2300 Stat Plus glucose/lactate analyzer) 
and aliquoted and stored at -80°C.  ELISAs were used to measure intact GLP-1, i.e. 
GLP-1 (7-36) amide and GLP-1 (7-37), as well as total GLP-1 and Exendin-4 where 
appropriate (Assays from LINCO Research, Phoenix Pharmaceuticals, Inc.).  Insulin was 
measured in Pigs 3, 4 and 5 with ELISA (ALPCO).   
 
Statistical Analysis 
All results are expressed as the mean ± SD.  Data were compared used one-way 
ANOVA with MEDSTAT for Excel v 5.2 software.  When the F value was significant, 
individual group means were compared using the Newman-Keuls method for multiple 
contrasts in GraphPad Prism 5 software.  When control data were not available, an 
unpaired Student’s t-test was used to compare treatment groups.  A P value of <0.05 
was considered significant.   
 
Results 
Isolated trabeculae model 
The half-life of GLP-1(7-36) was extended by the lack of DPP-4 in vitro, with 50-65% 
percent remaining at 30 minutes (average observed half-life 35.6 min).  Non-hypoxic 
tissue slowly declined in function over the course of the 4 hour experiment, to 
approximately 80% of initial function.  Treatment with GLP-1 or exendin-4 throughout the 
4 hours had no effect on force production (Figure A.7 and Figure A.8).  During hypoxia, 
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the forces produced by all trabeculae fell to about 40% of their initial value, then 
recovered to 50-60% during reperfusion.  There is very little difference among the 
groups with no statistically significant differences (Figure A.9 and Figure A.10).  
 
 
Figure A.7: Average of peak forces from each dose of GLP-1 relative to baseline.  The vertical dotted 
line indicates a buffer change.  GLP-1 was in the buffer throughout the entire experiment. 
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Figure A.8: Average of all peak forces from each dose of exendin-4 in trabeculae not subjected to 
hypoxia. The vertical dotted line indicates a buffer change.  Exendin-4 was in the buffer throughout 
the entire experiment. 
 
Figure A.9: Effects of GLP1 on porcine trabeculae subjected to hypoxia/reperfusion injury.  Tissue 
was hypoxic during time between hashed vertical lines. 
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Figure A.10: Average peak force from trabeculae treated with Exendin-4.  Tissue was hypoxic 
between vertical hashed lines. 
  
The rate of force development and decay were calculated as measures of contractility 
and relaxation.  Furthermore, baseline forces were measured as an indicator of preload.  
No differences were seen among any of these these groups (data not shown).  Tissue 
bath lactic acid levels were also measured in both the GLP-1 groups and the exendin-4 
groups at various points.  The levels of lactic acid increased through the experiment and 
there were no significant differences between the treatment groups during the hypoxic or 
non-hypoxic time points. 
 
Infarct Size 
In the acute MI model, the LAD was occluded for 45 minutes, and either GLP-1 or 
Exendin-4 was given just prior to 180 minutes of reperfusion.  The area at risk, or 
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ischemic zone, was similar among all groups:  18.4 ± 3.3% in the GLP-1 group, 19.0 ± 
7.7% in the Exendin-4 group, and 22.7 ± 8.1% in the control group.  As a percent of the 
total area at risk, the infarct area was not significantly different between the GLP-1 and 
control groups (55.4 ± 15.2% vs. 48.7 ± 19.7%).  However, infarct size was significantly 
reduced in the Exendin-4 group (18.3±12.4%) compared to both the GLP-1 and control 
groups (p<0.01 and p=0.03, respectively; see Figure A.11). 
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Figure A.11:  (A) Risk Zone, the percent of LV subjected to ischemia, and (B) Infarct Area, the 
percent of the risk zone that is infracted, for treatment and control groups. 
 
Arrhythmias 
There were no occurrences of VF in the GLP-1 group.  Ventricular fibrillation occurred in 
two animals in the Exendin-4 group, one instance in Pig 5 and five instances in Pig 7.  
No mortalities resulted from ventricular fibrillation in either group after defibrillation.  
Morbidity and mortality from VF in the historical control group was 25% and 17%, 
respectively.  There was no difference in the total arrhythmia score for each treatment 
group compared to control or between treatment groups during the reperfusion period 
(Figure A.12) as well as during the ischemic period (not shown).     
 
   
Figure A.12:  Arrhythmia score (A) over the 45-minute reperfusion period and (B) broken down over 
each 9-minute segment of the reperfusion period.   
 
Hemodynamics 
The hemodynamic plotted in Figure A.13.  Data include heart rates, mean arterial blood 
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systolic pressure (LVSP), left ventricular end diastolic pressure (LVEDP), ±LV dP/dt, and 
LV Tau.  Systolic and diastolic arterial pressures were not available for the control group, 
but comparisons were made between treatment groups.  
 
Of the parameters assessed, only mean and diastolic arterial pressures showed 
significant differences during the infusion period, with the Exendin-4 group higher 
compared to the GLP-1 group only (P<0.05).  LV –dP/dt as well as LV systolic and 
developed pressures showed differences between groups prior to infusions as well as 
during infusions.  The heart rate did increase in the infusion period in the GLP-1 and 
Exendin-4 groups by approximately 20 to 50 bpm, respectively, but the increase was not 
statistically significant.  In both treatment groups, the rise in heart rate plateaued 30 
minutes into reperfusion which coincided with cessation of infusions in dosing regimens 
A and B employed in 7 of 8 animals.    
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Figure A.13: Hemodynamic parameters including heart rate, mean arterial pressure, arterial diastolic 
pressure and arterial systolic pressure.  Mean arterial and diastolic pressures in Exendin-4 animals 
are significantly higher compared to GLP-1 treated animals 
 
Pharmacokinetics of GLP-1  
The total detected peptide is expressed as the area under the curve (AUC), which is 
displayed in Table A.4 along with maximum concentration (Cmax) achieved for each 
animal, as well as infarct area.  Area under the curve is higher in Animal #8 compared to 
others in the same treatment group due to the dosing regimens employed.  Of particular 
interest is that, though infusion rate was increased from 1.5 to 2.5 pmol/kg/min in Animal 
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8, the Cmax is not reflective of the higher dose.  In the Exendin-4 group, all animals 
received the same total dose under two dosing regimens administered over 30 minutes; 
however, the Exemdom-4 bolus loading dose in Animals 6 and 7 did not afford a 
comparable Cmax and AUC in relation to continuous infusion.  Representative traces of 
detected peptides are shown in Figure A.14. 
 
  
Table A.4:   Area under the curve (AUC), maximum concentration (Cmax). and Infarct area for GLP-1 
and Exendin-4 
 
 
Group Animal # AUC (pM·h) Cmax (pM)
Infarct Area (% 
risk zone)
GLP-1(7-36) 1 18.5 43.2 48.5%
2 5.1 12.7 43.3%
3 15.7 36.4 52.1%
8 55 25.5 77.6%
Mean ± SD 23.6 ± 21.7 29.5 ± 13.3 55.4 ± 15.2%
Exendin-4 4 192.6 233.4 2.79%
5 213.6 297.1 18.13%
6 110.4 97.8 33.01%
7 30.7 77 19.41%
Mean ± SD 136.8 ± 83.6 176.3 ± 106.3 18.3 ± 12.4%
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Figure A.14: Representative traces of plasma levels of intact (GLP-1(7-36)) and total GLP-1 (GLP-1(7-
36) + GLP-1(9-36)) in pig #3 (top) and plasma levels of Exendin-4 in pig #4.  Ischemia and reperfusion 
periods are displayed at the top, as well as the 30 minute infusion period for the treatment. 
 
Metabolics  
Insulin levels were measured in 3 animals (2 GLP-1 treated) as well as myocardial 
glucose balance in all animals.  Measurable increases in insulin were detected during 
treatment periods with both GLP-1 and exendin-4 confirming a physiologic response was 
elicited through peptide delivery.  Glucose levels in several of the animals were slightly 
elevated, which is contrary to the expected response (data not shown).   
              
Discussion 
Two GLP-1 analogs were investigated in this study to evaluate the cardioprotective 
potential of these peptides.  At the time the study was initiated, there was significant 
preclinical evidence in rodents, though some of it was controversial with conflicting 
results, and only a small number of studies in higher species.   
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In vitro model  
After four hours of functioning in vitro, the peak forces produced by the non-hypoxic 
trabeculae dropped to 70-85% of initial values.  Neither dose level of GLP-1 nor 
Exendin-4 affected contractile function in this model.  This suggests that neither has 
inotropic effect in porcine myocardial tissue.  
 
We saw that subjecting trabeculae to hypoxia and reoxygenation inflicts injury such that 
they can only recover to 50-60% of their original force after three hours of reperfusion.  
This is lower than trabeculae not subjected to hypoxia, indicating the hypoxic period 
damaged the myocardium.  However, treatment of swine myocardial tissue with GLP-1 
or exendin-4 at 3nM or 0.3nM concentrations had no observable effects that were 
manifested in this model.  This indicates that any contractile effects may be due to 
systemic effects of a given treatment, rather than direct action on the tissue. 
 
Acute MI model 
Dosing of 1.5 pmol/kg/min and duration of infusion of 30 minutes initiated just prior to 
infusion was chosen from the literature [5], [27–29].  As the study was being conducted, 
the Timmers study was published showing efficacy with a slightly different dosing 
strategy of Exendin-4 in which one IV dose and one subcutaneous dose were 
administered simultaneously 5 minutes prior to reperfusion [9].  Their dosing strategy 
was adopted in this study (dosing scheme B) with a bolus of Exendin-4 preceding 
continuous IV infusion for 30 minutes to emulate the slower absorption and 
bioavailability of the subcutaneously delivered peptide in the Timmers study.  While 
some reduction in infarct size was observed in the Exendin group, little response was 
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observed in the GLP-1 group, corroborating the study by Kavianipour reporting no 
reduction in infarct size or improvement in hemodynamics with GLP-1 [16].  In the final 
animal, the dose was increased and the infusion duration extended in response to input 
from a physician consultant.  Surprisingly, the infarct size was larger in this high-dose 
experiment compared to others in the same group or in the control group.  There has 
been one similar report in the literature with low-dose Exendin-4 reducing infarct area 
while high dose was ineffective [18].  Further replicates would be needed to determine if 
the higher dose is disadvantageous or less effective in cardioprotection.   
 
Despite the limitations of this small investigational study discussed herein, the key 
finding remains that Exendin-4, and not GLP-1(7-36), was shown to reduce infarct size.  
While some similar studies in isolated rodent hearts have shown GLP-1(7-36) to be 
cardioprotective [4], [5], [8], other studies have shown cardioprotection in either intact or 
isolated rodent hearts with GLP-1 only when it was co-administered with a DPP-4 
inhibitor [3], [7], or with exendin-4 [18] or other DPP-4-resistant analogs [30].  Literature 
in higher species is limited.  Within swine, our results on reduction of infarct area are 
consistent with the two studies in the literature [9], [16].  Specifically, Timmers et al. [9] 
reported a ~40% reduction with delivery of Exendin-4 compared to controls (32.7 ±6.4% 
vs. 53.6 ± 3.9%; p=0.031); the present study shows a 38% reduction in the Exendin-4 
group (13.3 ± 12.4% vs. 48.7 ± 19.7%, p=0.03).  There is notably more variation in our 
study compared to Timmers which highlights the importance of conducting additional 
studies to confirm this difference. With infusion of GLP-1(7-36), an earlier study showed 
only improved metabolics (decreased lactate and glucose levels but increased insulin) 
without reduction in infarct size or improved hemodynamics compared to controls [16]. 
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The presence of GLP-1 and exendin-4 in their respective animals confirmed successful 
delivery. Likewise, the present study showed no improvement in infarct size or 
hemodynamics in the GLP-1(7-36) group.  The cardioprotective effects of GLP-1 and its 
analogs in acute ischemia may be species specific.   
 
While some hemodynamic responses were observed, the impact on cardiac function 
was not conclusive in this study.   It is possible that myocardial stunning in this model 
may prevent any potential acute benefit regardless of infarct size, and that longer 
recovery over several hours or days may elucidate the beneficial response from the 
intervention, such as seen in the Timmers study.  However, the observed increase in 
mean and diastolic ABP in the exendin-4 group may have improved myocardial 
perfusion and aided in reducing infarct size. 
 
The literature is conflicting over whether or not GLP-1 and analogs have an effect on 
heart rate.  Due to the surgical intervention required in these experiments, the ischemia-
reperfusion model may not be the ideal experimental conditions to test the effect on 
heart rate.  However, there was a marked, though not significant, rise in heart rate during 
infusions in both treatment groups that was not observed in the control group.   
 
Limitations 
The major limitations of this study are inadequate sample size and use of historical 
controls with slight protocol variations from the current protocol.  Additional studies 
would increase confidence in the results, but were planned, but the limited available 
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resources were reprioritized to focus on chronic preclinical studies in existing heart 
failure models.  Use of historical controls prohibited improvements in the study protocol; 
for example, some of the data of interest in this study, such as myocardial glucose 
balance and insulin plasma levels, were not available from the prior study.  Since GLP-1 
is not being proposed as an antiarrhythmic, administration of amiodarone or other 
antiarrhythmics to prevent VF episodes would allow for a better assessment of 
metabolics and cardioprotective effects of GLP-1 without the added confounding factor. 
A further improvement would include recovery for at least two days prior to sacrifice.  
Additionally, there is some speculation that GLP-1 activates two pathways: one being 
the cAMP/Akt pathway for acute effects, while a secondary pathway requires at least 24 
hours of continuous infusion to elicit the response.  The Timmers study [9] employed this 
model and allowed reperfusion for three days with treatment with Exenatide continuing 
for two days resulting in a significant reduction in infarct size and loss of cardiac function.   
 
Conclusions 
Intravenous administration of Exendin-4, but not GLP-1(7-36) amide, significantly 
reduced infarct size in this small investigational study.  Though there was no significant 
difference in arrhythmia score among treatment and control groups, one or more 
episodes of ventricular fibrillation occurred in 50% of the Exendin-4 group, 25% of the 
control group, and 0% of the GLP-1 group.  There were no mortalities in either treatment 
group, while the control group experienced 17% mortality [23].  The effect of GLP-1 or 
analogs on hemodynamics and cardiac function post-ischemia is not clear in this study.  
GLP-1 or Exendin-4 was detected in the plasma of the respective treatment groups, 
confirming efficacious delivery of the peptides. Plasma insulin increased during 
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treatment period in 2 of the 3 animals tested, one in the GLP-1 group and one the 
Exendin-4 group, which may be due to administration of these insulinotropic peptides.  
The lack of effect on isolated trabeculae suggests any improvement in hemodynamics 
may be due to systemic effects of the treatment. 
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